US20060052739A1 - Electrokinetic delivery of medicaments - Google Patents
Electrokinetic delivery of medicaments Download PDFInfo
- Publication number
- US20060052739A1 US20060052739A1 US11/265,383 US26538305A US2006052739A1 US 20060052739 A1 US20060052739 A1 US 20060052739A1 US 26538305 A US26538305 A US 26538305A US 2006052739 A1 US2006052739 A1 US 2006052739A1
- Authority
- US
- United States
- Prior art keywords
- applicator
- medicament
- electrode
- pad
- treatment site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Definitions
- the present invention relates generally to the electrokinetic mass transfer of substances into and/or extracting substances from tissue and particularly to apparatus and methods for extracting, containing and/or delivering substance, e.g., a medicament to a treatment site.
- Electrokinetic delivery of medicaments for applying medication locally through an individual's skin is known.
- One type of electrokinetic delivery mechanism is iontophoresis, i.e., the application of an electric field to the skin to enhance the skin's permeability and to deliver various ionic agents, e.g., ions of soluble salts or other drugs.
- iontophoretic transdermal or transmucocutaneous delivery techniques have obviated the need for hypodermic injection for many medicaments, thereby eliminating the concomitant problem of trauma, pain and risk of infection to the individual.
- electrokinetic delivery mechanisms include electroosmosis, electroporation, electromigration, electrophoresis and endosmose, any or all of which are generally known as electrotransport, electromolecular transport or iontophoretic methods.
- the electrokinetic delivery mechanism may also be accompanied by ultrasonic vibration to further facilitate electrokinetic transport of the substance, e.g., by opening pores in the skin.
- Ultrasound may be employed in a number of ways such as (i) traditional piezoelectric elements, (ii) Application Specific Integrated Circuits (ASIC) with ultrasound transmitter built in or (iii) by thin foil sheets with incorporated piezoelectric dipole elements.
- ASIC Application Specific Integrated Circuits
- a portable, self-contained, hand-held lightweight, compact and wireless electrokinetic device for delivering or removing a substance, e.g., a medicament, and a unit dosage substance applicator for use with the device for the self-administration of a medicament to the skin.
- substance is meant a medicament as well as natural or homeopathic products that may be outside the definition of medicament, e.g., inks and pigments for tattoos, and more generally includes any substance capable of electrokinetic transport through skin or mucocutaneous membrane, e.g., into a treatment site or from a site, e.g., for diagnostic purposes.
- medicament any chemical or biologic that may be used on or administered to humans or animals as an aid in the diagnosis, treatment or prevention of disease or other abnormal or cosmetic condition or for the relief of pain or to control, diagnose or improve any physiologic or pathologic condition.
- Major therapeutic classes include but are not limited to, ACE inhibitors, such as ranitidine, anti-infectives such as antibacterials, antivirals and antimicrobials, vasodilators, including general, coronary, peripheral and cerebral, adrenocortical steroids, alpha-adrenergic agonists, alpha-adrenergic antagonists, selective alpha-two-adrenergic agonists, analgesics, and analgesic combinations, androgens, local and general anesthetics, antiaddictive agents, antiandrogens, antiarrhythmic agents, antiasthmatic agents, anticholinergic agents, anticholinesterase agents, xanthine derivatives, cardiovasculars including calcium channel blockers such as nifedipine, beta agonists such as dobutamine and ritodine, anticoagulants, including heparin, anticonvulsants, antidiabetic agents, antidiarrheal agents, antidiuretic, antiem
- Representative medicaments, their analogs and derivatives thereof, included by way of example and not for purposes of limitation, are interferons, e.g., ⁇ -2b interferon, amphotericin ⁇ , angiopeptin, baclofen, bepridil, buserelin, buspirone, calcitonin, ciclopirox, olamine, copper, cyclosporin, zinc, tropisetron, vapreotide, vasopressin, vasopressin antagonist analogs, verapamil, warfarin, zacopride, zotasetron, cromolyn sodium, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nitredipine, verapamil, isoproterenol, carterolol, labetalol, levobunolol, minoxidil, nadolol, penbuterol, pin
- benzodiazepines such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, triazolam and the like; antimuscarinic medicaments such as anistropine, atropine, clininium, cyclopentolate, dicyclomine, flavoxate, glycopyrrolate, hexocyclium, homatropine, ipratropium, isopropamide, mepenzolate, methantheline, oxyphencyclimine, pirenzepine, propantheline,
- medicaments such as anti-virals, for treating human papilloma virus, (HPV), e.g., warts (common, flat, plantar and genital), examples of which are Imiquimod® sold as AldaraTM by 3M for genital warts, a type (HPV), Acyclovir®, sodium salicylate, tretinion, benzoyl peroxide, bleomycin, interferons, Podocon-25, OTC products such as Wart Off by Pfizer and Compound W by MedTech or anti-picornavirus class substances, e.g., Pleconaril, to treat coughs and colds, anti-inflammatory medicaments such as dexamethasone and anti-bacterial agents, proteins, as well as steroids and salts thereof, non-steroidal anti-inflammatory drugs (NSAIDs), and salts thereof, hormones, cytokines, viruses, bacteria, DNA,
- HPV human papilloma virus
- warts common, flat, plantar
- bleaching agents e.g., Eldopaque 4% by ICN Pharmaceuticals, or a combination of Ketorolac, hydroquinone 4%, Glycolic Acid, lactic acid with suitable vehicle and anesthetics, such as lidocaine, xylocalne, prontocaine, prilocalne, fetanyl, remifentanil, sufentanil, alfentanil, novocaine, procaine, morphine HCL and EMLA either in stand alone fashion or with a vasodilator such as epinephrine.
- bleaching agents e.g., Eldopaque 4% by ICN Pharmaceuticals, or a combination of Ketorolac, hydroquinone 4%, Glycolic Acid, lactic acid with suitable vehicle and anesthetics, such as lidocaine, xylocalne, prontocaine, prilocalne, fetanyl, remifentan
- medicaments which inhibit fusion between the plasma membrane and viruses and other adventitious agents to prevent entry by viruses and/or other adventitious agents into cells may also be electrokinetically delivered, e.g., behenyl alcohols such as n-disocanol, its analogs or derivatives.
- Hair growth may be stimulated by Propecia (finasteride), minoxidil, blocking antidihydrotestosterones or antidihydroestrogens.
- Hair removal may be accomplished by dyeing the hair and or hair root to facilitate removal by laser means or by electrokinetically using, e.g., dihydrotestostersone or dihydroandrogens or dihydroestrogens.
- tattoos either temporary (reversible) or permanent may be applied to a treatment site and tattoos when permanent may be removed using suitable medicaments and the instant invention.
- Water soluble dyes and decals or templates may be employed in conjunction with the device and applicators.
- Prostate conditions e.g., prostatitis may be treated with antineoplastics.
- NSAIDs such as ketorolac or medicaments such as Benzamycin, benzoyl perixode, cleocin, T-Stat, over the counter (OTC) products two examples of which are Clearasil and Benz
- Psoriasis may be treated with an antimetabolite, retinoids, synthetic vitamin D, i.e., calciprotriene, cyclosporin A (CSA), Aristocort, from Lederle, anthrax-derm, by Dermik, methotrexate, cortisone like compounds psoralen or anthalin.
- Eczema and contact or atopic dermatitis may be treated with corticosteroids or antihistamines.
- Spider veins may be treated with antiangiogenics, or coagulants (clotting factors or fragmented cellulose polymer). Fluoride treatment of exposed single site hypersensitive dentin may be performed with this device and applicator system.
- Canker sores and RAS may be treated with, e.g., benzoin or sodium fluoride.
- Post herpetic neuralgia may be treated with local anesthetics mentioned throughout this disclosure and/or with antivirals, e.g., Acyclovir or combinations of anesthetic and antiviral.
- Erectile dysfunction may also be treated (transcutaneously at site of concern) using prostaglandins such as PGE or alprostadil, nitroglycerin, and the like or papaverine, yohimbine and the like or sildenafil citrate, i.e., iOS, or apomorphine HCl.
- diagnostic uses i.e., removal or extraction of animal or human bodily material, e.g., fluids, versus delivery of medicament include as examples, allergy screening, e.g., using an electrode mounted array of antigens with a multiplexed-multi-channel application electrode, glucose monitoring and drug testing using electrode mounted specific binders (binder assay) combined with reverse iontophoretic plasma extraction.
- allergy screening e.g., using an electrode mounted array of antigens with a multiplexed-multi-channel application electrode
- glucose monitoring and drug testing using electrode mounted specific binders (binder assay) combined with reverse iontophoretic plasma extraction e.g., body material such as fluids can be extracted into a pad on the electrokinetic device, for example, by reverse iontophoresis.
- Wounds such as scrapes, cuts, burns, plant allergies, punctures and insect bites or stings can be treated with antihistamines, antibiotics, anti-infectives such as bactracin, Diprolene, topical steroids, and the like, aloe or aloe containing products or OTC products such as Ambesol, Lanocaine and the like, other wound healing agents, such as epidermoid derived growth factors as well as peptides that modulate the inflammatory response and modulators of collagen deposition and modeling as well as other wound healing agents all electrokinetically delivered.
- Pre-treatment may also include desensitizing agents such as the aforementioned analgesics or salicylic acid.
- Pruritis, dry skin and keratosis may also be treated using, cortisones and the like, Benadryl itch creme, Lazer creme or EMLA and the like.
- Actinic keratoses may be treated by electrokinetic delivery of aminolevulinic acid as well as other established antimetabolite agents such as methotraxate, 3% DICLOFENAC IN 25% hyaluronic acid, 5FU, 5FU and isotretinion, and the like.
- Bursitis or mild arthritis may be treated with magnesium sulfate or Dororac from Genderm.
- a particular use of the device and applicator hereof is the delivery of Acyclovir® and derivatives and analogs thereof for treatment of recurrent herpetic symptoms, including lesions (oral or genital) and varicella zoster i.e., shingles.
- IUDR 5-iodo-2 deoxyuridine
- cytosine arabinoside Ara-C
- adenine arabinoside Ara-A
- vidarabine adenine arabinoside monophosphate
- Ara-AMP arabinofuranosyl hypoxanthine
- PAA phosphonoacetic acid
- thymine arabinoside Ara-T
- 5′-amino-2′,5′-dideoxy-5-iodouridine AIU
- 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil BV-ara-U
- sorivudine 1-beta-D-arabinofuranosyl-E-5(2-chlorovinyl)uracil
- CV-ara-U two halogenated deoxytidines
- topical agents including both Acyclovir® and IUDR have demonstrated only limited efficacy when applied topically to herpetic lesions, or pre-lesion stage sites including prodomal stage skin sites.
- demonstrably improved clinical results have been achieved when applied electrokinetically, e.g., electrophoretically, to treatment sites.
- Combinations may also be used including but not limited to IUDR and DMSO.
- a treatment site a target tissue, e.g., a diseased-tissue or diagnostic site for extraction of a substance, underlying or exposed through or on a human individual or lower animal's skin or mucocutaneous membrane including, the eye and also including, but not limited to body cavity and canal sites such as mouth, ear, nose, vagina, and rectum.
- body cavity and canal sites such as mouth, ear, nose, vagina, and rectum.
- an individual may privately self-administer the medicament by employing the self-powered hand-held device to electrokinetically drive the medicament from an applicator into the treatment site, e.g., through the skin or mucocutaneous membrane to a diseased tissue.
- the self-powered hand-held device to electrokinetically drive the medicament from an applicator into the treatment site, e.g., through the skin or mucocutaneous membrane to a diseased tissue.
- a low-cost throwaway single-use applicator is used to facilitate the flow of medicament into the skin under the influence of the electromotive force supplied to the medicament contained in the applicator by the self-powered hand-held wireless device.
- the hand-held device is preferably lightweight, compact, inexpensive and portable and comprises a housing configured for self-manipulation and containing a power source, for example, a battery, connected through first and second terminals and suitable electronics, including a current driver and voltage multiplier, with active and ground electrodes.
- a power source for example, a battery
- suitable electronics including a current driver and voltage multiplier, with active and ground electrodes.
- the active electrode is preferably mounted on the end of the device to facilitate manipulation of the device so that the active electrode may engage the applicator against the skin or mucocutaneous membrane.
- the second terminal of the power source is connected with the ground electrode, i.e., a tactile electrode, on the surface of the device for electrical contact with a second skin site, i.e., a portion of the individual's hand engaging and manipulating the device.
- self-manipulation is meant that the individual can engage the device in one hand or a portion thereof and freely orient the device to engage the active electrode of the device through the applicator or directly through medicament against the skin or mucocutaneous membrane generally wherever the treatment site is located and irrespective of whether an applicator is used and, if used, irrespective of whether the applicator is attached to the device or to the individual's skin or mucocutaneous membrane or interposed therebetween with the device subsequently applied to the applicator.
- the metal portions of any electrode construction may be of any of a variety of metals or metallic films, foils, screens, deposits, mesh, paints including but not limited to aluminum, carbon, gold, platinum, silver, silver chloride, copper or steel, specifically surgical or similar fine grade steel, titanium, zinc or alloys of the aforementioned materials.
- These metal materials may also be used as a component of an electrode with a plastic base, form or foundation such as Mylar and the like. It is also possible that if the active and ground electrodes are of dissimilar metals or have different half cell reactions the device may generate part or all of its electrical power by this galvanic couple system of which numerous systems are well known in the art and require no further description.
- surfactants to facilitate the rate of hydration may be employed in, on or about the medicament applicator electrode with materials such as the surfactant Tween 20 or 85, made by ICI America, Neodol 91-6, from Shell Chemical Co., Terigol 15-S-7 from Union Carbide, Pluronic Poloxamer F68 or F127 from BASF or Duponol C or XL made by Dupont Chemical Corp or isopropyl myristate.
- surfactant Tween 20 or 85 made by ICI America, Neodol 91-6, from Shell Chemical Co., Terigol 15-S-7 from Union Carbide, Pluronic Poloxamer F68 or F127 from BASF or Duponol C or XL made by Dupont Chemical Corp or isopropyl myristate.
- the applicator preferably comprises a substrate having a reservoir, e.g., an open-cellular structure, for containing a medicament.
- a reservoir e.g., an open-cellular structure
- This preferred open cellular or porous portion forms a minimum barrier to movement of medicament molecules under the influence of the applied current to transport the medicament molecules into the skin or mucocutaneous membrane.
- the applicator thus forms an electrode for application to the treatment site, e.g., an individual's skin and is preferably applied to the device prior to application of the device and attached applicator to the site. It will be appreciated, however, that the applicator electrode can be applied directly to or adjacent to the treatment site, e.g., by using an adhesive, prior to applying the device to the applicator.
- an adhesive is preferably employed, although other types of securement may be used, such as complementary hook-and-loop fasteners, tabs, post and hole, magnets or the like.
- an electrical circuit is completed through the active electrode of the device, the applicator electrode and the treatment site for return through the individual's skin in electrical contact with the ground electrode of the device upon application of the device and applicator electrode to the treatment site.
- an electrical circuit is completed from the device through the applicator electrode, the treatment site, the individual's torso, arm and hand and the tactile electrode.
- the applicator electrode may have a portion, which overlies the tactile electrode to facilitate the flow of electrical current.
- the applicator portion overlying the tactile electrode may be open cellular or porous and may contain an electrically conductive material, e.g., hydrogel.
- an electrically conductive material e.g., hydrogel.
- the material or the tactile electrode may be employed to further facilitate closure of the current loop in any or all applicator or device embodiments.
- the hydrogel may also have adhesive properties or may contain an adhesive and thereby serve or additionally serve as a mechanism for releasably securing the applicator to the device.
- the medicament may be applied to the applicator by the user just prior to use.
- the medicament can be prepackaged as a unit dose in the applicator electrode.
- the medicament also may take many forms, for example, the medicament may be formulated as a liquid, a gel, an ointment, a dry powder, a lotion, a foam, a solution or a cream.
- it may also be electrically conductive per se, or require ancillary substances to transport the medicament, e.g., an electrically conductive substance such as water or very weak trace saline to provide the necessary electrical conductivity.
- the applicator preferably includes a porous or open multi-cellular pad to which medicament can be supplied by the user just prior to use or in which the medicament may be prepackaged.
- the medicament is not sufficiently electrically conductive per se, or is not part of a hydrophilic formulation
- the user may hydrate the pad of the applicator to render the medicament transportable by the electromotive force of the electrical current flowing through the pad.
- the applicator is releasably secured, e.g., by adhesive, to the device.
- the applicator can be applied directly to the skin or mucocutaneous membrane on or surrounding the treatment site, for example, by employing a releasable adhesive or the inherent tack of the substance included with the applicator electrode.
- the medicament can be prepackaged in the pad of the applicator.
- one or more rupturable capsules containing the medicament can be located in or adjacent to the porous pad, the encapsulation of the medicament affording long shelf life.
- the medicament may be prepackaged in or adjacent to the cells of a porous pad with removable seals for preventing exposure of the medicament to ambient conditions thereby also affording long shelf life.
- different applicators can be prepackaged with different medicaments as required for various treatments.
- the capsule or capsules can be ruptured by the application of pressure to the applicator pad, thereby spreading the medicament in and among the interstices of the pad.
- seals are used in conjunction with a medicament contained in a porous applicator pad, the seals are preferably adhesively secured to the pad and removed. If necessary, the pad can then be hydrated by the user. This may be accomplished using a separate small sterile vial of fluid by which drops of solution are applied. The applicator is then applied by the user to the device or to the skin or mucocutaneous membrane overlying the treatment site or simply interposed between the device and the treatment site.
- both the medicament and an electrical conductor such as water can be encapsulated within the pad.
- pressure for example, finger pressure
- the medicament and hydrating capsules can be ruptured, intermingling the medicament and water within or adjacent to the porous multi-cellular applicator pad, rendering the medicament electrokinetically transportable under the influence of the current flow.
- a fourth alternative includes pre-hydrating the pad and sealing the pre-hydrated pad from the medicament. When the seals are broken, the hydrating material hydrates the medicament, enabling electrokinetic delivery of the medicament.
- the medicament may be encapsulated to isolate it from a pre-hydrated pad.
- a sixth alternative is to encapsulate the hydration material, e.g., water or water containing electrolytes to enhance conductivity and medicament transport.
- a seventh alternative is to package the medicament with a hydroscopic material which will allow it to pick up water from the air once it has been removed from its protective packaging.
- the pad containing the electrically conductive medicament or medicament hydrated to afford electrical conductivity through the pad affords a minimum barrier to the movement of the medicament molecules into the treatment site under the electromotive force applied by the completion of the electrical current.
- the substrate or pad is preferably thin and highly porous.
- the pad should be comfortable to the user and if possible be somewhat flexible so as to conform to the treatment site, providing full contact coverage when in place, e.g., fabrics, absorbent gels, cotton or open celled foam.
- the pad should also have sufficient interstices or open cells, i.e., porosity, to hold quantities of the electrically conductive medicament or the medicament and hydrating material to afford efficacious treatment, e.g., of herpes treatment sites, over a period of time, for example, up to 15 minutes. For most treatments, the period of application is limited, for example, within a range of 1-30 minutes.
- the hydrating material is preferably water or a very weak trace saline solution lying within a range of 0.001-0.1%.
- polypropylene glycol, polyethylene glycol or polyvinyl glycol may be used.
- the applicator electrode must be void of any short-circuit paths.
- the applicator includes a hydrogel on an applicator portion overlying the tactile electrode of the device
- the hydrogel must be electrically insulated from the active electrode and the conductive or hydrated medicament in the pad to ensure that the circuit is completed through the individual's skin rather than merely short-circuited through the device and applicator electrode.
- the distance between the medicament containing electrically conductive portion and the hydrogel serves as an electrical insulator, particularly where the substrate therebetween is non-wicking.
- distance between the active and ground electrodes of the device serve the same purpose.
- Additional physical barriers may be provided, e.g., spaces, openings, valleys and ridges of non-conductive material on either or both the device and the applicator electrode. When both are employed they may be of a complementary nature, e.g., a valley on the device and a ridge on the applicator electrode. A portion of the barrier may also be hydrophilic so as to absorb any of the small amounts of hydration material which may be employed.
- the applicator may contain a magnet for activating and deactivating the power supply in the device. Consequently, when the applicator electrode is applied to the device or to the treatment site and the device is applied to the applicator, the magnet cooperates with the internal electronics of the device to activate the device. Conversely, upon removal of the applicator from the device or the device from the applicator, the magnet in the electrode deactivates the electrical circuit.
- Other conventional switching means may also be employed, e.g., toggle, twist or push types or the magnet may be separate from the applicator.
- the applicator may also contain a code carrying system, e.g., bar code or another state of the art system, which when attached to the hand-held device, programs the device to deliver the correct amount of medicament.
- a code carrying system e.g., bar code or another state of the art system
- indicators may be provided on the device to indicate that the device is actuated such that the user can be assured that the medicament is being electromotively driven into the treatment site.
- one or more LEDs may be incorporated in the circuit to indicate activation of the circuit.
- Other indicators or the same indicator in a different mode e.g., solid vs.
- a variable timing device may be incorporated in the electrical circuit. The circuit may be activated for a selected predetermined length of time and automatically deactivated after that time period has lapsed. Alternately, a timer may offer an event signal or series of signals to the user without necessarily reprogramming the time period. For example, if the treatment is interrupted for a brief period of time, the timer may continue timing the treatment provided the interruption is only brief, e.g., a minute or two. If the interruption is prolonged, the timer is automatically reset to provide a period of treatment which is therapeutically effective. Also, a non-ultrasound generated vibration can be added or used in lieu of the LED to indicate working status of the device and that the device lies in a closed current loop via the individual's body surface.
- the applicator may comprise a splint-like strip for releasable securement to an individual's finger with self-contained electronics, a power source and active and ground electrodes formed integrally with the strip.
- the applicator strip may have a rectilinear, square, circular or shaped pad as the active electrode adjacent the individual's fingertip.
- the applicator strip preferably includes a split ring for releasably securing the applicator strip to and along an inside surface of an individual's finger.
- the applicator pad which may be integral with or form a disposable pad for the applicator strip, is in contact with the active electrode adjacent the individual's fingertip for application to the treatment site.
- the strip On the opposite side of the strip from the active electrode and in contact with the user's finger is a ground electrode.
- the batteries within the applicator strip may be air-actuated by removal of a tab overlying battery terminals.
- the user places the one-time use disposable applicator pad adjacent the user's fingertip and against the treatment site. This completes the circuit through the site and the user's skin.
- the strip With the applicator pad separate from the applicator strip, the strip may be reusable with other disposable pads. Alternately, the pad may be a built-in part of the strip with or without pre-packaged medicament and/or hydration means, thereby enabling the whole device disposable.
- the applicator may also be miniaturized to the extent that it may have a thimble-like configuration without a ring and may be frictionally retained on the tip of the individual's finger.
- the applicator may comprise a completely self-contained disposable unit having its own electronic circuitry and power source.
- the applicator may be provided (i) without the medicament and electrically conductive material (e.g., water), (ii) with the medicament in a prepackaged form within the applicator requiring only hydration upon use, if the medicament is not per se electrically conductive, or (iii) with both a medicament and hydration material.
- the applicator in this form may comprise a flexible substrate having a medicament pad on a treatment site side thereof, an optional hydration material layer, overlaid by a first electrode, electronic circuitry including a power source, e.g., a battery, a second electrode and, optionally, a conductive material such as a hydrogel.
- the self-contained disposable unit may be removed from its package by the individual upon contact of the individual's finger with a tacky hydrogel exposed on the unit after the package is opened. This finger contact with slight finger pressure may cause contact between the hydration material and the medicament prior to removal from the package. Also, the finger contact and removal from the package further allows highly intuitive manipulation of the unit to the treatment site and ease of use given the lightweight and compact size of the unit.
- the unit may also be placed in a position where the finger contact is replaced by the contact of another grounding site such as would be the case if, by example the unit were placed in the mouth between the gum and inside mucosal tissue of the mouth or if the unit were placed inside the arm and contacted the upper rib cage or if the unit were designed and formed in a fashion similar to a contact lens for ocular treatments. It should be appreciated that the orientation of the active and ground electrodes and placement of the medicament could be reversed in these or other like uses.
- the battery for the circuit for example, a zinc oxide battery, may be of the type activated by exposure to oxygen.
- a tab overlies battery terminals which, when the tab is removed, exposes the contacts to oxygen thereby activating the battery.
- miniaturized power sources may be provided, e.g., film sheet stacked batteries. It will also be appreciated that the medicament may be applied to the applicator pad by the user after the applicator is unpackaged and, if not per se conductive, the pad may also be hydrated by the user prior to application to the treatment site.
- the medicament may be prepackaged within the pad, for example, in one or more rupturable capsules and if not electrically conductive per se, one or more additional capsules containing hydrating fluid, e.g., a conductive fluid, such as water or saline may be prepackaged in the applicator as well.
- a conductive fluid such as water or saline
- the applicator electrode By squeezing the applicator electrode to rupture the capsule or capsules, the encapsulated medicament and, if necessary, the hydrating fluid, intermingle with one another and provide the necessary electrical conductivity through the applicator pad to enable electromotive transport of the medicament through the skin.
- the grounding electrode lies on the opposite side of the applicator from the active electrode and a circuit is therefore completed through the individual's finger or hand holding the applicator over the treatment site and the individual's arm and torso.
- the top or outer portion of the applicator remote from the medicament pad may contain a conductive hydrogel.
- the applicator comprises a self-contained disposable unit likewise having its own electronic circuitry and power source.
- the active electrode may form a portion of the applicator spaced from an electrically insulated ground electrode also forming part of the applicator.
- the applicator is configured such that the first or active electrode of the applicator lies in electrical contact with the applicator pad (electrode).
- the active applicator electrode is applied to the treatment site and the ground electrode on the applicator is placed in electrical contact with the user's skin.
- An electrical circuit is thereby completed through the applicator, the applicator electrode and the treatment site with the return circuit through the skin, and the ground electrode of the applicator.
- the spacing between the active electrode and the ground electrode in electrical contact with the treatment site and the skin, respectively, can be quite small, i.e., on the order of one-half inch.
- the medicament may be formulated as a liquid, gel, ointment, dry powder, lotion, foam, solution or cream.
- the applicator electrode for use with the device may include an electrically insulative housing, for example, a torus, for containing the liquid.
- a microporous film overlaid by a removable barrier, e.g., foil or inert material adhered to the insulated housing to prevent transfer of the liquid within the applicator electrode externally.
- the opposite side of the insulative housing may likewise be confined by a barrier overlying the housing.
- the insulative housing preferably has tabs for attaching the applicator electrode to the device similarly as previously described.
- a conductive plate may overlie the foil or the applicator electrode may be applied to the device directly with the active electrode of the device in electrical contact with the barrier.
- the active and ground electrodes may be spaced one from the other in a self-contained unit and separated by a malleable or tensioned arm.
- the ground electrode may be adhesively secured to the individual at a location adjacent the medicament delivery device and the active electrode placed in contact with the site.
- the springbiased or malleably tensioned arm holds the active electrode with an optional gimbal component in electrical contact with the treatment site in a fully flush or full contact manner, avoiding only partial contact and hence avoiding less than effective treatment. This permits hands' free electrokinetic delivery of the medicament to the treatment site.
- a self-contained unit having its own electronic circuitry and power source for hands' free application to the treatment site.
- a generally U-shaped clip having opposite ends which mount the ground and active electrodes, respectively, as well as the power source and electronic circuitry, may be applied in a gripping or clamping manner to clip the self-contained unit adjacent the treatment site such that the active electrode engages the treatment site for electrokinetic delivery of the medicament.
- electrokinetic medicament delivery may be applied in an ocular applicator similar to and worn like a contact lens.
- the mechanism of the electrokinetic delivery may be multi-channel, for example, as described and illustrated in U.S. Pat. No. 5,160,316, now Re. 36,626, incorporated herein by reference.
- a delivery device similar to a contact lens may be employed to therapeutically treat the conjunctiva for acute glaucoma using as an example, Xalatan or even to contour the eye by delivering agents that retain H 2 O, such as hyaluronidase or hyaluronic acid, which would swell the conjunctiva in specific sites of the eye.
- Antiviral drugs foscarnet and ganciclovir either alone or in combination may be electrokinetically delivered for treating herpetic eye infections, e.g., cytomegalovirus (CMV) and CMV retinitis. Differential levels of power and agent delivery are possible with the multi-channel delivery. In this manner, the refraction of the light can be modified by changing or altering the shape of the eye/conjunctiva.
- the medicament delivery device may be worn or applied periodically for various time periods, for example, within a range of 1 to 60 minutes.
- the circuitry limits the maximum current available to the applicator electrode to preferably less than about 1 milliampere per two square centimeters of the skin-contacting surface area of the electrode.
- the current level can vary from about 0.1 to about 1.2 milliamps. While higher currents have been used, user discomfort can be experienced. Buffers could be employed to overcome this milliamp range ceiling.
- the electrical current can be ramped up and ramped down, respectively, at the beginning and end of the treatment. See, for example, prior U.S. Pat. No. 5,160,316, now Re. 36,626, the disclosure of which is incorporated herein by reference. Ramping contours of different configurations can be used, for example, linear, non-linear, exponential, pulsed, or otherwise shaped. Also, while direct current is preferred, alternating current can be used.
- facilitators may be employed to minimize or eliminate the barrier to the transfer of the medicament molecules through the skin.
- acetic acid or dimethylsulfoxide (DMSO) alcohols, such as ethanol and isoproanol, ethyalactate, sulphoxides, fatty acids, such as oleic acid, lauric acid, capric acid and caprylic acid, sodium lauryl sulfate, acyl lactylates (except in their salt form), e.g., caprol lactyic acid and lauroyl lactylic acid, esters, (1-dedecylazacycheptan-2-one) (Azone), pyrrolidones, such as dodecyl pyrrolidone, dimethyl lauramide, linear dialiphatic or aliphathic, sulfoxides, unsubstituted or mono or di-substituted amides and di-substituted amines among
- DMSO dimethylsulfox
- a second facilitator or skin permeation enhancer which may be a monoglyceride or mixture of monoglyerides of fatty acids such as glycerol monolaurate (GML) or glycerol monooleate (GMO), lauramide diethanolamine (LDEA), or esters of fatty acids having from 10 to 20 carbon atoms.
- GML glycerol monolaurate
- GMO glycerol monooleate
- LDEA lauramide diethanolamine
- esters of fatty acids having from 10 to 20 carbon atoms By using these substances, the skin can be disrupted, enhancing the exposure of the dermis to electrokinetic forces.
- Another type of facilitator is a component which may encase a given molecule within a lipid barrier but makes it less polar and thereby facilitates penetration of the skin by the medicament.
- An example is gylcesol or phospholipids such as phosphaticylcholine.
- the device and applicator requires minimal instruction. Where the medicament is prepackaged with the applicator, there are no concerns regarding the dosage as a single unit dosage which is therapeutically effective over the period of application is provided. Moreover, the device and applicator do not require any calibration or settings as the supply of current is fixed by the device electronics. Further, there is no second or ground electrode separate from the device whereby the device is easily used without a separate ground electrode.
- the power source may be limited to providing only single use longevity. Thus, the power supply may be replaced when a device is reused or the device itself may be discarded. Numerous components may be constructed and linked for short life cycle upon use without negating a prior long shelf life. The applicator and even the device per se are readily disposable.
- an electrokinetic delivery system for personal use in self-administration of a medicament to a treatment site on an individual, comprising a device for releasable securement to an individual's finger and shaped in part to conform to at least a portion of the individual's finger, at least one of an electrically conductive medicament or a medicament with an electrically conductive carrier therefor, a retainer for releasably securing the device to the individual's finger, a self-contained power source carried by the device, a first electrode carried by the device adjacent a distal end portion thereof and adjacent the tip of the individual's finger upon retention of the device on the individual's finger, the first electrode being in electrical contact with the power source, a second electrode carried by the device for electrical contact with a portion of the individual's finger, the second electrode being in electrical contact with the power source whereby, upon application of the first electrode to a treatment site with the at least one medicament interposed between the first electrode and the treatment site and completion of
- a method of treatment by electrokinetic self-administration of a medicament into a treatment site for an individual comprising providing a device shaped in part to conform to at least a portion of an individual's finger and having a self-contained power source, first and second electrodes, and a substrate in electrical contact with the first electrode and having an exposed contact surface, providing at least one of an electrokinetically transportable medicament or a medicament with an electrically conductive carrier therefor, releasably retaining the device on the individual's finger, with the second electrode in electrical contact with the individual's finger, providing the at least one medicament in contact with the substrate or the treatment site, while the device remains retained on the individual's finger, placing the contact surface of the substrate into contact with the individual's treatment site and causing electrical current to flow through the first electrode, the electrically transportable medicament or the conductive carrier, the treatment site, the individual's body, the second electrode and the power source to electrokinetically drive the medicament into the treatment site.
- a delivery device for self-administration of a substance to a treatment site on an individual, comprising a self-contained disposable applicator including a pad for containing the substance, a power supply, a first electrode overlying the pad and electrically connected to the power supply and a second electrode having a tactile surface in electrical contact with the power supply and lying on a side of the applicator remote from the pad, the second electrode having an electrically conductive material overlying the tactile surface, whereby, upon the individual's hand or a portion thereof in contact with the tactile surface of the second electrode holding the applicator pad against the treatment site, an electrical circuit is completed between the first electrode through the treatment site and the second electrode via the tactile surface, the electrically conductive material and the individual's hand and body for electrokinetically driving the substance into the treatment site.
- FIG. 1 is a schematic illustration of an electrokinetic medicament delivery device for use with an applicator in accordance with the present invention
- FIG. 2 is a perspective view of the device with the applicator applied thereto;
- FIG. 2A is a view similar to FIG. 2 of a modified form of the device and applicator
- FIG. 3 is a perspective view illustrating the device and applicator in use by an individual and being applied to a lesion on the individual's chin;
- FIG. 4 is a plan view of an applicator from the skin side
- FIG. 5 is a plan view of the applicator from the device side
- FIG. 6 is an exploded side elevational view illustrating the various parts of the applicator
- FIGS. 7 and 8 are views of the applicator pad, respectively, illustrating an encapsulated medicament and a combination of encapsulated medicament and hydration fluid within the applicator pad;
- FIG. 9 is a perspective view of a splint-like strip forming a self-contained applicator electrode in accordance with a further embodiment of the present invention.
- FIG. 9A is a view similar to FIG. 9 illustrating a further form of the strip of FIG. 9 ;
- FIG. 10 is a schematic view of an electrical circuit for use with the applicator electrode of FIG. 9 ;
- FIGS. 11A, 11B and 11 C are schematic representations of a self-contained applicator illustrating the layers of the applicator within a packaging material
- FIG. 12 is a schematic representation of an applicator in accordance with a further embodiment of the present invention.
- FIGS. 13 and 14 are preferred forms of the applicator of FIG. 12 with an encapsulated medicament illustrated in FIG. 13 and encapsulated medicament and hydrating fluid illustrated in FIG. 14 ;
- FIG. 15 is a side elevational view of a further form of the present invention.
- FIG. 16 is an exploded schematic view of a still further form of applicator electrode in accordance with the present invention.
- FIG. 17 is a fragmentary view of the applicator of FIG. 16 applied to the end of a device
- FIG. 18 is an illustration of a hands' free electrokinetic medicament delivery device
- FIG. 19 is a schematic illustration of a still further hands' free electrokinetic delivery device according to the present invention.
- FIG. 20 is a perspective view of a further form of an applicator, illustrated with its packaging, for use with an electrokinetic delivery device;
- FIG. 21 is a view of the applicator of FIG. 20 without its packaging
- FIG. 22 is a schematic illustration of the applicator of FIGS. 20 and 21 applied to the electrokinetic device
- FIG. 23 is a perspective view of the device with the applicator applied ready for use
- FIG. 24 is a schematic representation of an alarm system for misplacement of the probe.
- FIG. 25 is a schematic illustration of an electrokinetic applicator in the form of a sock for treatment of fungal infestations between the toes;
- FIG. 26 is a view similar to FIG. 25 illustrating an electrokinetic applicator for treatment of a nail bed fungal infestation
- FIG. 27 is a schematic representation of a device for electrokinetically treating a fungal infestation of the nail beds of an individual's fingers
- FIG. 28 is a schematic illustration of the electronics and thimble pad applicator of the device of FIG. 27 ;
- FIG. 29 is a schematic representation of a device for electrokinetic ocular treatment
- FIG. 30 is a side elevational view of an ocular applicator according to this aspect of the invention.
- FIG. 31 is a planar view of the ocular applicator illustrating the multi-channel conductors.
- the device 10 includes an outer housing 12 containing a power source, for example, a battery 14 , and electronic circuitry including a voltage multiplier 16 and a current driver 18 .
- battery 14 includes a first terminal 20 and a second terminal 22 .
- the first terminal 20 is coupled to the voltage multiplier 16 which steps up the voltage supplied by the battery 14 and applies the stepped-up voltage to the current driver 18 .
- Current driver 18 is in contact with a first or active electrode 24 exposed through housing 12 , preferably at an end thereof.
- the second terminal 22 is in contact via a spring 26 and a conductor 28 , with a ground or tactile electrode 30 also exposed through housing 12 , preferably along a side wall thereof.
- housing 12 is sized and configured to be held within an individual's hand for orientation such that the first or active electrode 24 can be in electrical contact with a treatment site through a conductive medicament-containing pad of an applicator, described below.
- the housing 12 may be of a cylindrical form, with the first or active electrode 24 at one end of the cylinder.
- housing 12 can assume other shapes to facilitate the purposes of device 10 , namely to provide a portable, self-contained device having an integral power source which, in conjunction with the applicator, may electrokinetically drive medicament through an individual's skin or mucocutaneous membrane into a treatment site when the applicator and device are applied to and overlie the treatment site.
- the housing 12 a may have a bend intermediate its opposite ends forming a handle 32 at one end having a tactile ground electrode 30 a exposed through the handle. The opposite end terminates in an active or first electrode 24 a similarly as in FIG. 1 .
- the handle 32 forms a grip for orienting and manipulating the device 10 a relative to the treatment site.
- the circuitry limits the maximum current available to the applicator to preferably less than about 1 milliampere per two square centimeters of the treatment site-contacting surface area of the applicator. However, depending upon the working surface of the applicator pad in contact with the site, the current level can vary from about 0.1 to about 1.2 milliamps per two square centimeters to avoid minor discomfort and deleterious side effects. These limitations also apply to each channel of a multi-channel device as discussed herein with reference to U.S. Pat. No. 5,160,316, now Re. 36,626.
- the hand-held device 10 and 10 a may be modified to include a piezoelectric element 19 for imparting ultrasonic vibrational motion to the active electrode 24 to further facilitate transdermal or transmucocutaneous delivery of electrokinetically transportable substances, e.g., medicaments.
- the piezoelectric element 19 is located on the active electrode 24 . Power is supplied to energize the piezoelectric element 19 by a conductor 21 connected with the tactile electrode 30 , the piezoelectric element 19 being in electrical contact with the active electrode 24 .
- An optional switching element may be used to energize the piezoelectric element or not, as desired, depending upon the particular treatment mode.
- applicator 40 having a treatment site-contacting side and a device-contacting side as illustrated, respectively, in FIGS. 4 and 5 .
- applicator 40 includes a substrate 42 formed of a porous open cellular material.
- a suitable substrate material may comprise a fabric manufactured by Cerex of Pensacola, Fla., identified as Type DN, Group DN07&DN15.
- Other suitable types of materials may also be used, provided those materials, at least in the portion of the substrate through which the medicament will be transported to the treatment site, constitute a minimum barrier to the transfer of the medicament molecules from the applicator to the site.
- a pad 44 surrounded by a containment barrier 46 .
- the pad may likewise comprise a porous open-cellular material similar to the substrate but preferably comprises a more dense material such as cotton for retaining the medicament.
- Cotton is sufficiently porous and open-cellular to enable the medicament to be electromotively driven from the cotton pad into the site. It will be appreciated that the pad 44 should be inert to the medicament, as well as non-corrosive and stable when in contact with the medicament. While cotton is preferred, other suitable materials may include plastic pads such as polyethylene, paper, porous ceramics, open-celled porous polytetrafluoroethylene, polyurethane or other plastics, as well as open-celled silicone rubber and vinyl.
- the containment barrier 46 is formed of a non-electrically conductive material, which prevents the medicament from weeping or wicking onto portions of the substrate adjacent the medicament pad.
- barrier 46 comprises a closed-cell foam, for example, a foam manufactured by Avery Dennison of Pasadena, Calif., identified as Avery Foam Med 5637. While not shown, the foam is preferably adhesively secured to the substrate 42 with margins of the pad 44 frictionally or adhesively retained within the peripheral confines of the barrier 46 .
- a flap 48 overlies the exposed side of the pad and is preferably adhesively secured along one side to one side of the barrier 46 such that the pad 44 can be exposed by lifting or removing the flap.
- the pad 44 may be incorporated or embedded in the substrate 42 .
- the pad 44 may reside in a cutout portion in the substrate.
- the substrate extends to form wings 52 for releasably securing the applicator to the device.
- a releasable contact adhesive 50 is applied to the applicator wings 52 for releasably securing the applicator to the device 10 .
- the applicator 40 illustrated in the form of a strip has a central portion of the strip, i.e., the pad 44 , overlying the active electrode 24 at the end of housing 10 with the applicator wings 52 folded along opposite sides of the housing 10 and releasably secured thereto by the adhesive 50 .
- a release liner 54 is provided on the device side of the applicator overlying adhesive 50 and which liner 54 is removed by the user upon application of the applicator to the device. It will be appreciated that other methods of releasably securing the applicator to the device may be employed. For example, hook-and-loop type fasteners may be used with the hooks or loops on the device and the loops or hooks on the applicator. Magnets or spring clips or other mechanical-type fasteners may be employed.
- the applicator as illustrated in FIGS. 4-6 is also illustrated in the form of a strip similar to a Band-Aid. It will be appreciated, however, that other configurations and shapes of the applicator may be employed, depending upon the configuration of the device.
- an applicator 40 a having a pad formed of similar material as pad 44 may be employed for use with device 10 a of FIG. 2A .
- Applicator 40 a may be formed in a circular configuration without wings and may be adhesively or otherwise secured to the active electrode 24 a of housing 12 a .
- the peripheral margin of the applicator 40 a may have a releasable adhesive for releasable securement to the active electrode 24 a on the end of device 10 a .
- the applicator need not have conductive portions overlying the ground electrode 30 a .
- the applicator is formed of a flexible material generally conformable to the treatment site surfaces to the extent possible given the shape of the active electrode 24 , 24 a on the device 10 , 10 a.
- the applicator 40 is intended for a single use. That is, once the medicament has been electrokinetically driven from pad 44 into the site, the applicator may be removed from the device or the site and discarded. Where the medicament is prepackaged with the applicator, a coloring agent can be employed, such as iodine, which turns color upon contact with the starch in the open-celled material to visibly indicate that unit dose medicament has been used. Other types of coloring agents can be used to indicate usage of the applicator, e.g., pH indicators, wet saturation indicators or oxidizable pigments.
- the applicator may be provided to the user without medicament within the applicator pad 44 .
- the user may apply the medicament to the applicator pad 44 such that the medicament lies within the interstices of the material of the pad 44 .
- the pad containing the medicament may be hydrated by the application of water, for example, by using an eyedropper.
- the medicament is supplied and prepackaged with the applicator.
- the medicament may be contained within a rupturable polymer reservoir or capsule 56 , as illustrated in FIG. 7 . By encapsulating the medicament, a long shelf-life is assured.
- the capsule 56 can be ruptured by applying pressure to the pad 44 , for example, by pressing the pad between the individual's fingers or against the active electrode when the applicator is applied to device 10 , or against a surface of packaging in which one or more of the applicators are provided. By rupturing the capsule, the medicament permeates the interstices of the pad 44 . If the medicament requires hydration to afford electromotive transport into the treatment site, e.g., a lesion upon application of the electric current, the user may hydrate the pad similarly as previously described. Alternatively, an additional one or more capsules containing hydrating material, e.g., water or saline, may be prepackaged with the applicator.
- hydrating material e.g., water or saline
- the pad 44 includes one or more medicament capsules 56 and one or more hydration capsules. 58 .
- the capsules may be ruptured and the medicament and hydration material intermingled with one another within the interstices of the pad 44 , rendering the applicator pad susceptible to conducting current for the electrokinetic delivery of the medicament to the lesion.
- a magnet 60 is preferably incorporated into the substrate 42 on one or opposite sides of the pad 44 .
- the electrical circuit in the device may therefore include a magnetic field responsive switch for actuating and deactuating the electrical circuit.
- the circuit is activated and when removed, the circuit is deactivated.
- a conductive gel may be provided within the wings 52 of the porous substrate 42 .
- the wings 52 of the substrate overlie the tactile electrode 30 of the housing 10 .
- the conductive gel thus facilitates electrical conductivity between the individual's fingers or hand overlying the wing portions of the applicator and the tactile electrode 30 to complete the circuit.
- the cells of the substrate on one or both wings 52 may be provided with a conductive substance, e.g., a hydrogel. These wings with hydrogel are electrically insulated from the pad 44 and the medicament.
- electrical insulating barriers may be provided between the pad 44 and the conductive wing or wings. Such barriers may comprise substantial spacing between the pad and wing with non-conductive material therebetween or physical barriers such as openings, ridges or valleys in the substrate portions interconnecting the pad 44 and the one or more wings of conductive material.
- the applicator 40 is preferably applied to the device by aligning the pad 44 with the active electrode 24 on the end of housing 12 .
- the wings of the applicator are folded along opposite sides of the device and adhered or held to the device overlying the ground electrode 30 .
- the substrate being at least partially open celled, porous, or cutout, e.g., to contain medicament in gel, solution, cream, foam, ointment or liquid form, the individual's fingers pressing against the substrate and/or the tactile electrode 30 complete an electric circuit path between the device and the individual.
- hydrogel facilitates the completion of the circuit between the individual's hand or finger and the tactile electrode. Whether hydrogel is employed or not the individual may add water to his/her fingers or hand, thus facilitating electrical conductivity.
- the applicator 40 applied to the device the device is actuated, for example, by locating the magnet 60 in a position to close the magnetic switch within the electrical circuit. A conventional on/off switch may be used in lieu of the magnetic switch.
- the active electrode 24 is also in electrical contact with the medicament containing pad 44 by contact therewith. By manipulating the device, the pad 44 of the applicator is brought into the contact with the treatment site on the individual's skin.
- the applicator 40 a may be secured to the end of housing 12 a overlying the active electrode 24 a or applied to the treatment site.
- the individual holding the device 10 a makes electrical contact with the ground electrode 30 a of the handle 32 by grasping the handle. To ensure good electrical contact, the individual may also add water to his/her fingers or hand.
- the device 10 a is then manipulated to contact the active electrode 24 a through the applicator 40 a with the treatment site thereby completing the electrical circuit similarly as in the embodiment of FIG. 2 .
- the device per se may also be applied to a treatment site without a medicament, e.g., without use of the applicator 40 or 40 a .
- the current delivered to the treatment site by the device alone or with or without ultrasonic application or enhancement has beneficial and healing effects in the treatment of the various maladies noted previously.
- the self-contained unit includes a semi-flexible substrate 72 , for example, formed of a plastic material, for underlying an individual's finger and shaped according to the inside surface of an individual's finger.
- the substrate 72 passes along one or more of the finger joints.
- the substrate 72 includes batteries 74 , for example, conventional zinc oxide batteries which may be actuated by removal of a tab exposing battery contacts to the atmosphere.
- the substrate 72 includes electronics 76 for supplying a flow of current to an active electrode 78 carried at the fingertip end of the substrate 72 and angled relative to the linear extent of substrate 72 .
- the active electrode 78 is electrically coupled to the electronics 76 and batteries 74 .
- a ground electrode is electrically coupled to the other terminal of batteries 74 and is electrically insulated from the active electrode 78 .
- the ground electrode 80 may comprise a flexible material, portions of which may be in the form of a split ring 82 . Thus, the full length of the individual's finger may be in contact with the ground electrode, affording a good electrically conductive contact therewith.
- a retainer for example, a retaining strap 73
- the retaining strap 73 may include semi-rigid arcuate split ring portions, a full ring integral with substrate 72 or a flexible strap with fasteners to secure the strap ends to one another, for example, hook-and-loop type fasteners.
- FIG. 9A A similar self-contained unit 70 a is illustrated in FIG. 9A wherein like parts are designated by like reference numerals followed by the suffix “a.”
- the substrate 72 a extends along the underside of an individual's finger but only along the finger from its tip, past the first joint and terminating short of the second joint.
- substrate 72 a includes batteries 74 a , electronics 76 a , an active electrode 78 a at the fingertip, and a ground electrode 80 a including split ring 82 a .
- the tip 71 of the substrate 72 a may curve back over the fingertip to assist in securing the substrate to the fingertip.
- the electronic circuitry for the applicator electrodes 70 and 70 a of FIGS. 9 and 9 A is illustrated in FIG. 10 and which circuitry is applicable to all embodiments hereof.
- the power supply for the device 70 includes an air-activated battery 74 , coupled through a voltage booster 75 by way of an optional low battery indicator 77 .
- the air-activated batteries may be replaceable and other types of small batteries, such as lithium disks, could be used.
- the voltage booster 75 is connected to a servo controlled current source 79 and, optionally, to a current-monitor 81 .
- the current source 79 is electrically coupled to a current limiter 83 for limiting the current applied to the active electrode within the limits previously discussed.
- the current limiter 83 is coupled to the treatment electrode 78 .
- the treatment electrode is illustrated as applied to the treatment site, e.g., a lesion, through a medicament pad 44 a .
- the ground electrode is also illustrated as applied to the skin by way of an optional electrically conductive hydrogel 85 .
- the medicament pad 44 a may be releasably or permanently secured to the device 70 , preferably in overlying relation to the active electrode 78 .
- the device 70 may be a one-time-use disposable or, if the pad is separate, the device 70 may be reused with additional pads.
- the overlying pad 44 a may contain a prepackaged medicament M or any of the alternative combinations of pad, medicaments and hydration disclosed in this application.
- the pad 44 a may be provided in a separate package with the medicament in capsulated form as previously described. In either case, the medicament pad is applied between the active electrode 78 and the treatment site. By removing the tab overlying the battery terminals, the power supply is activated. This may be accomplished when opening the packaging or upon removal of the device from the packaging. When the active electrode 78 is placed in contact overlying the treatment site surface, the circuit is completed through the individual's body, including the finger in contact with the ground electrode.
- the applicator 70 is preferably a single-use applicator which may be discarded after use.
- the substrate 72 may be shaped in the form of a thimble for overlying the entirety of the fingertip of the individual.
- the electronics 76 and batteries 74 may be formed on the back side of the thimble opposite the side containing the active electrode, with the ground electrode lying along the inside surface of the thimble and electrically insulated from the active electrode.
- the applicator hereof comprised of a completely self-contained disposable unit or applicator 90 integrally containing the electronic circuitry and a power source.
- the applicator is prepackaged for one-time usage.
- the applicator 90 comprises a pad 92 for containing the medicament and, if necessary, a hydrating fluid.
- the first active electrode 94 electrically connected to electronics 96 within the applicator and which electronics 96 includes a power supply, for example, a battery, and the necessary electronics for flowing a current of a magnitude previously discussed through the pad to electrokinetically drive the medicament into the treatment site.
- a ground electrode 98 Overlying the electronics is a ground electrode 98 , the surface of which remote from pad 92 comprises a tactile surface. Illustrated by the dashed lines is a packaging material 100 , for example, plastic packaging typically employed for sterilized packages whereby the applicator 90 may be sealed within the material 100 . With the medicament prepackaged within the pad 92 , the user opens the package 90 . In a preferred form, the applicator 90 is connected with the packaging 100 via a tab 102 . By removing the applicator 90 from or opening the packaging material 100 , the tab 102 uncovers the battery terminals whereby the power supply is activated. In FIG. 11A , the applicator is provided without the medicament.
- the user applies the medicament to the pad, hydrates the pad if necessary, and applies the applicator to the treatment site.
- an electrical circuit is completed through the individual's finger and body and through the first electrode, the pad and treatment site whereby the medicament within the pad is electromotively transported to the site.
- the ground electrode may have an electrical conducting fluid, e.g., hydrogel, overlying its tactile surface.
- both the medicament and the hydrating fluid is self-contained in the pad.
- the medicament and the hydrating fluid can be provided in capsules rupturable by pressure applied between the opposite surfaces of the pad before, during or after removal of the applicator from the package 100 .
- a very weak, e.g., less than 0.05% saline solution encapsulated and integrated between the active foil electrode 94 and the medicament with or without a porous matrix reservoir interposed between the encapsulated hydration fluid and the medicament may be employed.
- adhesively attached or otherwise releasably attached seals for sealing the medicament and the hydration fluid, if necessary, to the applicator to ensure long shelf life and integrity of the foil electrode can be provided.
- the unit of FIGS. 11A-11C may have a tacky substance, e.g., hydrogel, not shown, overlying the ground electrode 98 within the package 100 .
- a tacky substance e.g., hydrogel
- the individual may contact his/her finger on the tacky substance, facilitating removal of the unit from the package 100 .
- This finger contact on the ground electrode side of the unit also facilitates ready, direct and intuitive manipulation and application of the unit to the treatment site by the individual.
- applicator body or substrate 110 which comprises a self-contained disposable unit having integral miniaturized electronic circuitry and a power source.
- the applicator may comprise a rectilinear or circular article having a centrally located pad 111 and electronic circuitry superposed over the pad.
- a first or active electrode 112 overlies the pad and the electronics previously described may overlie the first electrode.
- the battery 116 may overlie the electronics.
- the first terminal of the battery is connected through the electronics with the first electrode which, in turn, is in electrical contact with the pad 111 .
- the second terminal of the battery is in contact with a ground electrode 118 .
- the ground electrode may be provided around the margin of the applicator surrounding the pad.
- the ground electrode may comprise an annulus surrounding and electrically insulated from the pad 111 .
- the ground electrode may comprise the margin of the rectilinear applicator or lie at one end of the applicator.
- the electrical circuit is completed between the ground electrode and the pad.
- the distance between the ground electrode and the pad may be on the order of one-half inch or more.
- the ground electrode need not surround the pad but may be located to one side of the pad a suitable distance from the pad for completing the return circuit path through the skin between the treatment site and the ground electrode.
- the pad may be provided without the medicament and the user may apply the medicament to the pad upon removal of release liner 120 .
- the battery may be of the air-actuated type previously discussed.
- the user upon applying the medicament to the pad and removing the tab from the battery, may apply the applicator over the lesion, holding both the ground electrode about or spaced from the treatment site and the pad in contact with the treatment site. This completes the electrical circuit through the applicator and the individual's skin between the ground contacting surface and pad contacting surface.
- adhesive may be provided on the underside of the applicator body 110 and overlaid by the release liner 120 to releasably adhere the applicator including the pad 111 and ground electrode 118 to the individual's skin and overlying the treatment site. Upon completion of the treatment, the applicator may be discarded.
- the applicator may be prepackaged with the medicament encapsulated within the pad.
- the capsule is indicated at 122 .
- the individual may apply pressure to the pad to rupture the capsule, spreading the medicament into the interstices of the pad. This can be accomplished while the applicator remains in its packaging.
- the circuit is completed whereby the medicament is electrokinetically driven into the site.
- both the medicament and a hydrating fluid are encapsulated in the pad.
- the medicament and hydration fluid capsules are indicated at 122 and 124 , respectively.
- the applicator of FIG. 14 is employed similarly as described with respect to FIGS. 12 and 13 after the user ruptures the capsules to intermingle the electrically conductive water and the medicament.
- FIG. 15 there is illustrated a device 130 similar to the device of FIG. 1 and containing a power source, electronic circuitry including a voltage multiplier and a current driver and a tactile electrode 132 exposed through an outer surface of the device 130 .
- the active electrode 134 is mounted on the device 130 for movement in an axial direction. The movement is designed to open or close a pressure actuated switch in the electronic circuitry to activate the device.
- the active electrode 134 in an outermost position maintains the electronic circuitry in an off condition. Pressure applied to the first or active electrode 134 tending to displace it toward the device housing closes the switch, activating the electronic circuitry for electrokinetic delivery of the medicament.
- the distal face of the first electrode 134 may be provided with an electrical insulator ring 136 defining and surrounding a reservoir 138 .
- the medicament can be supplied from an ancillary tube, jar or the like in the form of a gel, cream, foam or the like and disposed by the user into the reservoir 138 within the insulating ring 136 prior to use.
- the device With the reservoir filled with medicament, the device can be applied to the treatment site similarly as the device of FIG. 2 is applied to the treatment site. By applying a slight pressure on the device toward the treatment site, the electrical circuit is closed.
- the medicament within the reservoir is electrokinetically motivated into the treatment site, the electrical circuit being completed through the treatment site, with the medicament, the first electrode 134 , the electronics, the tactile electrode 132 and the individual's hand and skin between the tactile electrode and the treatment site.
- an applicator in accordance with the present invention, may be used in conjunction with the device illustrated in FIG. 1 and which applicator is particularly useful for electrokinetically delivering a liquid medicament.
- the applicator 150 may comprise an insulated annular housing 152 in the form of a torus having a central reservoir 154 for confining the liquid.
- One side of the housing 152 comprises a microporous film 156 overlaid by a barrier, e.g., foil or inert tab 158 .
- the margin of the tab 158 has releasable adhesive 160 such that the barrier can be releasably attached to one side of the housing 152 .
- the barrier tab includes a finger tab 162 for ready removal of the barrier 158 from the applicator.
- the opposite end of the reservoir 154 is closed by a similar barrier layer 164 or by an optional conductive plate 166 .
- tabs 168 are secured along opposite sides of the housing 152 for releasably securing the housing 152 to the device, e.g., illustrated in FIG. 1 .
- the active electrode of the device bears against the optional conductive plate 166 which conducts electricity through the barrier layer 164 into the liquid medicament in the reservoir 154 .
- the liquid medicament when applied to the treatment site can be electrokinetically driven into the treatment site through the microporous film 156 .
- the liquid within the reservoir may be per se conductive or, if not conductive, may be provided with a carrier whereby the medicament can be driven through the porous membrane 156 into the treatment site.
- the ground electrode and the active electrode are separated one from the other by a malleable or tensionable arm 180 .
- the ground electrode 182 may be provided in a housing also containing the battery 184 and electronics 186 .
- the ground electrode 182 may be surrounded by an adhesive 188 for adhering the ground electrode to a site on an individual directly adjacent a treatment site.
- the active electrode 190 is connected to the battery and electronics via an electrical conductor indicated by the dashed lines 192 through an arm 180 .
- the arm may be flexed resiliently and retained in its flexed position.
- the ground electrode is adhered to the individual's-skin adjacent a treatment site by the adhesive 188 .
- the arm 180 is then flexed resiliently to engage the active electrode 190 with the treatment site.
- the entire surface of the active electrode 190 may contact the treatment site thereby avoiding less than effective treatment.
- a biased gimbal or pivotal connection between the arm 180 and the ground electrode 182 may also be employed rather than a resilient flexible arm 180 .
- the user may apply the device and have it operate hands' free, the electronics being activated by activation of the battery as previously described.
- FIG. 19 a similar type of hands' free electrokinetic medicament delivery device is illustrated in the form of an U-shaped clip.
- the ground and active electrodes 192 , 194 are placed at opposite distal ends of a clip 196 , preferably a spring clip.
- the clip may be applied to gently grip the treatment site, employing the tension of the clip to retain the clip on the treatment site whereby hands' free delivery of the medicament can be accomplished.
- the fully disposable U-shaped clip may have a built in unit dose applicator or may be reusable if fitted out for use with disposable applicators.
- Applicator 200 for use with an electrokinetic delivery device 202 ( FIGS. 22 and 23 ) illustrated in a flat configuration and within packaging 204 , for example, a plastic sealed package.
- Applicator 200 includes a flattened sleeve 206 open at its opposite ends and having an applicator pad 208 forming part of the sleeve and projecting from one end of the sleeve and along an edge thereof.
- the applicator pad 208 is circular in form, for reasons which will become apparent and is hinged to sleeve 200 along a hinge line 209 .
- the pad 208 is preferably a porous open cellular material through which the medicament may be transported to the treatment site.
- the pad 208 may contain the medicament within the pad within the interstices of the open cellular material or the medicament may be encapsulated within rupturable capsules 210 , similarly as illustrated with respect to FIGS. 7 and 8 .
- a further alternative provides a pad without medicament, the medicament, and hydration material, if necessary, being applied to the pad by the user at the time the user employs the device to electrokinetically deliver the medicament to the treatment site.
- the pad 208 may additionally contain hydration material in a hydration capsule 212 similarly as illustrated in FIG. 8 in the event the medicament is not per se electrokinetically transportable.
- the sleeve 206 is preferably formed of a fabric material similarly as the material of substrate 42 .
- suitable materials may be employed forming all or part of the sleeve, i.e., the substrate of any of the applicators disclosed herein may include, polyethylene, paper, cotton, ceramic, silicone rubber, polyurethane, vinyl, polytetrafluoroethlene and other plastics.
- a suitable barrier may be disposed between the pad 208 and the sleeve 206 to prevent migration of the medicament onto the sleeve or migration of any electrically conductive material such as hydrogel as noted below from the sleeve 206 onto the pad 208 .
- Opposite sides of the sleeve 200 may have cutouts 214 which open through the end of sleeve 206 opposite the pad 208 or which may be completely enclosed cutouts. Particularly, the cutouts 214 lie at circumferential positions about the sleeve 206 corresponding to the axial and circumferential positions of the tactile electrode, for example, electrode 30 as illustrated in FIG. 1 . Additionally, a tab 216 , preferably having a pressure sensitive adhesive on one face, projects from the pad 208 opposite from its connection with the sleeve 206 .
- the packaging 204 is removed from the applicator 200 .
- the pad may be compressed between the individual's fingers to rupture the capsule 210 and hence spread the medicament into the interstices of the pad.
- the hydration capsule 212 is likewise ruptured to mix the medicament and hydration material such that upon application of electric current, the medicament may be transported to the treatment site. If, of course, the medicament has previously been applied to the pad, the user need not compress the pad. Alternatively, if the pad contains no medicament, the user may apply the medicament to the pad and hydration material, e.g., water or a trace saline solution, if necessary.
- pressure applied in the direction of the illustrated arrows will form the flat applicator sleeve 206 into a cylinder for reception about the end of the electrokinetic delivery device mounting the active electrode, for example, the device illustrated in FIG. 1 .
- the cutouts 214 are aligned with the tactile electrode along the sides of the device 202 .
- the pad 208 is folded over the active electrode at the end of the device 202 and the adhesive tab secures the pad 208 in contact with the active electrode. The user may then grasp the device 202 with the user's fingers pressed against the tactile electrode of the device 202 to complete the electrical circuit, as previously described.
- the sleeve 206 may have, instead of cutouts 214 , areas impregnated with hydrogel to facilitate electrical contact between the individual's fingers and the tactile electrode of the electrokinetic delivery device.
- auxiliary hydration material e.g., water may be employed.
- the sleeve may also contain magnetic switch activation material.
- the above mechanisms may be monopolar or multi-channel (as in U.S. Pat. No. 5,160,316, now Re. 36,626, incorporated herein by reference), or hybrid multi-channel in nature.
- hybrid multi-channel it is meant that only one current driver is employed while more than one current limiter is employed to a corresponding number of two or more current distributive channels.
- electrokinetic devices e.g., iontophoretic devices
- iontophoretic devices is non-uniformity in contact pressure between the treatment surface and the active electrode surface. For a self-medicating patient using a probe-type iontophoretic device, if the probe is accidentally held at an oblique angle, non-uniform contact pressure occurs.
- the local electric resistance is low and therefore more current flows in this small area.
- the resulting current concentration not only prevents a uniform delivery of medicament but also can cause discomfort and even burns due to a high local current density. This detrimental occurrence can be prevented (for example, by using a multi-channel design (segmented electrode).
- the contact pressure becomes uneven, the resistance of each channel or segment varies.
- the current flowing in each channel remains constant due to servo control.
- the bias potential or voltage of each channel will change.
- the bias potential will decrease. Based on this decrease in bias potential, an early warning signal for uneven probe placement can be generated and transmitted to the patient for readjustment.
- FIG. 24 An example of how the presence of non-uniform contact pressure can be detected is illustrated in FIG. 24 .
- the treatment electrode is divided into four segments 25 a - d as shown in FIG. 24 .
- Treatment currents in equal amounts, flow to electrode segments 252 a - d , respectively.
- the current components are maintained by separate servo control loops to remain constant, irrespective of the skin and medicament conductivity, by varying the bias potential of each electrode segment. Under normal conditions in which the contact pressure is uniform, the bias potentials, Va, Vb, Vc and Vd for respective segments are substantially equal.
- the bias potential of each segment is connected to an analog multiplexer 254 , the output of which is, in turn, connected to an analog-to-digital (A-to-D) channel of a micro-controller 256 .
- Micro-controller 256 is an IC including a microprocessor core with digital inputs, outputs, A-to-D converter, timer, and other functional elements.
- the microprocessor can be programmed to conduct many diverse tasks. It can also be programmed, for example, to periodically measure and compare the bias potential of each electrode segment.
- the electrokinetic probe may be determined to be tilted downward by the patient such that the contact pressure is higher under segments C and D, and lower under segments A and B.
- the micro-controller can cause an alarm 258 to output an aural and/or visual alarm when the non-uniformity in contact pressure (as determined from the bias potentials) exceeds some predetermined value.
- the non-uniform pressure detection can also be accomplished by using discrete analog circuitry with operational amplifiers, comparators etc.
- the infections afflict age groups from childhood to late adulthood and the aged and immune suppressed population.
- the infections may include, for example, diaper rash, athlete's foot or jock itch and, in children, ringworm and other dermatophytosis.
- the current treatment of such infections involve anti-fungal agents applied topically. In healthy patients, the topical treatment works, although sometimes frustrating in its response time and chances for recurrence.
- the present invention offers a more rapid resolution of topical infections and more effective non-systemic treatment of the more refractory nail infections.
- the treatment method and apparatus for fungal infestation employs an electrokinetic, e.g., iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating.
- electrokinetic e.g., iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating.
- iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating.
- medicaments available on the market for this purpose.
- non-pharmaceutical level agents that may have a significant benefit to the treatment of fungal infections.
- an applicator 270 for the treatment of athlete's foot, e.g., where fungal infestation occurs between the toes.
- the applicator 270 is in the form of a flexible elastic sock electrode with an electronics package 271 containing a battery 272 , electronics 274 , ground electrode 276 and active electrodes 278 in registration with fungal infested areas between the individual's toes.
- the package 271 is strapped about the individual's ankle by a strap 273 .
- Discrete medicament-carrying pads 280 are shaped to extend between the toes along the interior potion of the toe region of the sock.
- Individual branch wires 284 overlying the pads 280 and with an electrically insulative covering, not shown, are coupled to the electronics package by conductive wire leads 285 disposed in an insulative protective ribbon 286 .
- a single treatment is sufficient to drive the anti-fungal medication carried by the pads 280 into the infected area between the toes to completely resolve the fungal infestation.
- the pads may form an integral part of the elastic sock 270 preferably along the inside portion of the toe region.
- the medicament is preferably pre-supplied within the pads, e.g., encapsulated and with or without hydration material as in prior embodiments hereof.
- the sock 270 may also be disposable with the electronics package 271 or the electronic package may be disconnected and reconnected to one or more additional socks as needed for applying additional medicament at the appropriate treatment intervals.
- the elastic sock 290 includes active electrode portions 292 overlying a pad 293 containing the anti-fungal agent in the region of the sock overlying the individual toenails.
- Each active electrode portion 292 may comprise short individual lead wires 294 coupled via individual leads 296 to an electronics package 298 similar to the package described and illustrated with respect to FIG. 25 .
- electrokinetic delivery of the medicament to the nail beds of the toes is provided upon completion of the circuit through the active electrodes 294 and ground electrode in the electronics package 298 through the ankle of the individual.
- This treatment requires prolonged and overnight wear of the sock electrode and may involve a plurality of treatments, for example, three treatments with a spacing of about two or three days.
- an applicator body 300 may be generally hemispherical in shape and is preferably formed of a resiliently elastic material.
- an applicator body 300 In the arcuate surface of the hemispherically-shaped body 300 , there is provided one or more fingerholes 302 into which the individual's fingernails may be received, e.g., up to about the first finger joint.
- five fingerholes 302 can be provided at various positions about the body 300 consistent with the anatomical orientation of an individual's bent fingers when his/her hand rests on the arcuate upper surface of the body 300 enabling the fingertips to be received in the openings 302 .
- the body 300 includes an active electrode 304 in each of the openings 302 at a location in registration with, i.e., opposite, the fingernail of the individual's finger when received in the hole.
- a medicament-containing porous pad for example, in the form of a thimble 306 , preferably pre-supplied with medicament or having encapsulated medicament along a forward edge thereof is provided.
- the individual user may apply the medicament to the thimble pad portion upon use.
- the thimble 306 may also contain a resilient elastic material 308 , for example, sponge material, such that upon placing the thimble about the individual's fingertip and the fingertip including thimble 306 in the hole 302 , the sponge material 308 biases the individual's nail forwardly into contact with the forwardmost pad portion of the thimble to make electrical contact with the active electrode 304 .
- a resilient elastic material 308 for example, sponge material, such that upon placing the thimble about the individual's fingertip and the fingertip including thimble 306 in the hole 302 , the sponge material 308 biases the individual's nail forwardly into contact with the forwardmost pad portion of the thimble to make electrical contact with the active electrode 304 .
- hydrating material may also be supplied integrally with the thimble, for example, in the form of encapsulated hydration material or the individual may hydrate the medicament in the thimble pad portion upon use.
- the ground electrode 310 is provided along an arcuate surface of the body 300 such that when the individual lays his/her hand over the arcuate portion of the body 300 , the palm of the hand rests against ground electrode 310 with the finger or fingers in the holes 302 bearing against the pad 306 and active electrodes 304 .
- each hole 302 has an active electrode 304 associated with that hole.
- the active and ground electrodes are coupled to the electronics 312 which, in turn, is coupled to a power source 314 integral with body 300 .
- the body 300 may have other shapes, for example, an elastic spherical shape, such that the individual can carry the electrokinetic delivery device in his/her hand for the duration of the treatment period.
- the body 300 may have a flat undersurface enabling the individual to rest his/her hand on the upper arcuate surface of the body 300 with body 300 supported, for example, on a desk or table.
- electrodes can be designed for size and contour for application to various parts of the human body.
- electrodes can be woven into undergarments to alleviate refractory infestation in the inguinal area, commonly described as jock itch.
- applicators such as the sock electrodes described, are disposable items with prescribed medication pre-supplied for specific application.
- various medicaments may be electrokinetically applied in an ocular application similar to and worn like a contact lens.
- an electronics package 320 comprised of a battery 322 , electronics 324 and a ground electrode 326 carried by a strap 328 designed to envelope the individual's head releasably securing the electronics package 320 on the forehead with the ground electrode engaging the individual's forehead.
- the mechanism of the electrokinetic delivery may be a multi-channel electrode as described in U.S. Pat. No. 5,160,316, now Re. 36,626, incorporated herein by reference. While delivery of medicament is illustrated as being applied to both eyes simultaneously, it will be appreciated that the electrokinetic delivery system hereof can be applied to only one eye.
- the electronics of the package 320 are coupled to an applicator electrode 330 for each eye via a ribbon cable connector 332 .
- the applicator electrodes 330 are each in the form of a concave-convex matrix formed of electrodispersive material sufficiently flexible to fit and overlie the various contours of individual eyes. Each matrix is similar to a contact lens.
- Applicator electrode 330 includes a combined handle and connector 334 which projects from the convex side of the applicator electrode 330 , facilitating a finger grip for the contact electrode 330 and an electrical connection for the ribbon connector 332 .
- the individual lead wires in the ribbon connector 332 are continued through the combined handle and connector 334 into the electrode 330 . As illustrated in FIG.
- these individual conductors or lead wires 336 extend from the combined handle and connector 334 , preferably in semi-circular patterns along opposite halves of the contact electrode 330 .
- Each of the conductors 336 has a plurality of short lead wires or supplemental conductors 338 at spaced positions along each connector 336 to provide increased contact area, i.e., to further distribute the electrical current flow along the surface of the eye.
- Each of the lead wires or connectors 336 has a discrete pad 339 associated with it for carrying the medicament and which medicament is electrokinetically driven into the eye upon completion of the electrical circuit between the applicator electrode 330 , the eye, the individual's skin between the active and ground electrodes, and the ground electrode 326 .
- the lead wires 336 in each contact electrode 330 may be electrically driven simultaneously or in sequential multiplex fashion.
- the current in each connector 336 being limited, for example, within the range previously discussed, current tunneling or current flow along the path of least resistance is substantially eliminated.
- the ocular electrokinetic delivery system described herein is preferably worn by an individual over a period of time, for example, up to an hour, with the multi-channel driver electrokinetically delivering the medicament into the cornea.
- the contour of the eye can be reshaped by delivering agents that retain water which would swell the conjunctiva in specific sites of the eye.
- the refraction of light can be modified by altering the shape of the eye.
Abstract
Description
- This application is a divisional of application Ser. No. 09/584,138, filed May 31, 2000, of common assignee herewith, the entire content of which is incorporated herein by reference.
- The present invention relates generally to the electrokinetic mass transfer of substances into and/or extracting substances from tissue and particularly to apparatus and methods for extracting, containing and/or delivering substance, e.g., a medicament to a treatment site.
- Electrokinetic delivery of medicaments for applying medication locally through an individual's skin is known. One type of electrokinetic delivery mechanism is iontophoresis, i.e., the application of an electric field to the skin to enhance the skin's permeability and to deliver various ionic agents, e.g., ions of soluble salts or other drugs. In certain situations, iontophoretic transdermal or transmucocutaneous delivery techniques have obviated the need for hypodermic injection for many medicaments, thereby eliminating the concomitant problem of trauma, pain and risk of infection to the individual. Other types of electrokinetic delivery mechanisms include electroosmosis, electroporation, electromigration, electrophoresis and endosmose, any or all of which are generally known as electrotransport, electromolecular transport or iontophoretic methods. The electrokinetic delivery mechanism may also be accompanied by ultrasonic vibration to further facilitate electrokinetic transport of the substance, e.g., by opening pores in the skin. Ultrasound may be employed in a number of ways such as (i) traditional piezoelectric elements, (ii) Application Specific Integrated Circuits (ASIC) with ultrasound transmitter built in or (iii) by thin foil sheets with incorporated piezoelectric dipole elements.
- There are several difficulties with electrokinetic delivery of substances such as medicaments. One is the heretofore need for somewhat cumbersome, bulky and costly equipment which oftentimes requires the presence of an individual at a doctor's office or treatment center and use of medical professionals to administer the medicament. Private, self-administration of medicaments or for diagnostic application by the individual at non-medical or non-professional facilities is highly desirable. Also, an easily transportable apparatus for electrokinetic delivery of medication, for example, a lightweight, compact portable device useful with an applicator packaged as a single or unit dosage applicator, appears ideal as a patient/consumer friendly self-administration system appropriate for many circumstances.
- In accordance with a preferred embodiment of the present invention, there is provided a portable, self-contained, hand-held lightweight, compact and wireless electrokinetic device for delivering or removing a substance, e.g., a medicament, and a unit dosage substance applicator for use with the device for the self-administration of a medicament to the skin. By the term substance is meant a medicament as well as natural or homeopathic products that may be outside the definition of medicament, e.g., inks and pigments for tattoos, and more generally includes any substance capable of electrokinetic transport through skin or mucocutaneous membrane, e.g., into a treatment site or from a site, e.g., for diagnostic purposes. The majority of applications using the present invention are for applying medicaments to treatment sites and therefore the term medicament is used in lieu of the term substance throughout this specification. By medicament is meant any chemical or biologic that may be used on or administered to humans or animals as an aid in the diagnosis, treatment or prevention of disease or other abnormal or cosmetic condition or for the relief of pain or to control, diagnose or improve any physiologic or pathologic condition.
- Major therapeutic classes include but are not limited to, ACE inhibitors, such as ranitidine, anti-infectives such as antibacterials, antivirals and antimicrobials, vasodilators, including general, coronary, peripheral and cerebral, adrenocortical steroids, alpha-adrenergic agonists, alpha-adrenergic antagonists, selective alpha-two-adrenergic agonists, analgesics, and analgesic combinations, androgens, local and general anesthetics, antiaddictive agents, antiandrogens, antiarrhythmic agents, antiasthmatic agents, anticholinergic agents, anticholinesterase agents, xanthine derivatives, cardiovasculars including calcium channel blockers such as nifedipine, beta agonists such as dobutamine and ritodine, anticoagulants, including heparin, anticonvulsants, antidiabetic agents, antidiarrheal agents, antidiuretic, antiemetic and prokinetic agents, antiepileptic agents, antiestrogens, antihypertensives, such as atenolol, antimigraine agents, antimotionsickness preparations such as scopolamine, ondansetron, meclizine, antinausants, antimuscarinic agents, antiprurtics, antipsychotics, antipyretics, antispasmodics such as gastrointestinal and urinary, antineoplastic agents, antiparasitic agents, anti-Parkinson's agents, antiplatelet agents, antiprogestins, antithyroid agents, antitussives, atypical antidepressants, azaspirodecanediones, barbituates, benzodiazepines, benzothiadiazides, beta blockers, antiarrythmics beta-adrenergic agonists, beta-adrenergic antagonists, selective beta-one-adrenergic antagonists, selective beta-two-adreneric antagonists, bile salts, medicaments affecting volume and composition of body fluids, butyrophenones, agents affecting calcification, catecholamines and sympathomimetics, cholergic agonists, cholinesterase reactivators, dermatological medicaments, diphenylbutylpiperines, diuretics, ergot alkaloids, estrogens, ganglionic blocking agents, ganglionic stimulating agents, hydantoins, agents for control of gastric acidity, and treatment of peptic ulcers, hematopoitic agents, hisamines, histamine antagonists, 5-hydroxytryptamine antagonists, hyperlipoproteinemia medicaments, hypnotics and sedatives, tranquilizers, hormones, including pituitary hormones such as HGH, HMG, HCG, desmopressin acetate and the like; follicle luteolds, α-ANF, growth factor releasing factor (GFRF), β-MSH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, corticotropin (ACTH), epidermal growth factor, erythropoietin, epoprostenol (platelet aggregation inhibitor), follicle stimulating hormone, glucagons, hirulog, hyaluronidase, insulin like growth factors, m[a]enotropins (urofollitropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen activator, urokinase, ACTH analogs, ANP, ANP clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists, antidiuretic hormone antagonists, bradykinin antagonists, CD4, ceredase, enkephalins, FAB fragments, IgE peptide suppressors, IGF-1, neurotrophic factors, colony stimulating factors, parathyroid hormone agonists, parathyroid hormone antagonists, pentigetide, protein C, protein S, rennin inhibitors, thymosin alpha-1, thrombolytics, TNF, vaccines, alpha-1 antitrypsin (recombinant), and TGF-beta, immunosuppressives, parasympatholytics, parasympathomimetics, psychostimulants, laxatives, methylxanthines, monomine oxidase inhibitors, neuromuscular blocking agents, organic nitrates, opoid analgesics and antagonists, pancreatic enzymes, phenothiazines, progestins, prostaglandins, e.g., alprostadil, agents for treatment of psychiatric disorders, sodium channel blockers, medicaments for spasticity and acute muscle spasms, e.g., muscle relaxants, succinimides, thioxanthines, thrombolytic agents, thyroid agents, tricyclic antidepressants, inhibitors of tubular transport of organic compounds, uterine motility affecting agents, and the like.
- Representative medicaments, their analogs and derivatives thereof, included by way of example and not for purposes of limitation, are interferons, e.g., α-2b interferon, amphotericin β, angiopeptin, baclofen, bepridil, buserelin, buspirone, calcitonin, ciclopirox, olamine, copper, cyclosporin, zinc, tropisetron, vapreotide, vasopressin, vasopressin antagonist analogs, verapamil, warfarin, zacopride, zotasetron, cromolyn sodium, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nitredipine, verapamil, isoproterenol, carterolol, labetalol, levobunolol, minoxidil, nadolol, penbuterol, pindolol, propranolol, sotalol, timolol, acebutolol, betaxolol, esmolol, metaproterenol, pirbuterol, ritodrine, terbutaline, alclometasone, aldosterone, amcinonide, beclomethasone, dipropionate, betamethasone, clobetasol, clocortolone, cortisol, cortisone, corticosterone, desonide, desoximetasone, 11-desoxycortiosterone, 11-desoxycortisol, diflorasone, fludrocortisone, flunisolide, fluocinolone, fluocinonide, fluorometholone, flurandrenolide, G-CSF, GM-CSF, M-CSF, GHRF, GHRH, gonadorelin, goserlin, granisetron, halcinonide, hydrocortisone, indomethacin, insulin, insulinotropin, interleukins, e.g., interleukin-2, isosorbide dinitrate, leuprolide, lisinopril, LHRH, LHRH analogs such as buserlin and leuprolide, octreotide, endorphin, TRH, NT-36(-[[(s)4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide), liprecin, LMW heparin, i.e., enoxaparin, melatonin, medrysone, 6α-methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tetrahydrocortisol, trimcinolone, benoxinate, benzocaine, bupivacaine, chloroprocaine, dibucaine, dyclonine, etidocaine, mepivacaine, pramoxine, procaine, proparacaine, tetracaine, chloroform, cloned, cycloproane, desflurane, diethyl ether, droperidol, enflurane, etomidate, halothane, isoflurane, ketamine, hydrochloride, meperidine, methohexital, methoxylflurane, nitrogylcerine, propofol, scvoflurane, thiamyal, thiopental, acctaminophen, allopurinol, apazone, aspirin, auranofin, aurothioglucose, colchiine, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, gold sodium thiomalate, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenanic acid, meselamine, methyl salicylate, nabumetone, naproxen, oxyphenbutazone, phenacetin, phenylbutazone, piroxicam, salicylamide, salicylate, salicylic acid, salsalate, sulfasalazine, sulindae, tometin, acetophenazine, chlorpromazine, fluphenazine, mesoridazine, perphenazine, thioridazine, triflurperazine, triflupromazine, disopyramide, encainide, flecinide, indecainide, mexiletine, moricizine, phenyloin, procainamide, propafenone, quinidine, tocaine, cisapride, domperdone, dronabinol, haloperidol, metoclopramide, nabilone, nicotine, prochlorperazine, promethazine, thiethylperazine, trimethobenzamide, buprenorphine, butorphanol, codeine, dezocine, diphenoxylate, drocode, doxazosin, hydrocodone, hydromorphone, levallorphan, levorphanol, lopermide, meptazinol, methadone, nalbuphine, nalmefene, naloxone, naltrexone, oxybutynin, oxycodone, oxymorphone, pentazocine, propoxyphene, isosobide, dinitrate, nitroglycerin, theophylline, phenylephrine, ephedrine, pilocarpine, furosemide, tetracycline, chlorpheniramine, ketorolac, bromocriptine, guanabenz, prazisin, doxazosin, and flufenamic acid.
- Also, representative of medicaments, their analogs and derivatives thereof, which may be delivered are benzodiazepines such as alprazolam, brotizolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, flumazenil, flurazepam, halazepam, lorazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, triazolam and the like; antimuscarinic medicaments such as anistropine, atropine, clininium, cyclopentolate, dicyclomine, flavoxate, glycopyrrolate, hexocyclium, homatropine, ipratropium, isopropamide, mepenzolate, methantheline, oxyphencyclimine, pirenzepine, propantheline, scopolamine, telenzepine, tridihexethyl, tropicamide, and the like; an estrogen such as chlorotrianisene, siethylstilbestrol, methyl estradiol, estrone, estrone sodium sulfate, estropipate, mestranol, quinestrol, sodium equilin sulfate, 17β-estradiol (or estradiol), semi-synthetic estrogen derivatives such as esters of natural estrogen, such as estradiol-17β-enanthate, estradiol-17β-valerate, estradiol-3-benzoate, estradiol-17β-undecenoate,
estradiol 16,17-hemisuccinate or estradiol-17β-cypionate, and the 17-alkylated estrogens, such as ethinyl estradiol, ethinyl estradiol-3-isopropylsulphonate, and the like; an androgen such as danazol, fluoxymestetone, methandrostenolone, methyltestosterone, nadrolone decanoate, nandrolone, phenpropionate, oxandrolone, oxymetholone, stanozolol, testolactone, testosterone, testosterone cypionate, testosterone enanthate, testosterone propionate, and the like; or a progestin such as ethynodiol diacetate, gestodene, hydroxyprogesterone caproate, levonnorgestrel, medroxyprogesterone acetate, megestrol acetate, norethindrone, norethindrone acetate, norethynodrel, norgestrel, progesterone and the like. - For example, by employing the device and the applicator hereof, it is possible to electrokinetically deliver medicaments such as anti-virals, for treating human papilloma virus, (HPV), e.g., warts (common, flat, plantar and genital), examples of which are Imiquimod® sold as Aldara™ by 3M for genital warts, a type (HPV), Acyclovir®, sodium salicylate, tretinion, benzoyl peroxide, bleomycin, interferons, Podocon-25, OTC products such as Wart Off by Pfizer and Compound W by MedTech or anti-picornavirus class substances, e.g., Pleconaril, to treat coughs and colds, anti-inflammatory medicaments such as dexamethasone and anti-bacterial agents, proteins, as well as steroids and salts thereof, non-steroidal anti-inflammatory drugs (NSAIDs), and salts thereof, hormones, cytokines, viruses, bacteria, DNA, RNA, (and fragments of both), antihistamines, oligonuceotides, anti-proliferative agents (cancer), specifically 5-fluorouracil (5-FU) and cisplatin, Efudex, or a combination of 5-FU and soviudine, anti-angiogenics such as thalidomide, antibiotics, peptides and peptidomimetics and assemblages of amino acids, phenols and polyphenols, an example of which is PolyphenonE and cosmetic agents, such as retinoids, e.g., hyaluronic acid, vitamins and/or water, skin bulking agents, e.g., collagen, reactive monomers which may polymerize under the skin in non aqueous carriers and be activated by water, botulinum toxins, e.g. botox, bleaching agents, e.g., Eldopaque 4% by ICN Pharmaceuticals, or a combination of Ketorolac, hydroquinone 4%, Glycolic Acid, lactic acid with suitable vehicle and anesthetics, such as lidocaine, xylocalne, prontocaine, prilocalne, fetanyl, remifentanil, sufentanil, alfentanil, novocaine, procaine, morphine HCL and EMLA either in stand alone fashion or with a vasodilator such as epinephrine. Also, medicaments which inhibit fusion between the plasma membrane and viruses and other adventitious agents to prevent entry by viruses and/or other adventitious agents into cells may also be electrokinetically delivered, e.g., behenyl alcohols such as n-disocanol, its analogs or derivatives. Hair growth may be stimulated by Propecia (finasteride), minoxidil, blocking antidihydrotestosterones or antidihydroestrogens. Hair removal may be accomplished by dyeing the hair and or hair root to facilitate removal by laser means or by electrokinetically using, e.g., dihydrotestostersone or dihydroandrogens or dihydroestrogens. Using pigments, tattoos, either temporary (reversible) or permanent may be applied to a treatment site and tattoos when permanent may be removed using suitable medicaments and the instant invention. Water soluble dyes and decals or templates may be employed in conjunction with the device and applicators. Prostate conditions e.g., prostatitis may be treated with antineoplastics. Additionally, the diagnostic sweat test for cystic fibrosis using pilocarpine, peripheral vascular disease using vasodilators, eye (corneal) treatment using florescein, acne treatments with one or more steroids, NSAIDs, such as ketorolac or medicaments such as Benzamycin, benzoyl perixode, cleocin, T-Stat, over the counter (OTC) products two examples of which are Clearasil and Benzac or Accutane, tazarotene sold as Tazorac, adapalene sold as Differin by Allergan and Galderma respectfully or azelaic acid, a topical cream also sold by Allergan, erythromycin as well as combinations of such medicaments may be electrokinetically delivered. Psoriasis may be treated with an antimetabolite, retinoids, synthetic vitamin D, i.e., calciprotriene, cyclosporin A (CSA), Aristocort, from Lederle, anthrax-derm, by Dermik, methotrexate, cortisone like compounds psoralen or anthalin. Eczema and contact or atopic dermatitis may be treated with corticosteroids or antihistamines. Spider veins may be treated with antiangiogenics, or coagulants (clotting factors or fragmented cellulose polymer). Fluoride treatment of exposed single site hypersensitive dentin may be performed with this device and applicator system. Canker sores and RAS may be treated with, e.g., benzoin or sodium fluoride. Post herpetic neuralgia may be treated with local anesthetics mentioned throughout this disclosure and/or with antivirals, e.g., Acyclovir or combinations of anesthetic and antiviral. Erectile dysfunction may also be treated (transcutaneously at site of concern) using prostaglandins such as PGE or alprostadil, nitroglycerin, and the like or papaverine, yohimbine and the like or sildenafil citrate, i.e., viagra, or apomorphine HCl. Other diagnostic uses i.e., removal or extraction of animal or human bodily material, e.g., fluids, versus delivery of medicament include as examples, allergy screening, e.g., using an electrode mounted array of antigens with a multiplexed-multi-channel application electrode, glucose monitoring and drug testing using electrode mounted specific binders (binder assay) combined with reverse iontophoretic plasma extraction. As a further diagnostic application, body material such as fluids can be extracted into a pad on the electrokinetic device, for example, by reverse iontophoresis. Wounds such as scrapes, cuts, burns, plant allergies, punctures and insect bites or stings can be treated with antihistamines, antibiotics, anti-infectives such as bactracin, Diprolene, topical steroids, and the like, aloe or aloe containing products or OTC products such as Ambesol, Lanocaine and the like, other wound healing agents, such as epidermoid derived growth factors as well as peptides that modulate the inflammatory response and modulators of collagen deposition and modeling as well as other wound healing agents all electrokinetically delivered. Pre-treatment may also include desensitizing agents such as the aforementioned analgesics or salicylic acid. Pruritis, dry skin and keratosis may also be treated using, cortisones and the like, Benadryl itch creme, Lazer creme or EMLA and the like. Actinic keratoses may be treated by electrokinetic delivery of aminolevulinic acid as well as other established antimetabolite agents such as methotraxate, 3% DICLOFENAC IN 25% hyaluronic acid, 5FU, 5FU and isotretinion, and the like. Bursitis or mild arthritis may be treated with magnesium sulfate or Dororac from Genderm.
- A particular use of the device and applicator hereof is the delivery of Acyclovir® and derivatives and analogs thereof for treatment of recurrent herpetic symptoms, including lesions (oral or genital) and varicella zoster i.e., shingles. Other anti-herpetic medicaments capable of electrokinetic delivery in accordance with the present invention are 5-iodo-2 deoxyuridine (IUDR), cytosine arabinoside (Ara-C), adenine arabinoside (Ara-A), also known as vidarabine, adenine arabinoside monophosphate (Ara-AMP), arabinofuranosyl hypoxanthine (Ara-Hx), phosphonoacetic acid (PAA), thymine arabinoside (Ara-T), 5′-amino-2′,5′-dideoxy-5-iodouridine (AIU), 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (BV-ara-U), also known as sorivudine, 1-beta-D-arabinofuranosyl-E-5(2-chlorovinyl)uracil (CV-ara-U), two halogenated deoxytidines (BrCdR and ICdR), bromovinyideoxyuridine (BVDU), trifluorothymidin and Penciclovir®, its prodrug, Famciclovir® and analogs and derivatives thereof, e.g., penciclovir. Most if not all topical agents including both Acyclovir® and IUDR have demonstrated only limited efficacy when applied topically to herpetic lesions, or pre-lesion stage sites including prodomal stage skin sites. However, demonstrably improved clinical results have been achieved when applied electrokinetically, e.g., electrophoretically, to treatment sites. Combinations may also be used including but not limited to IUDR and DMSO. By a treatment site is meant a target tissue, e.g., a diseased-tissue or diagnostic site for extraction of a substance, underlying or exposed through or on a human individual or lower animal's skin or mucocutaneous membrane including, the eye and also including, but not limited to body cavity and canal sites such as mouth, ear, nose, vagina, and rectum. Some embodiments would not be appropriate for human infants and lower animals and human application to the animal would obviously replace self-application.
- In a first aspect of the present invention, an individual may privately self-administer the medicament by employing the self-powered hand-held device to electrokinetically drive the medicament from an applicator into the treatment site, e.g., through the skin or mucocutaneous membrane to a diseased tissue. Preferably, a low-cost throwaway single-use applicator is used to facilitate the flow of medicament into the skin under the influence of the electromotive force supplied to the medicament contained in the applicator by the self-powered hand-held wireless device. The hand-held device is preferably lightweight, compact, inexpensive and portable and comprises a housing configured for self-manipulation and containing a power source, for example, a battery, connected through first and second terminals and suitable electronics, including a current driver and voltage multiplier, with active and ground electrodes. The active electrode is preferably mounted on the end of the device to facilitate manipulation of the device so that the active electrode may engage the applicator against the skin or mucocutaneous membrane. The second terminal of the power source is connected with the ground electrode, i.e., a tactile electrode, on the surface of the device for electrical contact with a second skin site, i.e., a portion of the individual's hand engaging and manipulating the device. By self-manipulation is meant that the individual can engage the device in one hand or a portion thereof and freely orient the device to engage the active electrode of the device through the applicator or directly through medicament against the skin or mucocutaneous membrane generally wherever the treatment site is located and irrespective of whether an applicator is used and, if used, irrespective of whether the applicator is attached to the device or to the individual's skin or mucocutaneous membrane or interposed therebetween with the device subsequently applied to the applicator.
- It will be appreciated that the metal portions of any electrode construction may be of any of a variety of metals or metallic films, foils, screens, deposits, mesh, paints including but not limited to aluminum, carbon, gold, platinum, silver, silver chloride, copper or steel, specifically surgical or similar fine grade steel, titanium, zinc or alloys of the aforementioned materials. These metal materials may also be used as a component of an electrode with a plastic base, form or foundation such as Mylar and the like. It is also possible that if the active and ground electrodes are of dissimilar metals or have different half cell reactions the device may generate part or all of its electrical power by this galvanic couple system of which numerous systems are well known in the art and require no further description. At times when hydration, ancillary or otherwise may be required, surfactants to facilitate the rate of hydration, i.e., wetting action, may be employed in, on or about the medicament applicator electrode with materials such as the surfactant Tween 20 or 85, made by ICI America, Neodol 91-6, from Shell Chemical Co., Terigol 15-S-7 from Union Carbide, Pluronic Poloxamer F68 or F127 from BASF or Duponol C or XL made by Dupont Chemical Corp or isopropyl myristate.
- In a preferred embodiment employing an applicator, the applicator preferably comprises a substrate having a reservoir, e.g., an open-cellular structure, for containing a medicament. This preferred open cellular or porous portion forms a minimum barrier to movement of medicament molecules under the influence of the applied current to transport the medicament molecules into the skin or mucocutaneous membrane. The applicator thus forms an electrode for application to the treatment site, e.g., an individual's skin and is preferably applied to the device prior to application of the device and attached applicator to the site. It will be appreciated, however, that the applicator electrode can be applied directly to or adjacent to the treatment site, e.g., by using an adhesive, prior to applying the device to the applicator. To secure the applicator electrode to the device prior to application to the treatment site, an adhesive is preferably employed, although other types of securement may be used, such as complementary hook-and-loop fasteners, tabs, post and hole, magnets or the like. It will also be appreciated that an electrical circuit is completed through the active electrode of the device, the applicator electrode and the treatment site for return through the individual's skin in electrical contact with the ground electrode of the device upon application of the device and applicator electrode to the treatment site. Thus, by grasping the device with the individual's hand or finger in contact with the tactile electrode, an electrical circuit is completed from the device through the applicator electrode, the treatment site, the individual's torso, arm and hand and the tactile electrode. To facilitate completion of the electrical circuit, the applicator electrode may have a portion, which overlies the tactile electrode to facilitate the flow of electrical current. For example, the applicator portion overlying the tactile electrode may be open cellular or porous and may contain an electrically conductive material, e.g., hydrogel. When this applicator substrate portion is pressed against the tactile electrode, electrical contact between the tactile electrode and the individual's skin is facilitated. Auxiliary hydration, e.g., wetting the fingers, the material or the tactile electrode may be employed to further facilitate closure of the current loop in any or all applicator or device embodiments. The hydrogel may also have adhesive properties or may contain an adhesive and thereby serve or additionally serve as a mechanism for releasably securing the applicator to the device.
- The medicament may be applied to the applicator by the user just prior to use. Alternatively, the medicament can be prepackaged as a unit dose in the applicator electrode. The medicament also may take many forms, for example, the medicament may be formulated as a liquid, a gel, an ointment, a dry powder, a lotion, a foam, a solution or a cream. Depending upon the nature of the medicament, it may also be electrically conductive per se, or require ancillary substances to transport the medicament, e.g., an electrically conductive substance such as water or very weak trace saline to provide the necessary electrical conductivity. The applicator preferably includes a porous or open multi-cellular pad to which medicament can be supplied by the user just prior to use or in which the medicament may be prepackaged. Where the medicament is not sufficiently electrically conductive per se, or is not part of a hydrophilic formulation, the user may hydrate the pad of the applicator to render the medicament transportable by the electromotive force of the electrical current flowing through the pad. Preferably, the applicator is releasably secured, e.g., by adhesive, to the device. Alternatively, the applicator can be applied directly to the skin or mucocutaneous membrane on or surrounding the treatment site, for example, by employing a releasable adhesive or the inherent tack of the substance included with the applicator electrode. In either mode of use, when the device, applicator pad and treatment site lie in series contact with one another and the circuit is completed through the individual's skin, electrical current flows through the pad and skin, driving the medicament into the treatment site, e.g., transdermally into an underlying site.
- In another form of the invention and as noted above, the medicament can be prepackaged in the pad of the applicator. For example, one or more rupturable capsules containing the medicament can be located in or adjacent to the porous pad, the encapsulation of the medicament affording long shelf life. Alternatively, the medicament may be prepackaged in or adjacent to the cells of a porous pad with removable seals for preventing exposure of the medicament to ambient conditions thereby also affording long shelf life. Further, different applicators can be prepackaged with different medicaments as required for various treatments. With a prepackaged encapsulated, (including micro encapsulation) medicament, the capsule or capsules can be ruptured by the application of pressure to the applicator pad, thereby spreading the medicament in and among the interstices of the pad. Where seals are used in conjunction with a medicament contained in a porous applicator pad, the seals are preferably adhesively secured to the pad and removed. If necessary, the pad can then be hydrated by the user. This may be accomplished using a separate small sterile vial of fluid by which drops of solution are applied. The applicator is then applied by the user to the device or to the skin or mucocutaneous membrane overlying the treatment site or simply interposed between the device and the treatment site. In this manner, the device, applicator electrode and skin or membrane are serially connected with one another for electrokinetic self-administration of the medicament into the treatment site. As a third alternative, both the medicament and an electrical conductor such as water can be encapsulated within the pad. By applying pressure, for example, finger pressure, the medicament and hydrating capsules can be ruptured, intermingling the medicament and water within or adjacent to the porous multi-cellular applicator pad, rendering the medicament electrokinetically transportable under the influence of the current flow. A fourth alternative includes pre-hydrating the pad and sealing the pre-hydrated pad from the medicament. When the seals are broken, the hydrating material hydrates the medicament, enabling electrokinetic delivery of the medicament. Alternatively, the medicament may be encapsulated to isolate it from a pre-hydrated pad. A sixth alternative is to encapsulate the hydration material, e.g., water or water containing electrolytes to enhance conductivity and medicament transport. A seventh alternative is to package the medicament with a hydroscopic material which will allow it to pick up water from the air once it has been removed from its protective packaging.
- It will be appreciated that the pad containing the electrically conductive medicament or medicament hydrated to afford electrical conductivity through the pad affords a minimum barrier to the movement of the medicament molecules into the treatment site under the electromotive force applied by the completion of the electrical current. Thus, at least a portion of the substrate or pad is preferably thin and highly porous. The pad should be comfortable to the user and if possible be somewhat flexible so as to conform to the treatment site, providing full contact coverage when in place, e.g., fabrics, absorbent gels, cotton or open celled foam. The pad should also have sufficient interstices or open cells, i.e., porosity, to hold quantities of the electrically conductive medicament or the medicament and hydrating material to afford efficacious treatment, e.g., of herpes treatment sites, over a period of time, for example, up to 15 minutes. For most treatments, the period of application is limited, for example, within a range of 1-30 minutes. The hydrating material is preferably water or a very weak trace saline solution lying within a range of 0.001-0.1%. As an additional example of hydrating material, polypropylene glycol, polyethylene glycol or polyvinyl glycol may be used.
- Further, the applicator electrode must be void of any short-circuit paths. For example, where the applicator includes a hydrogel on an applicator portion overlying the tactile electrode of the device, the hydrogel must be electrically insulated from the active electrode and the conductive or hydrated medicament in the pad to ensure that the circuit is completed through the individual's skin rather than merely short-circuited through the device and applicator electrode. The distance between the medicament containing electrically conductive portion and the hydrogel serves as an electrical insulator, particularly where the substrate therebetween is non-wicking. Likewise distance between the active and ground electrodes of the device serve the same purpose. Additional physical barriers may be provided, e.g., spaces, openings, valleys and ridges of non-conductive material on either or both the device and the applicator electrode. When both are employed they may be of a complementary nature, e.g., a valley on the device and a ridge on the applicator electrode. A portion of the barrier may also be hydrophilic so as to absorb any of the small amounts of hydration material which may be employed.
- In a further preferred embodiment of the present invention, the applicator may contain a magnet for activating and deactivating the power supply in the device. Consequently, when the applicator electrode is applied to the device or to the treatment site and the device is applied to the applicator, the magnet cooperates with the internal electronics of the device to activate the device. Conversely, upon removal of the applicator from the device or the device from the applicator, the magnet in the electrode deactivates the electrical circuit. Other conventional switching means may also be employed, e.g., toggle, twist or push types or the magnet may be separate from the applicator. The applicator may also contain a code carrying system, e.g., bar code or another state of the art system, which when attached to the hand-held device, programs the device to deliver the correct amount of medicament. This allows the hand held device to be used with a range of medicaments without having to reprogram the hand held unit. Also, indicators may be provided on the device to indicate that the device is actuated such that the user can be assured that the medicament is being electromotively driven into the treatment site. Thus, for example, one or more LEDs may be incorporated in the circuit to indicate activation of the circuit. Other indicators or the same indicator in a different mode, e.g., solid vs. flashing may be employed to indicate when the device and applicator electrode are operating satisfactorily to electrokinetically drive the medicament into the treatment site. An additional indicator can be employed to indicate low battery problems. Also, a variable timing device may be incorporated in the electrical circuit. The circuit may be activated for a selected predetermined length of time and automatically deactivated after that time period has lapsed. Alternately, a timer may offer an event signal or series of signals to the user without necessarily reprogramming the time period. For example, if the treatment is interrupted for a brief period of time, the timer may continue timing the treatment provided the interruption is only brief, e.g., a minute or two. If the interruption is prolonged, the timer is automatically reset to provide a period of treatment which is therapeutically effective. Also, a non-ultrasound generated vibration can be added or used in lieu of the LED to indicate working status of the device and that the device lies in a closed current loop via the individual's body surface.
- In another form, the applicator may comprise a splint-like strip for releasable securement to an individual's finger with self-contained electronics, a power source and active and ground electrodes formed integrally with the strip. The applicator strip may have a rectilinear, square, circular or shaped pad as the active electrode adjacent the individual's fingertip. The applicator strip preferably includes a split ring for releasably securing the applicator strip to and along an inside surface of an individual's finger. The applicator pad, which may be integral with or form a disposable pad for the applicator strip, is in contact with the active electrode adjacent the individual's fingertip for application to the treatment site. On the opposite side of the strip from the active electrode and in contact with the user's finger is a ground electrode. The batteries within the applicator strip may be air-actuated by removal of a tab overlying battery terminals. After the applicator strip is secured to the user's finger, the user then places the one-time use disposable applicator pad adjacent the user's fingertip and against the treatment site. This completes the circuit through the site and the user's skin. With the applicator pad separate from the applicator strip, the strip may be reusable with other disposable pads. Alternately, the pad may be a built-in part of the strip with or without pre-packaged medicament and/or hydration means, thereby enabling the whole device disposable. The applicator may also be miniaturized to the extent that it may have a thimble-like configuration without a ring and may be frictionally retained on the tip of the individual's finger.
- In another aspect of the present invention, the applicator may comprise a completely self-contained disposable unit having its own electronic circuitry and power source. In this aspect, the applicator may be provided (i) without the medicament and electrically conductive material (e.g., water), (ii) with the medicament in a prepackaged form within the applicator requiring only hydration upon use, if the medicament is not per se electrically conductive, or (iii) with both a medicament and hydration material. For example, the applicator in this form may comprise a flexible substrate having a medicament pad on a treatment site side thereof, an optional hydration material layer, overlaid by a first electrode, electronic circuitry including a power source, e.g., a battery, a second electrode and, optionally, a conductive material such as a hydrogel. By applying the medicament-containing pad to the treatment site and holding the applicator on the site by a finger or hand of the individual pressing on the applicator opposite the site, an electrical circuit is completed through the second electrode, the electronics, the medicament applicator electrode and the skin or mucocutaneous membrane between the site and the individual's finger or hand (i.e., along the finger or hand, the individual's arm, torso and site). Consequently, the medicament is electromotively driven by the electrical current into the site. The self-contained disposable unit may be removed from its package by the individual upon contact of the individual's finger with a tacky hydrogel exposed on the unit after the package is opened. This finger contact with slight finger pressure may cause contact between the hydration material and the medicament prior to removal from the package. Also, the finger contact and removal from the package further allows highly intuitive manipulation of the unit to the treatment site and ease of use given the lightweight and compact size of the unit. The unit may also be placed in a position where the finger contact is replaced by the contact of another grounding site such as would be the case if, by example the unit were placed in the mouth between the gum and inside mucosal tissue of the mouth or if the unit were placed inside the arm and contacted the upper rib cage or if the unit were designed and formed in a fashion similar to a contact lens for ocular treatments. It should be appreciated that the orientation of the active and ground electrodes and placement of the medicament could be reversed in these or other like uses.
- The battery for the circuit, for example, a zinc oxide battery, may be of the type activated by exposure to oxygen. In that battery, a tab overlies battery terminals which, when the tab is removed, exposes the contacts to oxygen thereby activating the battery. Various other types of miniaturized power sources may be provided, e.g., film sheet stacked batteries. It will also be appreciated that the medicament may be applied to the applicator pad by the user after the applicator is unpackaged and, if not per se conductive, the pad may also be hydrated by the user prior to application to the treatment site. Alternatively, the medicament may be prepackaged within the pad, for example, in one or more rupturable capsules and if not electrically conductive per se, one or more additional capsules containing hydrating fluid, e.g., a conductive fluid, such as water or saline may be prepackaged in the applicator as well. By squeezing the applicator electrode to rupture the capsule or capsules, the encapsulated medicament and, if necessary, the hydrating fluid, intermingle with one another and provide the necessary electrical conductivity through the applicator pad to enable electromotive transport of the medicament through the skin. It will be appreciated that the grounding electrode lies on the opposite side of the applicator from the active electrode and a circuit is therefore completed through the individual's finger or hand holding the applicator over the treatment site and the individual's arm and torso. To ensure electrical contact with the individual's hand or finger and the ground electrode, the top or outer portion of the applicator remote from the medicament pad may contain a conductive hydrogel.
- In a further alternative form hereof, the applicator comprises a self-contained disposable unit likewise having its own electronic circuitry and power source. In this form, the active electrode may form a portion of the applicator spaced from an electrically insulated ground electrode also forming part of the applicator. The applicator is configured such that the first or active electrode of the applicator lies in electrical contact with the applicator pad (electrode). The active applicator electrode is applied to the treatment site and the ground electrode on the applicator is placed in electrical contact with the user's skin. An electrical circuit is thereby completed through the applicator, the applicator electrode and the treatment site with the return circuit through the skin, and the ground electrode of the applicator. The spacing between the active electrode and the ground electrode in electrical contact with the treatment site and the skin, respectively, can be quite small, i.e., on the order of one-half inch.
- As mentioned previously, the medicament may be formulated as a liquid, gel, ointment, dry powder, lotion, foam, solution or cream. Where a liquid constitutes the medicament, the applicator electrode for use with the device may include an electrically insulative housing, for example, a torus, for containing the liquid. On one side of and secured to the torus is a microporous film overlaid by a removable barrier, e.g., foil or inert material adhered to the insulated housing to prevent transfer of the liquid within the applicator electrode externally. The opposite side of the insulative housing may likewise be confined by a barrier overlying the housing. The insulative housing preferably has tabs for attaching the applicator electrode to the device similarly as previously described. A conductive plate may overlie the foil or the applicator electrode may be applied to the device directly with the active electrode of the device in electrical contact with the barrier. By removal of the adhesively secured barrier layer and application of the applicator electrode to the site, electrokinetic transfer of the medicament can be accomplished.
- In a further form, the active and ground electrodes may be spaced one from the other in a self-contained unit and separated by a malleable or tensioned arm. For example, the ground electrode may be adhesively secured to the individual at a location adjacent the medicament delivery device and the active electrode placed in contact with the site. The springbiased or malleably tensioned arm holds the active electrode with an optional gimbal component in electrical contact with the treatment site in a fully flush or full contact manner, avoiding only partial contact and hence avoiding less than effective treatment. This permits hands' free electrokinetic delivery of the medicament to the treatment site.
- In a still further form, a self-contained unit having its own electronic circuitry and power source for hands' free application to the treatment site is provided. In this form, a generally U-shaped clip having opposite ends which mount the ground and active electrodes, respectively, as well as the power source and electronic circuitry, may be applied in a gripping or clamping manner to clip the self-contained unit adjacent the treatment site such that the active electrode engages the treatment site for electrokinetic delivery of the medicament.
- In a still further form of the present invention, electrokinetic medicament delivery may be applied in an ocular applicator similar to and worn like a contact lens. The mechanism of the electrokinetic delivery may be multi-channel, for example, as described and illustrated in U.S. Pat. No. 5,160,316, now Re. 36,626, incorporated herein by reference. Thus, a delivery device similar to a contact lens may be employed to therapeutically treat the conjunctiva for acute glaucoma using as an example, Xalatan or even to contour the eye by delivering agents that retain H2O, such as hyaluronidase or hyaluronic acid, which would swell the conjunctiva in specific sites of the eye. Antiviral drugs foscarnet and ganciclovir either alone or in combination may be electrokinetically delivered for treating herpetic eye infections, e.g., cytomegalovirus (CMV) and CMV retinitis. Differential levels of power and agent delivery are possible with the multi-channel delivery. In this manner, the refraction of the light can be modified by changing or altering the shape of the eye/conjunctiva. The medicament delivery device may be worn or applied periodically for various time periods, for example, within a range of 1 to 60 minutes.
- In the above aspects of the present invention, the circuitry limits the maximum current available to the applicator electrode to preferably less than about 1 milliampere per two square centimeters of the skin-contacting surface area of the electrode. Depending upon the working electrode's skin-contacting surface configuration, the current level can vary from about 0.1 to about 1.2 milliamps. While higher currents have been used, user discomfort can be experienced. Buffers could be employed to overcome this milliamp range ceiling. It is also another feature hereof that the electrical current can be ramped up and ramped down, respectively, at the beginning and end of the treatment. See, for example, prior U.S. Pat. No. 5,160,316, now Re. 36,626, the disclosure of which is incorporated herein by reference. Ramping contours of different configurations can be used, for example, linear, non-linear, exponential, pulsed, or otherwise shaped. Also, while direct current is preferred, alternating current can be used.
- In all of the foregoing embodiments, facilitators may be employed to minimize or eliminate the barrier to the transfer of the medicament molecules through the skin. For example, acetic acid or dimethylsulfoxide (DMSO), alcohols, such as ethanol and isoproanol, ethyalactate, sulphoxides, fatty acids, such as oleic acid, lauric acid, capric acid and caprylic acid, sodium lauryl sulfate, acyl lactylates (except in their salt form), e.g., caprol lactyic acid and lauroyl lactylic acid, esters, (1-dedecylazacycheptan-2-one) (Azone), pyrrolidones, such as dodecyl pyrrolidone, dimethyl lauramide, linear dialiphatic or aliphathic, sulfoxides, unsubstituted or mono or di-substituted amides and di-substituted amines among others, urea, cis-urocanic acid or polyoles may be used. It may also be useful in electrokinetic transport of some medicaments to use a second facilitator or skin permeation enhancer which may be a monoglyceride or mixture of monoglyerides of fatty acids such as glycerol monolaurate (GML) or glycerol monooleate (GMO), lauramide diethanolamine (LDEA), or esters of fatty acids having from 10 to 20 carbon atoms. By using these substances, the skin can be disrupted, enhancing the exposure of the dermis to electrokinetic forces. Another type of facilitator is a component which may encase a given molecule within a lipid barrier but makes it less polar and thereby facilitates penetration of the skin by the medicament. An example is gylcesol or phospholipids such as phosphaticylcholine.
- It will be appreciated from the foregoing that usage of the device and applicator requires minimal instruction. Where the medicament is prepackaged with the applicator, there are no concerns regarding the dosage as a single unit dosage which is therapeutically effective over the period of application is provided. Moreover, the device and applicator do not require any calibration or settings as the supply of current is fixed by the device electronics. Further, there is no second or ground electrode separate from the device whereby the device is easily used without a separate ground electrode. The power source may be limited to providing only single use longevity. Thus, the power supply may be replaced when a device is reused or the device itself may be discarded. Numerous components may be constructed and linked for short life cycle upon use without negating a prior long shelf life. The applicator and even the device per se are readily disposable.
- In a preferred embodiment according to the present invention, there is provided an electrokinetic delivery system for personal use in self-administration of a medicament to a treatment site on an individual, comprising a device for releasable securement to an individual's finger and shaped in part to conform to at least a portion of the individual's finger, at least one of an electrically conductive medicament or a medicament with an electrically conductive carrier therefor, a retainer for releasably securing the device to the individual's finger, a self-contained power source carried by the device, a first electrode carried by the device adjacent a distal end portion thereof and adjacent the tip of the individual's finger upon retention of the device on the individual's finger, the first electrode being in electrical contact with the power source, a second electrode carried by the device for electrical contact with a portion of the individual's finger, the second electrode being in electrical contact with the power source whereby, upon application of the first electrode to a treatment site with the at least one medicament interposed between the first electrode and the treatment site and completion of an electrical circuit through the first electrode, the at least one medicament, the treatment site, the individual's body, the second electrode and the power source, the device causes an electrical current to flow for electrokinetically driving the at least one medicament into the treatment site.
- In a further preferred embodiment according to the present invention, there is provided a method of treatment by electrokinetic self-administration of a medicament into a treatment site for an individual, comprising providing a device shaped in part to conform to at least a portion of an individual's finger and having a self-contained power source, first and second electrodes, and a substrate in electrical contact with the first electrode and having an exposed contact surface, providing at least one of an electrokinetically transportable medicament or a medicament with an electrically conductive carrier therefor, releasably retaining the device on the individual's finger, with the second electrode in electrical contact with the individual's finger, providing the at least one medicament in contact with the substrate or the treatment site, while the device remains retained on the individual's finger, placing the contact surface of the substrate into contact with the individual's treatment site and causing electrical current to flow through the first electrode, the electrically transportable medicament or the conductive carrier, the treatment site, the individual's body, the second electrode and the power source to electrokinetically drive the medicament into the treatment site.
- In a further preferred embodiment according to the present invention, there is provided a delivery device for self-administration of a substance to a treatment site on an individual, comprising a self-contained disposable applicator including a pad for containing the substance, a power supply, a first electrode overlying the pad and electrically connected to the power supply and a second electrode having a tactile surface in electrical contact with the power supply and lying on a side of the applicator remote from the pad, the second electrode having an electrically conductive material overlying the tactile surface, whereby, upon the individual's hand or a portion thereof in contact with the tactile surface of the second electrode holding the applicator pad against the treatment site, an electrical circuit is completed between the first electrode through the treatment site and the second electrode via the tactile surface, the electrically conductive material and the individual's hand and body for electrokinetically driving the substance into the treatment site.
-
FIG. 1 is a schematic illustration of an electrokinetic medicament delivery device for use with an applicator in accordance with the present invention; -
FIG. 2 is a perspective view of the device with the applicator applied thereto; -
FIG. 2A is a view similar toFIG. 2 of a modified form of the device and applicator; -
FIG. 3 is a perspective view illustrating the device and applicator in use by an individual and being applied to a lesion on the individual's chin; -
FIG. 4 is a plan view of an applicator from the skin side; -
FIG. 5 is a plan view of the applicator from the device side; -
FIG. 6 is an exploded side elevational view illustrating the various parts of the applicator; -
FIGS. 7 and 8 are views of the applicator pad, respectively, illustrating an encapsulated medicament and a combination of encapsulated medicament and hydration fluid within the applicator pad; -
FIG. 9 is a perspective view of a splint-like strip forming a self-contained applicator electrode in accordance with a further embodiment of the present invention; -
FIG. 9A is a view similar toFIG. 9 illustrating a further form of the strip ofFIG. 9 ; -
FIG. 10 is a schematic view of an electrical circuit for use with the applicator electrode ofFIG. 9 ; -
FIGS. 11A, 11B and 11C are schematic representations of a self-contained applicator illustrating the layers of the applicator within a packaging material; -
FIG. 12 is a schematic representation of an applicator in accordance with a further embodiment of the present invention; -
FIGS. 13 and 14 are preferred forms of the applicator ofFIG. 12 with an encapsulated medicament illustrated inFIG. 13 and encapsulated medicament and hydrating fluid illustrated inFIG. 14 ; -
FIG. 15 is a side elevational view of a further form of the present invention; -
FIG. 16 is an exploded schematic view of a still further form of applicator electrode in accordance with the present invention; -
FIG. 17 is a fragmentary view of the applicator ofFIG. 16 applied to the end of a device; -
FIG. 18 is an illustration of a hands' free electrokinetic medicament delivery device; -
FIG. 19 is a schematic illustration of a still further hands' free electrokinetic delivery device according to the present invention; -
FIG. 20 is a perspective view of a further form of an applicator, illustrated with its packaging, for use with an electrokinetic delivery device; -
FIG. 21 is a view of the applicator ofFIG. 20 without its packaging; -
FIG. 22 is a schematic illustration of the applicator ofFIGS. 20 and 21 applied to the electrokinetic device; -
FIG. 23 is a perspective view of the device with the applicator applied ready for use; -
FIG. 24 is a schematic representation of an alarm system for misplacement of the probe; -
FIG. 25 is a schematic illustration of an electrokinetic applicator in the form of a sock for treatment of fungal infestations between the toes; -
FIG. 26 is a view similar toFIG. 25 illustrating an electrokinetic applicator for treatment of a nail bed fungal infestation; -
FIG. 27 is a schematic representation of a device for electrokinetically treating a fungal infestation of the nail beds of an individual's fingers; -
FIG. 28 is a schematic illustration of the electronics and thimble pad applicator of the device ofFIG. 27 ; -
FIG. 29 is a schematic representation of a device for electrokinetic ocular treatment; -
FIG. 30 is a side elevational view of an ocular applicator according to this aspect of the invention; and -
FIG. 31 is a planar view of the ocular applicator illustrating the multi-channel conductors. - Referring now to the drawing figures, particularly to
FIG. 1 , there is illustrated a portable, self-contained, lightweight, compact, hand-held electrokinetic medicament delivery device, generally indicated 10, adapted for use with an applicator, described in detail below. Thedevice 10 includes anouter housing 12 containing a power source, for example, abattery 14, and electronic circuitry including avoltage multiplier 16 and acurrent driver 18. As illustrated,battery 14 includes afirst terminal 20 and asecond terminal 22. Thefirst terminal 20 is coupled to thevoltage multiplier 16 which steps up the voltage supplied by thebattery 14 and applies the stepped-up voltage to thecurrent driver 18.Current driver 18 is in contact with a first oractive electrode 24 exposed throughhousing 12, preferably at an end thereof. Thesecond terminal 22 is in contact via aspring 26 and aconductor 28, with a ground ortactile electrode 30 also exposed throughhousing 12, preferably along a side wall thereof. It will be appreciated thathousing 12 is sized and configured to be held within an individual's hand for orientation such that the first oractive electrode 24 can be in electrical contact with a treatment site through a conductive medicament-containing pad of an applicator, described below. Thus, in a preferred embodiment, thehousing 12 may be of a cylindrical form, with the first oractive electrode 24 at one end of the cylinder. It will be appreciated, however, thathousing 12 can assume other shapes to facilitate the purposes ofdevice 10, namely to provide a portable, self-contained device having an integral power source which, in conjunction with the applicator, may electrokinetically drive medicament through an individual's skin or mucocutaneous membrane into a treatment site when the applicator and device are applied to and overlie the treatment site. For example, and referring toFIG. 2A , thehousing 12 a may have a bend intermediate its opposite ends forming ahandle 32 at one end having atactile ground electrode 30 a exposed through the handle. The opposite end terminates in an active orfirst electrode 24 a similarly as inFIG. 1 . Thus, thehandle 32 forms a grip for orienting and manipulating thedevice 10 a relative to the treatment site. - The circuitry limits the maximum current available to the applicator to preferably less than about 1 milliampere per two square centimeters of the treatment site-contacting surface area of the applicator. However, depending upon the working surface of the applicator pad in contact with the site, the current level can vary from about 0.1 to about 1.2 milliamps per two square centimeters to avoid minor discomfort and deleterious side effects. These limitations also apply to each channel of a multi-channel device as discussed herein with reference to U.S. Pat. No. 5,160,316, now Re. 36,626.
- The hand-held
device piezoelectric element 19 for imparting ultrasonic vibrational motion to theactive electrode 24 to further facilitate transdermal or transmucocutaneous delivery of electrokinetically transportable substances, e.g., medicaments. Thepiezoelectric element 19 is located on theactive electrode 24. Power is supplied to energize thepiezoelectric element 19 by aconductor 21 connected with thetactile electrode 30, thepiezoelectric element 19 being in electrical contact with theactive electrode 24. An optional switching element may be used to energize the piezoelectric element or not, as desired, depending upon the particular treatment mode. The combination of an electrokinetically delivered substance into a tissue, together with inducing an ultrasonic vibration in the tissue, enables an opening of pores further facilitating penetration of the medicament. It also facilitates removal of coloration, such as a blemish, freckle or tattoo within the skin by delivery of a suitable bleaching agent, provided as the medicament in the applicator, which will now be described. - Referring to
FIGS. 4-6 , there is illustrated an applicator, generally designated 40, having a treatment site-contacting side and a device-contacting side as illustrated, respectively, inFIGS. 4 and 5 . As best illustrated inFIG. 6 ,applicator 40 includes asubstrate 42 formed of a porous open cellular material. A suitable substrate material may comprise a fabric manufactured by Cerex of Pensacola, Fla., identified as Type DN, Group DN07&DN15. Other suitable types of materials may also be used, provided those materials, at least in the portion of the substrate through which the medicament will be transported to the treatment site, constitute a minimum barrier to the transfer of the medicament molecules from the applicator to the site. On the skin or mucocutaneous side of theapplicator 40 as illustrated inFIGS. 4 and 6 , there is provided apad 44 surrounded by acontainment barrier 46. The pad may likewise comprise a porous open-cellular material similar to the substrate but preferably comprises a more dense material such as cotton for retaining the medicament. Cotton is sufficiently porous and open-cellular to enable the medicament to be electromotively driven from the cotton pad into the site. It will be appreciated that thepad 44 should be inert to the medicament, as well as non-corrosive and stable when in contact with the medicament. While cotton is preferred, other suitable materials may include plastic pads such as polyethylene, paper, porous ceramics, open-celled porous polytetrafluoroethylene, polyurethane or other plastics, as well as open-celled silicone rubber and vinyl. - The
containment barrier 46 is formed of a non-electrically conductive material, which prevents the medicament from weeping or wicking onto portions of the substrate adjacent the medicament pad. Preferably, however,barrier 46 comprises a closed-cell foam, for example, a foam manufactured by Avery Dennison of Pasadena, Calif., identified as Avery Foam Med 5637. While not shown, the foam is preferably adhesively secured to thesubstrate 42 with margins of thepad 44 frictionally or adhesively retained within the peripheral confines of thebarrier 46. Aflap 48 overlies the exposed side of the pad and is preferably adhesively secured along one side to one side of thebarrier 46 such that thepad 44 can be exposed by lifting or removing the flap. It will also be appreciated that thepad 44 may be incorporated or embedded in thesubstrate 42. For example, thepad 44 may reside in a cutout portion in the substrate. - On the device side of the applicator and on opposite sides of the
pad 44, the substrate extends to formwings 52 for releasably securing the applicator to the device. Preferably, a releasable contact adhesive 50 is applied to theapplicator wings 52 for releasably securing the applicator to thedevice 10. For example, as illustrated inFIG. 2 , theapplicator 40 illustrated in the form of a strip has a central portion of the strip, i.e., thepad 44, overlying theactive electrode 24 at the end ofhousing 10 with theapplicator wings 52 folded along opposite sides of thehousing 10 and releasably secured thereto by the adhesive 50. Arelease liner 54 is provided on the device side of the applicator overlying adhesive 50 and whichliner 54 is removed by the user upon application of the applicator to the device. It will be appreciated that other methods of releasably securing the applicator to the device may be employed. For example, hook-and-loop type fasteners may be used with the hooks or loops on the device and the loops or hooks on the applicator. Magnets or spring clips or other mechanical-type fasteners may be employed. The applicator as illustrated inFIGS. 4-6 is also illustrated in the form of a strip similar to a Band-Aid. It will be appreciated, however, that other configurations and shapes of the applicator may be employed, depending upon the configuration of the device. For example, anapplicator 40 a having a pad formed of similar material aspad 44 may be employed for use withdevice 10 a ofFIG. 2A .Applicator 40 a may be formed in a circular configuration without wings and may be adhesively or otherwise secured to theactive electrode 24 a ofhousing 12 a. For example, the peripheral margin of theapplicator 40 a may have a releasable adhesive for releasable securement to theactive electrode 24 a on the end ofdevice 10 a. In this form, the applicator need not have conductive portions overlying theground electrode 30 a. It will also be appreciated that the applicator is formed of a flexible material generally conformable to the treatment site surfaces to the extent possible given the shape of theactive electrode device - The
applicator 40 is intended for a single use. That is, once the medicament has been electrokinetically driven frompad 44 into the site, the applicator may be removed from the device or the site and discarded. Where the medicament is prepackaged with the applicator, a coloring agent can be employed, such as iodine, which turns color upon contact with the starch in the open-celled material to visibly indicate that unit dose medicament has been used. Other types of coloring agents can be used to indicate usage of the applicator, e.g., pH indicators, wet saturation indicators or oxidizable pigments. - The applicator may be provided to the user without medicament within the
applicator pad 44. Thus, when using the applicator, the user may apply the medicament to theapplicator pad 44 such that the medicament lies within the interstices of the material of thepad 44. If the applied medicament is not per se conductive, the pad containing the medicament may be hydrated by the application of water, for example, by using an eyedropper. In a preferred form, however, the medicament is supplied and prepackaged with the applicator. For example, the medicament may be contained within a rupturable polymer reservoir orcapsule 56, as illustrated inFIG. 7 . By encapsulating the medicament, a long shelf-life is assured. To use the applicator with the encapsulated medicament, thecapsule 56 can be ruptured by applying pressure to thepad 44, for example, by pressing the pad between the individual's fingers or against the active electrode when the applicator is applied todevice 10, or against a surface of packaging in which one or more of the applicators are provided. By rupturing the capsule, the medicament permeates the interstices of thepad 44. If the medicament requires hydration to afford electromotive transport into the treatment site, e.g., a lesion upon application of the electric current, the user may hydrate the pad similarly as previously described. Alternatively, an additional one or more capsules containing hydrating material, e.g., water or saline, may be prepackaged with the applicator. A very weak trace saline solution within a range of 0.001-0.1% and preferably less than 0.05% may be used. As illustrated inFIG. 8 , thepad 44 includes one ormore medicament capsules 56 and one or more hydration capsules. 58. By applying pressure to the two or more capsules, the capsules may be ruptured and the medicament and hydration material intermingled with one another within the interstices of thepad 44, rendering the applicator pad susceptible to conducting current for the electrokinetic delivery of the medicament to the lesion. - Referring back to
FIGS. 4-6 , amagnet 60 is preferably incorporated into thesubstrate 42 on one or opposite sides of thepad 44. The electrical circuit in the device may therefore include a magnetic field responsive switch for actuating and deactuating the electrical circuit. Thus, when the applicator is applied to the device, the circuit is activated and when removed, the circuit is deactivated. - Instead of or in addition to the adhesive 50, a conductive gel may be provided within the
wings 52 of theporous substrate 42. It will be appreciated that as the applicator electrode is applied to the device 10 (FIG. 2 ), thewings 52 of the substrate overlie thetactile electrode 30 of thehousing 10. The conductive gel thus facilitates electrical conductivity between the individual's fingers or hand overlying the wing portions of the applicator and thetactile electrode 30 to complete the circuit. Thus, the cells of the substrate on one or bothwings 52 may be provided with a conductive substance, e.g., a hydrogel. These wings with hydrogel are electrically insulated from thepad 44 and the medicament. Thus, electrical insulating barriers may be provided between thepad 44 and the conductive wing or wings. Such barriers may comprise substantial spacing between the pad and wing with non-conductive material therebetween or physical barriers such as openings, ridges or valleys in the substrate portions interconnecting thepad 44 and the one or more wings of conductive material. - To use the combination device and applicator illustrated in
FIGS. 1-8 , theapplicator 40 is preferably applied to the device by aligning thepad 44 with theactive electrode 24 on the end ofhousing 12. The wings of the applicator are folded along opposite sides of the device and adhered or held to the device overlying theground electrode 30. With the substrate being at least partially open celled, porous, or cutout, e.g., to contain medicament in gel, solution, cream, foam, ointment or liquid form, the individual's fingers pressing against the substrate and/or thetactile electrode 30 complete an electric circuit path between the device and the individual. Where hydrogel is applied to thewings 52 of theapplicator 40, the hydrogel facilitates the completion of the circuit between the individual's hand or finger and the tactile electrode. Whether hydrogel is employed or not the individual may add water to his/her fingers or hand, thus facilitating electrical conductivity. With theapplicator 40 applied to the device, the device is actuated, for example, by locating themagnet 60 in a position to close the magnetic switch within the electrical circuit. A conventional on/off switch may be used in lieu of the magnetic switch. Theactive electrode 24 is also in electrical contact with themedicament containing pad 44 by contact therewith. By manipulating the device, thepad 44 of the applicator is brought into the contact with the treatment site on the individual's skin. Upon contact, electrical current flows between theactive electrode 24 in the handpiece, through the medicament-containingpad 44 into the treatment site, through the patient's skin, along the torso and arm for return through the finger or hand to theground electrode 30. Consequently, the medicament is electromotively transported through the individual's skin or mucocutaneous membrane, thus enhancing local delivery of the medicament to the treatment site. - When using the
device 10 a ofFIG. 2A , theapplicator 40 a may be secured to the end ofhousing 12 a overlying theactive electrode 24 a or applied to the treatment site. The individual holding thedevice 10 a makes electrical contact with theground electrode 30 a of thehandle 32 by grasping the handle. To ensure good electrical contact, the individual may also add water to his/her fingers or hand. Thedevice 10 a is then manipulated to contact theactive electrode 24 a through theapplicator 40 a with the treatment site thereby completing the electrical circuit similarly as in the embodiment ofFIG. 2 . - The device per se may also be applied to a treatment site without a medicament, e.g., without use of the
applicator - Referring now to the embodiments hereof illustrated in
FIGS. 9 and 10 , there is illustrated a completely self-contained disposable unit containing electronic circuitry and a power source for electrokinetically delivering medicament to a treatment site. As illustrated, the self-contained unit, generally designated 70, includes asemi-flexible substrate 72, for example, formed of a plastic material, for underlying an individual's finger and shaped according to the inside surface of an individual's finger. Thesubstrate 72 passes along one or more of the finger joints. Thesubstrate 72 includesbatteries 74, for example, conventional zinc oxide batteries which may be actuated by removal of a tab exposing battery contacts to the atmosphere. Additionally, thesubstrate 72 includeselectronics 76 for supplying a flow of current to anactive electrode 78 carried at the fingertip end of thesubstrate 72 and angled relative to the linear extent ofsubstrate 72. It will be appreciated that theactive electrode 78 is electrically coupled to theelectronics 76 andbatteries 74. Additionally, a ground electrode is electrically coupled to the other terminal ofbatteries 74 and is electrically insulated from theactive electrode 78. Theground electrode 80 may comprise a flexible material, portions of which may be in the form of asplit ring 82. Thus, the full length of the individual's finger may be in contact with the ground electrode, affording a good electrically conductive contact therewith. Additionally, a retainer, for example, a retainingstrap 73, is provided adjacent the inner end of thesubstrate 72 to, in addition to thesplit ring 82, releasably secure the applicator electrode to the individual's finger. The retainingstrap 73 may include semi-rigid arcuate split ring portions, a full ring integral withsubstrate 72 or a flexible strap with fasteners to secure the strap ends to one another, for example, hook-and-loop type fasteners. - A similar self-contained
unit 70 a is illustrated inFIG. 9A wherein like parts are designated by like reference numerals followed by the suffix “a.” Thesubstrate 72 a extends along the underside of an individual's finger but only along the finger from its tip, past the first joint and terminating short of the second joint. As in the embodiment ofFIG. 9 ,substrate 72 a includesbatteries 74 a,electronics 76 a, anactive electrode 78 a at the fingertip, and aground electrode 80 a includingsplit ring 82 a. Additionally, thetip 71 of thesubstrate 72 a may curve back over the fingertip to assist in securing the substrate to the fingertip. - The electronic circuitry for the
applicator electrodes FIGS. 9 and 9 A is illustrated inFIG. 10 and which circuitry is applicable to all embodiments hereof. The power supply for thedevice 70 includes an air-activatedbattery 74, coupled through avoltage booster 75 by way of an optionallow battery indicator 77. The air-activated batteries may be replaceable and other types of small batteries, such as lithium disks, could be used. Thevoltage booster 75 is connected to a servo controlledcurrent source 79 and, optionally, to a current-monitor 81. Thecurrent source 79 is electrically coupled to acurrent limiter 83 for limiting the current applied to the active electrode within the limits previously discussed. Thecurrent limiter 83 is coupled to thetreatment electrode 78. InFIG. 10 , the treatment electrode is illustrated as applied to the treatment site, e.g., a lesion, through amedicament pad 44 a. The ground electrode is also illustrated as applied to the skin by way of an optional electricallyconductive hydrogel 85. Themedicament pad 44 a may be releasably or permanently secured to thedevice 70, preferably in overlying relation to theactive electrode 78. Thus, thedevice 70 may be a one-time-use disposable or, if the pad is separate, thedevice 70 may be reused with additional pads. Theoverlying pad 44 a may contain a prepackaged medicament M or any of the alternative combinations of pad, medicaments and hydration disclosed in this application. Alternatively, thepad 44 a may be provided in a separate package with the medicament in capsulated form as previously described. In either case, the medicament pad is applied between theactive electrode 78 and the treatment site. By removing the tab overlying the battery terminals, the power supply is activated. This may be accomplished when opening the packaging or upon removal of the device from the packaging. When theactive electrode 78 is placed in contact overlying the treatment site surface, the circuit is completed through the individual's body, including the finger in contact with the ground electrode. - The
applicator 70 is preferably a single-use applicator which may be discarded after use. In an alternate form, thesubstrate 72 may be shaped in the form of a thimble for overlying the entirety of the fingertip of the individual. Theelectronics 76 andbatteries 74 may be formed on the back side of the thimble opposite the side containing the active electrode, with the ground electrode lying along the inside surface of the thimble and electrically insulated from the active electrode. - Referring now to
FIGS. 11A-11C , there is provided a further form of the applicator hereof comprised of a completely self-contained disposable unit orapplicator 90 integrally containing the electronic circuitry and a power source. In this form, the applicator is prepackaged for one-time usage. For example, as illustrated inFIG. 11A , theapplicator 90 comprises apad 92 for containing the medicament and, if necessary, a hydrating fluid. Overlying thepad 92 is the firstactive electrode 94 electrically connected toelectronics 96 within the applicator and whichelectronics 96 includes a power supply, for example, a battery, and the necessary electronics for flowing a current of a magnitude previously discussed through the pad to electrokinetically drive the medicament into the treatment site. Overlying the electronics is aground electrode 98, the surface of which remote frompad 92 comprises a tactile surface. Illustrated by the dashed lines is apackaging material 100, for example, plastic packaging typically employed for sterilized packages whereby theapplicator 90 may be sealed within thematerial 100. With the medicament prepackaged within thepad 92, the user opens thepackage 90. In a preferred form, theapplicator 90 is connected with thepackaging 100 via atab 102. By removing theapplicator 90 from or opening thepackaging material 100, thetab 102 uncovers the battery terminals whereby the power supply is activated. InFIG. 11A , the applicator is provided without the medicament. The user applies the medicament to the pad, hydrates the pad if necessary, and applies the applicator to the treatment site. By applying the pad directly over the treatment site and pressing a finger on the tactile surface of the ground electrode, i.e., on the opposite side of the applicator from the pad, an electrical circuit is completed through the individual's finger and body and through the first electrode, the pad and treatment site whereby the medicament within the pad is electromotively transported to the site. To facilitate good electrical connection, the ground electrode may have an electrical conducting fluid, e.g., hydrogel, overlying its tactile surface. - In
FIG. 11B , the medicament is prepackaged in thepad 92. InFIG. 11C , both the medicament and the hydrating fluid is self-contained in the pad. For example, the medicament and the hydrating fluid can be provided in capsules rupturable by pressure applied between the opposite surfaces of the pad before, during or after removal of the applicator from thepackage 100. Further, a very weak, e.g., less than 0.05% saline solution encapsulated and integrated between theactive foil electrode 94 and the medicament with or without a porous matrix reservoir interposed between the encapsulated hydration fluid and the medicament may be employed. Alternatively, adhesively attached or otherwise releasably attached seals for sealing the medicament and the hydration fluid, if necessary, to the applicator to ensure long shelf life and integrity of the foil electrode can be provided. - Additionally, the unit of
FIGS. 11A-11C may have a tacky substance, e.g., hydrogel, not shown, overlying theground electrode 98 within thepackage 100. Upon opening the package, the individual may contact his/her finger on the tacky substance, facilitating removal of the unit from thepackage 100. This finger contact on the ground electrode side of the unit also facilitates ready, direct and intuitive manipulation and application of the unit to the treatment site by the individual. - Referring now to the embodiment hereof illustrated in
FIGS. 12-14 , there is illustrated a further form of applicator body orsubstrate 110 which comprises a self-contained disposable unit having integral miniaturized electronic circuitry and a power source. In this form, the applicator may comprise a rectilinear or circular article having a centrally locatedpad 111 and electronic circuitry superposed over the pad. Thus, a first oractive electrode 112 overlies the pad and the electronics previously described may overlie the first electrode. Thebattery 116 may overlie the electronics. The first terminal of the battery is connected through the electronics with the first electrode which, in turn, is in electrical contact with thepad 111. The second terminal of the battery is in contact with aground electrode 118. The ground electrode may be provided around the margin of the applicator surrounding the pad. For example, if the applicator is shaped in the form of a circle, the ground electrode may comprise an annulus surrounding and electrically insulated from thepad 111. Alternatively, if the applicator is rectilinear, the ground electrode may comprise the margin of the rectilinear applicator or lie at one end of the applicator. In this form, the electrical circuit is completed between the ground electrode and the pad. The distance between the ground electrode and the pad may be on the order of one-half inch or more. The ground electrode need not surround the pad but may be located to one side of the pad a suitable distance from the pad for completing the return circuit path through the skin between the treatment site and the ground electrode. - In the applicator illustrated in
FIG. 12 , the pad may be provided without the medicament and the user may apply the medicament to the pad upon removal ofrelease liner 120. The battery may be of the air-actuated type previously discussed. Thus, the user, upon applying the medicament to the pad and removing the tab from the battery, may apply the applicator over the lesion, holding both the ground electrode about or spaced from the treatment site and the pad in contact with the treatment site. This completes the electrical circuit through the applicator and the individual's skin between the ground contacting surface and pad contacting surface. If desired, adhesive may be provided on the underside of theapplicator body 110 and overlaid by therelease liner 120 to releasably adhere the applicator including thepad 111 andground electrode 118 to the individual's skin and overlying the treatment site. Upon completion of the treatment, the applicator may be discarded. - Alternatively, as illustrated in
FIG. 13 , the applicator may be prepackaged with the medicament encapsulated within the pad. The capsule is indicated at 122. If the medicament is itself electrically conductive, the individual may apply pressure to the pad to rupture the capsule, spreading the medicament into the interstices of the pad. This can be accomplished while the applicator remains in its packaging. By applying the applicator to the treatment site similarly as previously described in connection withFIG. 12 , the circuit is completed whereby the medicament is electrokinetically driven into the site. - In
FIG. 14 , both the medicament and a hydrating fluid are encapsulated in the pad. The medicament and hydration fluid capsules are indicated at 122 and 124, respectively. The applicator ofFIG. 14 is employed similarly as described with respect toFIGS. 12 and 13 after the user ruptures the capsules to intermingle the electrically conductive water and the medicament. - Referring now to
FIG. 15 , there is illustrated adevice 130 similar to the device ofFIG. 1 and containing a power source, electronic circuitry including a voltage multiplier and a current driver and atactile electrode 132 exposed through an outer surface of thedevice 130. Instead of having the active or first electrode fixed to the end of thedevice 130, theactive electrode 134 is mounted on thedevice 130 for movement in an axial direction. The movement is designed to open or close a pressure actuated switch in the electronic circuitry to activate the device. Thus, theactive electrode 134 in an outermost position maintains the electronic circuitry in an off condition. Pressure applied to the first oractive electrode 134 tending to displace it toward the device housing closes the switch, activating the electronic circuitry for electrokinetic delivery of the medicament. - In this form of the invention and instead of an applicator releasably secured to an electrokinetic device, the distal face of the
first electrode 134 may be provided with anelectrical insulator ring 136 defining and surrounding areservoir 138. It will be appreciated that the medicament can be supplied from an ancillary tube, jar or the like in the form of a gel, cream, foam or the like and disposed by the user into thereservoir 138 within the insulatingring 136 prior to use. With the reservoir filled with medicament, the device can be applied to the treatment site similarly as the device ofFIG. 2 is applied to the treatment site. By applying a slight pressure on the device toward the treatment site, the electrical circuit is closed. Thus, the medicament within the reservoir is electrokinetically motivated into the treatment site, the electrical circuit being completed through the treatment site, with the medicament, thefirst electrode 134, the electronics, thetactile electrode 132 and the individual's hand and skin between the tactile electrode and the treatment site. - Referring now to
FIGS. 16 and 17 , there is illustrated a further form of applicator in accordance with the present invention. In this form, an applicator, generally designated 150, may be used in conjunction with the device illustrated inFIG. 1 and which applicator is particularly useful for electrokinetically delivering a liquid medicament. Theapplicator 150 may comprise an insulatedannular housing 152 in the form of a torus having acentral reservoir 154 for confining the liquid. One side of thehousing 152 comprises amicroporous film 156 overlaid by a barrier, e.g., foil orinert tab 158. The margin of thetab 158 has releasable adhesive 160 such that the barrier can be releasably attached to one side of thehousing 152. The barrier tab includes afinger tab 162 for ready removal of thebarrier 158 from the applicator. The opposite end of thereservoir 154 is closed by asimilar barrier layer 164 or by an optionalconductive plate 166. Additionally,tabs 168 are secured along opposite sides of thehousing 152 for releasably securing thehousing 152 to the device, e.g., illustrated inFIG. 1 . - As illustrated in
FIG. 17 , the active electrode of the device bears against the optionalconductive plate 166 which conducts electricity through thebarrier layer 164 into the liquid medicament in thereservoir 154. Upon removal of thetab 158, the liquid medicament when applied to the treatment site can be electrokinetically driven into the treatment site through themicroporous film 156. As noted previously, the liquid within the reservoir may be per se conductive or, if not conductive, may be provided with a carrier whereby the medicament can be driven through theporous membrane 156 into the treatment site. - Referring now to
FIG. 18 , there is illustrated a self-contained electrokinetic medicament delivery device. In this form, however, the ground electrode and the active electrode are separated one from the other by a malleable ortensionable arm 180. For example, theground electrode 182 may be provided in a housing also containing thebattery 184 andelectronics 186. Theground electrode 182 may be surrounded by an adhesive 188 for adhering the ground electrode to a site on an individual directly adjacent a treatment site. Theactive electrode 190 is connected to the battery and electronics via an electrical conductor indicated by the dashedlines 192 through anarm 180. The arm may be flexed resiliently and retained in its flexed position. In utilizing the device ofFIG. 18 , the ground electrode is adhered to the individual's-skin adjacent a treatment site by the adhesive 188. Thearm 180 is then flexed resiliently to engage theactive electrode 190 with the treatment site. By proper manipulation of thearm 180, the entire surface of theactive electrode 190 may contact the treatment site thereby avoiding less than effective treatment. A biased gimbal or pivotal connection between thearm 180 and theground electrode 182 may also be employed rather than a resilientflexible arm 180. Thus, the user may apply the device and have it operate hands' free, the electronics being activated by activation of the battery as previously described. - Referring now to
FIG. 19 , a similar type of hands' free electrokinetic medicament delivery device is illustrated in the form of an U-shaped clip. The ground andactive electrodes clip 196, preferably a spring clip. By placing the electrodes on the inside of the clip, the clip may be applied to gently grip the treatment site, employing the tension of the clip to retain the clip on the treatment site whereby hands' free delivery of the medicament can be accomplished. The fully disposable U-shaped clip may have a built in unit dose applicator or may be reusable if fitted out for use with disposable applicators. - Referring now to
FIG. 20 , there is illustrated a further form of anapplicator 200 for use with an electrokinetic delivery device 202 (FIGS. 22 and 23 ) illustrated in a flat configuration and withinpackaging 204, for example, a plastic sealed package.Applicator 200 includes a flattenedsleeve 206 open at its opposite ends and having anapplicator pad 208 forming part of the sleeve and projecting from one end of the sleeve and along an edge thereof. Preferably, theapplicator pad 208 is circular in form, for reasons which will become apparent and is hinged tosleeve 200 along ahinge line 209. Thepad 208 is preferably a porous open cellular material through which the medicament may be transported to the treatment site. As in prior embodiments, thepad 208 may contain the medicament within the pad within the interstices of the open cellular material or the medicament may be encapsulated withinrupturable capsules 210, similarly as illustrated with respect toFIGS. 7 and 8 . A further alternative provides a pad without medicament, the medicament, and hydration material, if necessary, being applied to the pad by the user at the time the user employs the device to electrokinetically deliver the medicament to the treatment site. Thepad 208 may additionally contain hydration material in ahydration capsule 212 similarly as illustrated inFIG. 8 in the event the medicament is not per se electrokinetically transportable. - As illustrated, the
sleeve 206 is preferably formed of a fabric material similarly as the material ofsubstrate 42. Other suitable materials may be employed forming all or part of the sleeve, i.e., the substrate of any of the applicators disclosed herein may include, polyethylene, paper, cotton, ceramic, silicone rubber, polyurethane, vinyl, polytetrafluoroethlene and other plastics. A suitable barrier may be disposed between thepad 208 and thesleeve 206 to prevent migration of the medicament onto the sleeve or migration of any electrically conductive material such as hydrogel as noted below from thesleeve 206 onto thepad 208. Opposite sides of thesleeve 200 may havecutouts 214 which open through the end ofsleeve 206 opposite thepad 208 or which may be completely enclosed cutouts. Particularly, thecutouts 214 lie at circumferential positions about thesleeve 206 corresponding to the axial and circumferential positions of the tactile electrode, for example,electrode 30 as illustrated inFIG. 1 . Additionally, atab 216, preferably having a pressure sensitive adhesive on one face, projects from thepad 208 opposite from its connection with thesleeve 206. - To use the
applicator 200 in conjunction with theelectrokinetic delivery device 202, thepackaging 204 is removed from theapplicator 200. Where the medicament is encapsulated, the pad may be compressed between the individual's fingers to rupture thecapsule 210 and hence spread the medicament into the interstices of the pad. Where the medicament is not per se capable of electrokinetic transport, thehydration capsule 212 is likewise ruptured to mix the medicament and hydration material such that upon application of electric current, the medicament may be transported to the treatment site. If, of course, the medicament has previously been applied to the pad, the user need not compress the pad. Alternatively, if the pad contains no medicament, the user may apply the medicament to the pad and hydration material, e.g., water or a trace saline solution, if necessary. - As illustrated in
FIG. 21 , pressure applied in the direction of the illustrated arrows will form theflat applicator sleeve 206 into a cylinder for reception about the end of the electrokinetic delivery device mounting the active electrode, for example, the device illustrated inFIG. 1 . Upon application ofsleeve 206 to thedevice 202, thecutouts 214 are aligned with the tactile electrode along the sides of thedevice 202. Additionally, thepad 208 is folded over the active electrode at the end of thedevice 202 and the adhesive tab secures thepad 208 in contact with the active electrode. The user may then grasp thedevice 202 with the user's fingers pressed against the tactile electrode of thedevice 202 to complete the electrical circuit, as previously described. It will be appreciated that thesleeve 206 may have, instead ofcutouts 214, areas impregnated with hydrogel to facilitate electrical contact between the individual's fingers and the tactile electrode of the electrokinetic delivery device. In any embodiment, auxiliary hydration material, e.g., water may be employed. The sleeve may also contain magnetic switch activation material. After application of the device illustrated inFIG. 23 to the treatment site, the user removes theapplicator 200 from the end of thedevice 202 and discards the applicator. Thedevice 202 remains for subsequent use with a similar applicator or other applicators disclosed herein. - The above mechanisms may be monopolar or multi-channel (as in U.S. Pat. No. 5,160,316, now Re. 36,626, incorporated herein by reference), or hybrid multi-channel in nature. By hybrid multi-channel it is meant that only one current driver is employed while more than one current limiter is employed to a corresponding number of two or more current distributive channels. A potential problem which may possibly be encountered with hand-held, electrokinetic devices, e.g., iontophoretic devices, is non-uniformity in contact pressure between the treatment surface and the active electrode surface. For a self-medicating patient using a probe-type iontophoretic device, if the probe is accidentally held at an oblique angle, non-uniform contact pressure occurs. In the small area where the contact pressure is high, the local electric resistance is low and therefore more current flows in this small area. The resulting current concentration not only prevents a uniform delivery of medicament but also can cause discomfort and even burns due to a high local current density. This detrimental occurrence can be prevented (for example, by using a multi-channel design (segmented electrode). As the contact pressure becomes uneven, the resistance of each channel or segment varies. For small changes in contact pressure and resistance, the current flowing in each channel remains constant due to servo control. However, the bias potential or voltage of each channel will change. For an area with higher contact pressure, and therefore lower resistance, the bias potential will decrease. Based on this decrease in bias potential, an early warning signal for uneven probe placement can be generated and transmitted to the patient for readjustment. If this warning is ignored, and the pressure concentration deteriorates further, some channel will reach its maximum bias potential limit and the current and the concomitant medicament delivery will decrease from the pre-set level. For the channels where the contact pressure is high and resistance is low, the current remains constant (due to servo control of the current) in spite of the reduction in resistance. This is one of the benefits of a multi-channel system where current density remains unchanged under each segmented electrode. The non-uniform contact pressure can still cause global non-uniform medicament delivery but not burns.
- An example of how the presence of non-uniform contact pressure can be detected is illustrated in
FIG. 24 . For ease of explanation, assume that the treatment electrode is divided into four segments 25 a-d as shown inFIG. 24 . Treatment currents in equal amounts, flow to electrode segments 252 a-d, respectively. The current components are maintained by separate servo control loops to remain constant, irrespective of the skin and medicament conductivity, by varying the bias potential of each electrode segment. Under normal conditions in which the contact pressure is uniform, the bias potentials, Va, Vb, Vc and Vd for respective segments are substantially equal. - As shown in
FIG. 24 , the bias potential of each segment is connected to ananalog multiplexer 254, the output of which is, in turn, connected to an analog-to-digital (A-to-D) channel of amicro-controller 256.Micro-controller 256 is an IC including a microprocessor core with digital inputs, outputs, A-to-D converter, timer, and other functional elements. The microprocessor can be programmed to conduct many diverse tasks. It can also be programmed, for example, to periodically measure and compare the bias potential of each electrode segment. If, for example, Va and Vb are found to be greater than Vc and Vd by a predetermined margin, the electrokinetic probe may be determined to be tilted downward by the patient such that the contact pressure is higher under segments C and D, and lower under segments A and B. The micro-controller can cause analarm 258 to output an aural and/or visual alarm when the non-uniformity in contact pressure (as determined from the bias potentials) exceeds some predetermined value. Instead of using a micro-controller, the non-uniform pressure detection can also be accomplished by using discrete analog circuitry with operational amplifiers, comparators etc. - Fungal infestations of skin and its appendages are also quite common and multiple therapies are available. The infections afflict age groups from childhood to late adulthood and the aged and immune suppressed population. The infections may include, for example, diaper rash, athlete's foot or jock itch and, in children, ringworm and other dermatophytosis. The current treatment of such infections involve anti-fungal agents applied topically. In healthy patients, the topical treatment works, although sometimes frustrating in its response time and chances for recurrence.
- Fungal infections of the nail bed are more refractory to standard management. These frequently distort the nails both on the feet and hand and commonly occur in people working in gardens. These infections create deformity of the nails and patients frequently ask for treatment. Unfortunately, the current treatment involves systemic drugs that have significant liver toxicity as well as side effects. Many patients fail to undergo the typical eight weeks of treatment required to control such infections.
- As described herein, the present invention offers a more rapid resolution of topical infections and more effective non-systemic treatment of the more refractory nail infections. As in the prior embodiments, the treatment method and apparatus for fungal infestation employs an electrokinetic, e.g., iontophoretic transport mechanism including electronics to drive the medicament into the infected (treatment) site to ultimately prevent the fungus from replicating. There are numerous medicaments available on the market for this purpose. In addition, there are several non-pharmaceutical level agents that may have a significant benefit to the treatment of fungal infections.
- Referring to
FIG. 25 , there is illustrated anapplicator 270 for the treatment of athlete's foot, e.g., where fungal infestation occurs between the toes. Theapplicator 270 is in the form of a flexible elastic sock electrode with anelectronics package 271 containing abattery 272,electronics 274,ground electrode 276 andactive electrodes 278 in registration with fungal infested areas between the individual's toes. Thepackage 271 is strapped about the individual's ankle by astrap 273. Discrete medicament-carryingpads 280 are shaped to extend between the toes along the interior potion of the toe region of the sock.Individual branch wires 284 overlying thepads 280 and with an electrically insulative covering, not shown, are coupled to the electronics package by conductive wire leads 285 disposed in an insulativeprotective ribbon 286. By wearing the sock, e.g., one to two hours, and completing the circuit between eachactive electrode 284 and theground electrode 276 through the individual's ankle, a single treatment is sufficient to drive the anti-fungal medication carried by thepads 280 into the infected area between the toes to completely resolve the fungal infestation. It will be appreciated that the pads may form an integral part of theelastic sock 270 preferably along the inside portion of the toe region. The medicament is preferably pre-supplied within the pads, e.g., encapsulated and with or without hydration material as in prior embodiments hereof. Thesock 270 may also be disposable with theelectronics package 271 or the electronic package may be disconnected and reconnected to one or more additional socks as needed for applying additional medicament at the appropriate treatment intervals. - A similar arrangement is illustrated in
FIG. 26 for electrokinetic application of medicaments to toenail fungal beds. In this form, theelastic sock 290 includesactive electrode portions 292 overlying apad 293 containing the anti-fungal agent in the region of the sock overlying the individual toenails. Eachactive electrode portion 292 may comprise short individuallead wires 294 coupled via individual leads 296 to anelectronics package 298 similar to the package described and illustrated with respect toFIG. 25 . Thus, electrokinetic delivery of the medicament to the nail beds of the toes is provided upon completion of the circuit through theactive electrodes 294 and ground electrode in theelectronics package 298 through the ankle of the individual. This treatment requires prolonged and overnight wear of the sock electrode and may involve a plurality of treatments, for example, three treatments with a spacing of about two or three days. - Referring now to
FIGS. 27 and 28 , there is illustrated an applicator for the treatment of fingernail fungal beds. In this form; anapplicator body 300 may be generally hemispherical in shape and is preferably formed of a resiliently elastic material. In the arcuate surface of the hemispherically-shapedbody 300, there is provided one ormore fingerholes 302 into which the individual's fingernails may be received, e.g., up to about the first finger joint. Thus, fivefingerholes 302 can be provided at various positions about thebody 300 consistent with the anatomical orientation of an individual's bent fingers when his/her hand rests on the arcuate upper surface of thebody 300 enabling the fingertips to be received in theopenings 302. - As best illustrated in
FIG. 28 , thebody 300 includes anactive electrode 304 in each of theopenings 302 at a location in registration with, i.e., opposite, the fingernail of the individual's finger when received in the hole. A medicament-containing porous pad, for example, in the form of athimble 306, preferably pre-supplied with medicament or having encapsulated medicament along a forward edge thereof is provided. Alternatively, the individual user may apply the medicament to the thimble pad portion upon use. Thethimble 306 may also contain a resilientelastic material 308, for example, sponge material, such that upon placing the thimble about the individual's fingertip and thefingertip including thimble 306 in thehole 302, thesponge material 308 biases the individual's nail forwardly into contact with the forwardmost pad portion of the thimble to make electrical contact with theactive electrode 304. As in the prior embodiments, hydrating material may also be supplied integrally with the thimble, for example, in the form of encapsulated hydration material or the individual may hydrate the medicament in the thimble pad portion upon use. - As illustrated in
FIG. 28 , theground electrode 310 is provided along an arcuate surface of thebody 300 such that when the individual lays his/her hand over the arcuate portion of thebody 300, the palm of the hand rests againstground electrode 310 with the finger or fingers in theholes 302 bearing against thepad 306 andactive electrodes 304. It will be appreciated that eachhole 302 has anactive electrode 304 associated with that hole. The active and ground electrodes are coupled to theelectronics 312 which, in turn, is coupled to apower source 314 integral withbody 300. It will be appreciated that thebody 300 may have other shapes, for example, an elastic spherical shape, such that the individual can carry the electrokinetic delivery device in his/her hand for the duration of the treatment period. Alternatively, as illustrated, thebody 300 may have a flat undersurface enabling the individual to rest his/her hand on the upper arcuate surface of thebody 300 withbody 300 supported, for example, on a desk or table. - As will be appreciated from the above description, a variety of active electrodes can be designed for size and contour for application to various parts of the human body. For example, electrodes can be woven into undergarments to alleviate refractory infestation in the inguinal area, commonly described as jock itch. Moreover, applicators such as the sock electrodes described, are disposable items with prescribed medication pre-supplied for specific application.
- Referring now to the embodiment hereof illustrated in
FIGS. 29-31 , various medicaments may be electrokinetically applied in an ocular application similar to and worn like a contact lens. For example, as illustrated inFIG. 29 , there is provided anelectronics package 320 comprised of abattery 322,electronics 324 and aground electrode 326 carried by astrap 328 designed to envelope the individual's head releasably securing theelectronics package 320 on the forehead with the ground electrode engaging the individual's forehead. Contrary to the preceding embodiment, the mechanism of the electrokinetic delivery may be a multi-channel electrode as described in U.S. Pat. No. 5,160,316, now Re. 36,626, incorporated herein by reference. While delivery of medicament is illustrated as being applied to both eyes simultaneously, it will be appreciated that the electrokinetic delivery system hereof can be applied to only one eye. - As illustrated, the electronics of the
package 320 are coupled to anapplicator electrode 330 for each eye via aribbon cable connector 332. Theapplicator electrodes 330 are each in the form of a concave-convex matrix formed of electrodispersive material sufficiently flexible to fit and overlie the various contours of individual eyes. Each matrix is similar to a contact lens.Applicator electrode 330 includes a combined handle andconnector 334 which projects from the convex side of theapplicator electrode 330, facilitating a finger grip for thecontact electrode 330 and an electrical connection for theribbon connector 332. The individual lead wires in theribbon connector 332 are continued through the combined handle andconnector 334 into theelectrode 330. As illustrated inFIG. 31 , these individual conductors orlead wires 336 extend from the combined handle andconnector 334, preferably in semi-circular patterns along opposite halves of thecontact electrode 330. Each of theconductors 336 has a plurality of short lead wires orsupplemental conductors 338 at spaced positions along eachconnector 336 to provide increased contact area, i.e., to further distribute the electrical current flow along the surface of the eye. Each of the lead wires orconnectors 336 has adiscrete pad 339 associated with it for carrying the medicament and which medicament is electrokinetically driven into the eye upon completion of the electrical circuit between theapplicator electrode 330, the eye, the individual's skin between the active and ground electrodes, and theground electrode 326. - As noted in the aforementioned patent, the
lead wires 336 in eachcontact electrode 330 may be electrically driven simultaneously or in sequential multiplex fashion. With the current in eachconnector 336 being limited, for example, within the range previously discussed, current tunneling or current flow along the path of least resistance is substantially eliminated. For delivering medicaments, the ocular electrokinetic delivery system described herein is preferably worn by an individual over a period of time, for example, up to an hour, with the multi-channel driver electrokinetically delivering the medicament into the cornea. Further, the contour of the eye can be reshaped by delivering agents that retain water which would swell the conjunctiva in specific sites of the eye. By applying differential levels of power and agent delivery through use of a multi-channel system, the refraction of light can be modified by altering the shape of the eye. - While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood that the invention is not to be limited to the disclosed embodiment, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/265,383 US20060052739A1 (en) | 2000-05-31 | 2005-11-03 | Electrokinetic delivery of medicaments |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/584,138 US6477410B1 (en) | 2000-05-31 | 2000-05-31 | Electrokinetic delivery of medicaments |
US10/245,337 US6735470B2 (en) | 2000-05-31 | 2002-09-18 | Electrokinetic delivery of medicaments |
US10/807,295 US7069073B2 (en) | 2000-05-31 | 2004-03-24 | Electrokinetic delivery of medicaments |
US11/265,383 US20060052739A1 (en) | 2000-05-31 | 2005-11-03 | Electrokinetic delivery of medicaments |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/807,295 Division US7069073B2 (en) | 2000-05-31 | 2004-03-24 | Electrokinetic delivery of medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060052739A1 true US20060052739A1 (en) | 2006-03-09 |
Family
ID=24336071
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/584,138 Expired - Fee Related US6477410B1 (en) | 1999-03-12 | 2000-05-31 | Electrokinetic delivery of medicaments |
US10/245,337 Expired - Lifetime US6735470B2 (en) | 1999-03-12 | 2002-09-18 | Electrokinetic delivery of medicaments |
US10/807,295 Expired - Fee Related US7069073B2 (en) | 2000-05-31 | 2004-03-24 | Electrokinetic delivery of medicaments |
US11/104,568 Abandoned US20050182351A1 (en) | 2000-05-31 | 2005-04-13 | Electrokinetic delivery of medicaments |
US11/265,383 Abandoned US20060052739A1 (en) | 2000-05-31 | 2005-11-03 | Electrokinetic delivery of medicaments |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/584,138 Expired - Fee Related US6477410B1 (en) | 1999-03-12 | 2000-05-31 | Electrokinetic delivery of medicaments |
US10/245,337 Expired - Lifetime US6735470B2 (en) | 1999-03-12 | 2002-09-18 | Electrokinetic delivery of medicaments |
US10/807,295 Expired - Fee Related US7069073B2 (en) | 2000-05-31 | 2004-03-24 | Electrokinetic delivery of medicaments |
US11/104,568 Abandoned US20050182351A1 (en) | 2000-05-31 | 2005-04-13 | Electrokinetic delivery of medicaments |
Country Status (11)
Country | Link |
---|---|
US (5) | US6477410B1 (en) |
EP (2) | EP2277584A1 (en) |
JP (1) | JP4199457B2 (en) |
CN (1) | CN1287877C (en) |
AU (5) | AU7485101A (en) |
BR (1) | BR0111288A (en) |
CA (1) | CA2413806C (en) |
HK (1) | HK1054338A1 (en) |
MX (1) | MXPA02011842A (en) |
RU (1) | RU2268075C2 (en) |
WO (1) | WO2001091853A1 (en) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070060860A1 (en) * | 2005-08-18 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20070060859A1 (en) * | 2005-08-08 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20070066930A1 (en) * | 2005-06-20 | 2007-03-22 | Transcutaneous Technologies, Inc. | Iontophoresis device and method of producing the same |
US20070066932A1 (en) * | 2005-09-15 | 2007-03-22 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20070093787A1 (en) * | 2005-09-30 | 2007-04-26 | Transcutaneous Technologies Inc. | Iontophoresis device to deliver multiple active agents to biological interfaces |
US20070197955A1 (en) * | 2005-10-12 | 2007-08-23 | Transcutaneous Technologies Inc. | Mucous membrane adhesion-type iontophoresis device |
US20080004564A1 (en) * | 2006-03-30 | 2008-01-03 | Transcutaneous Technologies Inc. | Controlled release membrane and methods of use |
US20080033398A1 (en) * | 2005-12-29 | 2008-02-07 | Transcutaneous Technologies Inc. | Device and method for enhancing immune response by electrical stimulation |
US20080033338A1 (en) * | 2005-12-28 | 2008-02-07 | Smith Gregory A | Electroosmotic pump apparatus and method to deliver active agents to biological interfaces |
US20080058701A1 (en) * | 2006-07-05 | 2008-03-06 | Transcutaneous Technologies Inc. | Delivery device having self-assembling dendritic polymers and method of use thereof |
US20080114282A1 (en) * | 2006-09-05 | 2008-05-15 | Transcu Ltd. | Transdermal drug delivery systems, devices, and methods using inductive power supplies |
US20080175895A1 (en) * | 2007-01-16 | 2008-07-24 | Kentaro Kogure | System, devices, and methods for iontophoretic delivery of compositions including antioxidants encapsulated in liposomes |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
US20080262581A1 (en) * | 2007-04-17 | 2008-10-23 | Transport Pharmaceuticals, Inc. | Current density detection and control system and method for an electrokinetic delivery of medicaments |
US20090005721A1 (en) * | 2005-12-09 | 2009-01-01 | Tti Ellebeau, Inc. | Packaged iontophoresis system |
US20090022784A1 (en) * | 2007-06-12 | 2009-01-22 | Kentaro Kogure | Systems, devices, and methods for iontophoretic delivery of compositions including liposome-encapsulated insulin |
US20090187134A1 (en) * | 2005-09-30 | 2009-07-23 | Hidero Akiyama | Iontophoresis Device Controlling Amounts of a Sleep-Inducing Agent and a Stimulant to be Administered and Time at Which the Drugs are Administered |
US20090216175A1 (en) * | 2005-08-05 | 2009-08-27 | Transcu Ltd. | Transdermal Administration Device and Method of Controlling the Same |
US20090216177A1 (en) * | 2005-09-16 | 2009-08-27 | Tti Ellebeau,Inc | Catheter-type iontophoresis device |
US20090214625A1 (en) * | 2005-07-15 | 2009-08-27 | Mizuo Nakayama | Drug delivery patch |
US20090299265A1 (en) * | 2005-09-30 | 2009-12-03 | Tti Ellebeau, Inc. | Electrode Assembly for Iontophoresis Having Shape-Memory Separator and Iontophoresis Device Using the Same |
US20100016781A1 (en) * | 2005-08-29 | 2010-01-21 | Mizuo Nakayama | Iontophoresis device selecting drug to be administered on the basis of information form sensor |
US20100021530A1 (en) * | 2008-07-25 | 2010-01-28 | Innovation Biomedical Devices, Inc. | Enhanced trans-keratin drug delivery |
US20100030128A1 (en) * | 2005-09-06 | 2010-02-04 | Kazuma Mitsuguchi | Iontophoresis device |
US20100069877A1 (en) * | 2008-09-10 | 2010-03-18 | Smith Gregory A | Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process |
US7793666B2 (en) | 2005-07-28 | 2010-09-14 | Innovation Biomedical Devices, Inc. | Apparatus and method for treatment of infected nail |
US7848801B2 (en) | 2005-12-30 | 2010-12-07 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
US20100312168A1 (en) * | 2009-06-09 | 2010-12-09 | Yoshimasa Yoshida | Long life high capacity electrode, device, and method of manufacture |
US8062783B2 (en) | 2006-12-01 | 2011-11-22 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
US20140378889A1 (en) * | 2012-06-18 | 2014-12-25 | Michael Tavger | Method and system for delivering solution into the pores of recipient human skin |
WO2015027055A1 (en) * | 2013-08-23 | 2015-02-26 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US9186278B2 (en) | 2013-11-27 | 2015-11-17 | Elwha Llc | Systems and devices for sampling and profiling microbiota of skin |
US9390312B2 (en) | 2013-08-23 | 2016-07-12 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9456777B2 (en) | 2013-08-23 | 2016-10-04 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9526480B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9526450B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9549703B2 (en) | 2013-11-27 | 2017-01-24 | Elwha Llc | Devices and methods for sampling and profiling microbiota of skin |
US9557331B2 (en) | 2013-08-23 | 2017-01-31 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9610037B2 (en) | 2013-11-27 | 2017-04-04 | Elwha Llc | Systems and devices for profiling microbiota of skin |
US9713632B2 (en) | 2014-10-21 | 2017-07-25 | Hexima Limited | Method of treatment |
US9805171B2 (en) | 2013-08-23 | 2017-10-31 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9811641B2 (en) | 2013-08-23 | 2017-11-07 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US10010704B2 (en) | 2013-08-23 | 2018-07-03 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US10152529B2 (en) | 2013-08-23 | 2018-12-11 | Elwha Llc | Systems and methods for generating a treatment map |
RU2709159C1 (en) * | 2018-10-26 | 2019-12-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Владимирский Государственный Университет имени Александра Григорьевича и Николая Григорьевича Столетовых" (ВлГУ) | Device for treating fungal infections of nails |
US20210282831A1 (en) * | 2016-08-01 | 2021-09-16 | Drexel University | Devices and methods for treatment of skin conditions |
Families Citing this family (272)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
US20110075507A1 (en) * | 1997-10-24 | 2011-03-31 | Revalesio Corporation | Diffuser/emulsifier |
US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
US7127285B2 (en) * | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
US6792306B2 (en) | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
US6641591B1 (en) | 1999-08-26 | 2003-11-04 | John H. Shadduck | Instruments and techniques for controlled removal of epidermal layers |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US20050049578A1 (en) * | 2000-04-14 | 2005-03-03 | Hosheng Tu | Implantable ocular pump to reduce intraocular pressure |
US20040111050A1 (en) * | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US7465382B2 (en) * | 2001-06-13 | 2008-12-16 | Eksigent Technologies Llc | Precision flow control system |
US20020189947A1 (en) | 2001-06-13 | 2002-12-19 | Eksigent Technologies Llp | Electroosmotic flow controller |
EP1418919A4 (en) * | 2001-07-20 | 2007-06-13 | Iomed Inc | The use of 5 fluorourcil, delivered by inotophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin |
US8788031B2 (en) * | 2001-09-21 | 2014-07-22 | Encore Medical Asset Corporation | Method and device for the iontophoretic delivery of a drug |
FR2830766B1 (en) * | 2001-10-12 | 2004-03-12 | Optis France Sa | DEVICE OF ISSUE OF DRUGS THROUGH IONTOPHORESIS TRANSPALPEBRALE |
CA2464949A1 (en) * | 2001-10-24 | 2003-05-01 | Daniela Mavor | Device and method for controlled delivery of active substance into the skin |
US20030144625A1 (en) * | 2002-01-28 | 2003-07-31 | Garry Sherman | Method and apparatus for the treatment of infections of the nail matrix and nail plate |
AU2007203591B2 (en) * | 2002-04-08 | 2010-07-29 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments |
US7483736B2 (en) * | 2002-04-24 | 2009-01-27 | Rocky Mountain Biosystems, Inc. | Feedback control device for transcutaneous drug delivery and uses therefor |
US7517440B2 (en) | 2002-07-17 | 2009-04-14 | Eksigent Technologies Llc | Electrokinetic delivery systems, devices and methods |
US7235164B2 (en) * | 2002-10-18 | 2007-06-26 | Eksigent Technologies, Llc | Electrokinetic pump having capacitive electrodes |
FR2844719B1 (en) * | 2002-09-24 | 2004-11-19 | Francois Duret | ELECTROCHEMICAL DEVICE FOR BLEACHING A BODY |
KR20050098277A (en) * | 2003-01-29 | 2005-10-11 | 이-필 파마 리미티드 | Active drug delivery in the gastrointestinal tract |
US20040267240A1 (en) * | 2003-01-29 | 2004-12-30 | Yossi Gross | Active drug delivery in the gastrointestinal tract |
US7220597B2 (en) * | 2003-01-30 | 2007-05-22 | Zin Benedict L | Assay test device and method of making same |
US20040158194A1 (en) * | 2003-02-06 | 2004-08-12 | Wolff Andy And Beiski Ben Z. | Oral devices and methods for controlled drug release |
US20040225217A1 (en) * | 2003-02-14 | 2004-11-11 | Voegele James W. | Fingertip ultrasound medical instrument |
US20040193211A1 (en) * | 2003-02-14 | 2004-09-30 | Voegele James W. | Fingertip surgical instruments |
US20040199204A1 (en) * | 2003-02-14 | 2004-10-07 | Voegele James W. | Multifunctional surgical instrument |
US8118722B2 (en) | 2003-03-07 | 2012-02-21 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
US7153256B2 (en) * | 2003-03-07 | 2006-12-26 | Neuronetics, Inc. | Reducing discomfort caused by electrical stimulation |
FR2855761B1 (en) * | 2003-06-03 | 2006-02-24 | Optis France Sa | OCULAR DEVICE FOR VARIABLE DELIVERY OF ACTIVE PRINCIPLES BY IONTOPHORESIS |
US8016810B2 (en) * | 2003-06-23 | 2011-09-13 | Transpharma Medical Ltd. | Transdermal delivery system for cosmetic agents |
US20040267283A1 (en) * | 2003-06-25 | 2004-12-30 | Daniela Mavor | Method, device and kit for body decoration |
US20040265395A1 (en) * | 2003-06-30 | 2004-12-30 | Ying Sun | Device for delivery of reducing agents to barrier membranes |
US7486989B2 (en) * | 2003-06-30 | 2009-02-03 | Johnson & Johnson Consumer Companies, Inc. | Device for delivery of oxidizing agents to barrier membranes |
US7477940B2 (en) * | 2003-06-30 | 2009-01-13 | J&J Consumer Companies, Inc. | Methods of administering an active agent to a human barrier membrane with galvanic generated electricity |
US7479133B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating acne and rosacea with galvanic generated electricity |
US7507228B2 (en) * | 2003-06-30 | 2009-03-24 | Johnson & Johnson Consumer Companies, Inc. | Device containing a light emitting diode for treatment of barrier membranes |
US7476222B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of reducing the appearance of pigmentation with galvanic generated electricity |
US7480530B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
US7477938B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Cosumer Companies, Inc. | Device for delivery of active agents to barrier membranes |
US8734421B2 (en) | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US7477939B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating a wound with galvanic generated electricity |
US7477941B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of exfoliating the skin with electricity |
JP4728235B2 (en) * | 2003-07-14 | 2011-07-20 | パワー ペーパー リミティド | Method, apparatus and kit for treating onychomycosis using electrokinetic transport of substances |
US8455228B2 (en) * | 2003-07-16 | 2013-06-04 | University Of South Florida | Method to facilitate directed delivery and electroporation using a charged stream |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
US8313776B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
US8313775B2 (en) | 2003-07-21 | 2012-11-20 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
EP1653925A1 (en) | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
CA2535398C (en) | 2003-08-12 | 2013-11-12 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
JP5686494B2 (en) | 2003-08-29 | 2015-03-18 | シオノギ インコーポレイテッド | Antibiotic preparations, their use and preparation |
JP2007513869A (en) | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | Antibiotic preparations, their use and preparation |
US20050096550A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transrectal delivery of a denervating agent to the prostate gland |
US20050096549A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transperineal delivery of a denervating agent to the prostate gland |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
JP5138229B2 (en) * | 2003-12-24 | 2013-02-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Tissue ablation by irreversible electroporation |
US20050148833A1 (en) * | 2003-12-24 | 2005-07-07 | Gregory Skover | Apparatus containing a sensing element for the treatment of skin |
US20050142187A1 (en) * | 2003-12-24 | 2005-06-30 | Treacy Donald J.Jr. | Enhanced absorption of modified release dosage forms |
US8666486B2 (en) | 2004-03-04 | 2014-03-04 | Hadasit Medical Research Services & Development Limited | Safe device for iontophoretic delivery of drugs |
US8454543B2 (en) * | 2004-03-10 | 2013-06-04 | Vision Quest Industries Incorporated | Electrodes for orthotic device |
US8936560B2 (en) * | 2004-03-10 | 2015-01-20 | Vision Quest Industries Incorporated | Bracing and electrostimulation for arthritis |
US20080234225A1 (en) * | 2004-03-15 | 2008-09-25 | John Lezdey | Method of treatment |
US7521140B2 (en) * | 2004-04-19 | 2009-04-21 | Eksigent Technologies, Llc | Fuel cell system with electrokinetic pump |
US7559356B2 (en) * | 2004-04-19 | 2009-07-14 | Eksident Technologies, Inc. | Electrokinetic pump driven heat transfer system |
WO2005115225A2 (en) | 2004-05-27 | 2005-12-08 | Ben Zion Beiski | Intraoral apparatus and method for blood and saliva monitoring & sensing |
US7826726B2 (en) * | 2004-06-07 | 2010-11-02 | Mccoy Mark S | Intra-convertible thermal vapor extraction and delivery system |
US8715727B2 (en) | 2004-07-02 | 2014-05-06 | Shionogi Inc. | Tablet for pulsed delivery |
US20070292445A1 (en) * | 2004-07-06 | 2007-12-20 | Transpharma Medical Ltd. | Delivery system for transdermal immunization |
TWI259091B (en) * | 2004-07-09 | 2006-08-01 | Nat Univ Chung Cheng | Electrical energy assisting device for transdermal patch |
US7794415B2 (en) * | 2004-07-13 | 2010-09-14 | S.C. Johnson & Son, Inc. | Surface treatment device |
US20060095001A1 (en) * | 2004-10-29 | 2006-05-04 | Transcutaneous Technologies Inc. | Electrode and iontophoresis device |
US7857746B2 (en) | 2004-10-29 | 2010-12-28 | Nueronetics, Inc. | System and method to reduce discomfort using nerve stimulation |
WO2006064502A2 (en) * | 2004-12-14 | 2006-06-22 | E-Pill Pharma, Ltd. | Local delivery of drugs or substances using electronic permeability increase |
US8349352B2 (en) * | 2005-02-04 | 2013-01-08 | Auburn University | Therapeutic contact lenses with anti-fungal delivery |
WO2006084275A2 (en) * | 2005-02-04 | 2006-08-10 | Auburn University | Contact drug delivery system |
US8388995B1 (en) | 2006-02-03 | 2013-03-05 | Auburn University | Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform |
US9238003B2 (en) | 2005-02-04 | 2016-01-19 | Auburn University | Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules |
US8157807B2 (en) * | 2005-06-02 | 2012-04-17 | The Invention Science Fund I, Llc | Skin treatment including patterned light |
US20060276859A1 (en) * | 2005-06-02 | 2006-12-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Photopatterning of skin |
JP4360497B2 (en) * | 2005-03-09 | 2009-11-11 | 国立大学法人 東京大学 | Electric tactile presentation device and electric tactile presentation method |
US20060264804A1 (en) * | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
US20060229524A1 (en) * | 2005-04-08 | 2006-10-12 | Alden Ozment | Method for the accurate placement of EKG electrodes |
US7856263B2 (en) * | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
US7300409B2 (en) * | 2005-05-12 | 2007-11-27 | S.C. Johnson & Son, Inc. | Therapy patch |
JP2008540023A (en) * | 2005-05-19 | 2008-11-20 | イー−ピル ファーマ リミティド | Ingestible device for nitric oxide production in tissues |
US20070106138A1 (en) * | 2005-05-26 | 2007-05-10 | Beiski Ben Z | Intraoral apparatus for non-invasive blood and saliva monitoring & sensing |
US20070032846A1 (en) * | 2005-08-05 | 2007-02-08 | Bran Ferren | Holographic tattoo |
US20070045337A1 (en) * | 2005-06-24 | 2007-03-01 | Hornsby James R | Dispensing device |
US20070038270A1 (en) * | 2005-07-05 | 2007-02-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multi step photopatterning of skin |
US20070009542A1 (en) * | 2005-07-05 | 2007-01-11 | Galit Levin | Method and device for transdermal immunization |
US20070016277A1 (en) * | 2005-07-05 | 2007-01-18 | Carol Karat | Lip augmentation device |
US7824324B2 (en) | 2005-07-27 | 2010-11-02 | Neuronetics, Inc. | Magnetic core for medical procedures |
US8295922B2 (en) | 2005-08-08 | 2012-10-23 | Tti Ellebeau, Inc. | Iontophoresis device |
CA2618519C (en) | 2005-08-12 | 2016-09-27 | Rick B. Yeager | System and method for applying a reflectance modifying agent to improve the visual attractiveness of human skin |
US20070048340A1 (en) * | 2005-08-31 | 2007-03-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multi step patterning of a skin surface |
US20070185432A1 (en) * | 2005-09-19 | 2007-08-09 | Transport Pharmaceuticals, Inc. | Electrokinetic system and method for delivering methotrexate |
US20070066934A1 (en) | 2005-09-19 | 2007-03-22 | Transport Pharmaceuticals, Inc. | Electrokinetic delivery system and methods therefor |
EP1937226A2 (en) * | 2005-09-23 | 2008-07-02 | Alza Corporation | Transdermal galantamine delivery system |
WO2007037324A1 (en) * | 2005-09-28 | 2007-04-05 | Transcu Ltd. | Dry electrode construct for iontophoresis |
US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
US20070078445A1 (en) * | 2005-09-30 | 2007-04-05 | Curt Malloy | Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces |
US20070232983A1 (en) * | 2005-09-30 | 2007-10-04 | Smith Gregory A | Handheld apparatus to deliver active agents to biological interfaces |
EP1957794B1 (en) | 2005-11-23 | 2014-07-02 | Eksigent Technologies, LLC | Electrokinetic pump designs and drug delivery systems |
US8099162B2 (en) * | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
FR2893852B1 (en) * | 2005-11-29 | 2010-09-03 | Eyegate Pharma Sa | OCULAR IONTOPHORESIS DEVICE |
CA2624133A1 (en) * | 2005-11-30 | 2007-06-07 | Transport Pharmaceuticals, Inc. | An applicator cartridge for an electrokinetic delivery system for self administration of medicaments |
WO2007064723A1 (en) * | 2005-11-30 | 2007-06-07 | Transport Pharmaceuticals, Inc. | Combination cartridge and device for electrokinetic delivery of medicament to a treatment site |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8048089B2 (en) | 2005-12-30 | 2011-11-01 | Edge Systems Corporation | Apparatus and methods for treating the skin |
WO2007098058A2 (en) * | 2006-02-16 | 2007-08-30 | Biodel, Inc. | Device for sublingual drug delivery using iontophoresis |
US8036738B2 (en) * | 2006-03-14 | 2011-10-11 | New Jersey Institute Of Technology | Iontophoretic transdermal drug delivery system based on conductive polyaniline membrane |
TW200740410A (en) * | 2006-03-22 | 2007-11-01 | Emotiv Systems Pty Ltd | Electrode and electrode headset |
US10172644B2 (en) | 2006-03-29 | 2019-01-08 | Edge Systems Llc | Devices, systems and methods for treating the skin |
US9566088B2 (en) | 2006-03-29 | 2017-02-14 | Edge Systems Llc | Devices, systems and methods for treating the skin |
EP2206494B1 (en) | 2006-03-31 | 2015-12-02 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
FR2899487A1 (en) * | 2006-04-10 | 2007-10-12 | Galderma Res & Dev | APPLICATION OF ULTRASOUNDS TO NAILS |
KR20090023574A (en) * | 2006-04-20 | 2009-03-05 | 트랜스포트 파마슈티컬스, 인코포레이티드 | Pharmaceutical formulations for iontophoretic drug delivery |
WO2007124372A2 (en) * | 2006-04-20 | 2007-11-01 | Transport Pharmaceuticals, Inc. | Pharmaceutical formulations for iontophoretic methotrexate delivery |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20070276318A1 (en) * | 2006-05-26 | 2007-11-29 | Mit, Llp | Iontosonic-microneedle applicator apparatus and methods |
US20070282246A1 (en) * | 2006-06-05 | 2007-12-06 | Mit, Llp | Iontosonic-microneedle biosensor apparatus and methods |
NZ594136A (en) * | 2006-06-15 | 2013-03-28 | Seagull Ip Pty Ltd | Delivery of bound material from body to surface using ultrasonic signal |
WO2007147043A2 (en) * | 2006-06-16 | 2007-12-21 | Transport Pharmaceutical, Inc. | Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery |
US8184901B2 (en) | 2007-02-12 | 2012-05-22 | Tcms Transparent Beauty Llc | System and method for applying a reflectance modifying agent to change a person's appearance based on a digital image |
US20080077076A1 (en) * | 2006-08-29 | 2008-03-27 | Transcutaneous Technologies Inc. | Iontophoresis device and method for operation with a usb (universal serial bus) power source |
JP2010502263A (en) * | 2006-08-30 | 2010-01-28 | エルジー ハウスホールド アンド ヘルス ケア エルティーディー. | Iontophoresis device |
US7832920B2 (en) * | 2006-10-25 | 2010-11-16 | Revalesio Corporation | Mixing device for creating an output mixture by mixing a first material and a second material |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
EP2083876A4 (en) | 2006-10-25 | 2012-09-19 | Revalesio Corp | Methods of wound care and treatment |
US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US20080138408A1 (en) * | 2006-11-13 | 2008-06-12 | Siddharth Venkatesh | Drug delivery system and method |
CN101541374B (en) * | 2006-11-24 | 2012-12-05 | 皇家飞利浦电子股份有限公司 | Iontophoretic device |
US7867592B2 (en) | 2007-01-30 | 2011-01-11 | Eksigent Technologies, Inc. | Methods, compositions and devices, including electroosmotic pumps, comprising coated porous surfaces |
US10486174B2 (en) | 2007-02-12 | 2019-11-26 | Tcms Transparent Beauty Llc | System and method for applying a reflectance modifying agent electrostatically to improve the visual attractiveness of human skin |
US8070770B2 (en) * | 2007-02-22 | 2011-12-06 | Ethicon Endo-Surgery, Inc. | Iris valve with novel locking mechanism |
US8075482B2 (en) * | 2007-02-22 | 2011-12-13 | Ethicon Endo-Surgery, Inc. | IRIS valve with control ring |
WO2008109694A1 (en) * | 2007-03-06 | 2008-09-12 | Emotiv Systems Pty Ltd | Electrode and electrode headset |
WO2008121709A1 (en) * | 2007-03-30 | 2008-10-09 | Transport Pharmaceuticals, Inc. | Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug |
US20080262414A1 (en) * | 2007-04-20 | 2008-10-23 | Transport Pharmaceuticals, Inc. | Single use applicator cartridge for an electrokinetic delivery system and method for self administration of medicaments |
US10092082B2 (en) | 2007-05-29 | 2018-10-09 | Tcms Transparent Beauty Llc | Apparatus and method for the precision application of cosmetics |
US8197844B2 (en) | 2007-06-08 | 2012-06-12 | Activatek, Inc. | Active electrode for transdermal medicament administration |
US8845630B2 (en) | 2007-06-15 | 2014-09-30 | Syneron Medical Ltd | Devices and methods for percutaneous energy delivery |
WO2008157485A1 (en) * | 2007-06-15 | 2008-12-24 | Transport Pharmaceuticals, Inc. | Current concentration system and method for electrokinetic delivery of medicaments |
US20120143178A9 (en) * | 2007-06-15 | 2012-06-07 | Primaeva Medical, Inc. | Devices and methods for percutaneous energy delivery |
US20080312579A1 (en) * | 2007-06-15 | 2008-12-18 | Transport Pharmaceuticals, Inc. | Method and system for mitigating current concentration in electrokinetic drug delivery |
US20080319371A1 (en) * | 2007-06-19 | 2008-12-25 | Transport Pharmaceuticals, Inc. | Method and system for treating of onychomycosis with an applicator having a gel medicament layer |
CN101820944A (en) * | 2007-07-30 | 2010-09-01 | 西帖费有限公司 | Medical device, in particular for electroporation treatment |
JP5466161B2 (en) * | 2007-10-09 | 2014-04-09 | トランスファーマ メディカル リミテッド | Magnetic patch connector |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
EP2207669A4 (en) * | 2007-10-25 | 2011-11-02 | Revalesio Corp | Bacteriostatic or bacteriocidal compositions and methods |
MX2010006062A (en) | 2007-12-05 | 2010-09-14 | Syneron Medical Ltd | A disposable electromagnetic energy applicator and method of using it. |
WO2009076134A1 (en) | 2007-12-11 | 2009-06-18 | Eksigent Technologies, Llc | Electrokinetic pump with fixed stroke volume |
JP5508285B2 (en) | 2008-01-04 | 2014-05-28 | エッジ システムズ コーポレーション | Apparatus and method for treating skin |
KR101626167B1 (en) | 2008-01-17 | 2016-05-31 | 시네론 메디컬 리미티드 | A hair removal apparatus for personal use and the method of using same |
US8862223B2 (en) | 2008-01-18 | 2014-10-14 | Activatek, Inc. | Active transdermal medicament patch and circuit board for same |
JP2011509791A (en) | 2008-01-24 | 2011-03-31 | シネロン メディカル リミテッド | Apparatus, device and method for adipose tissue treatment |
WO2009097451A1 (en) | 2008-01-29 | 2009-08-06 | Edge Systems Corporation | Apparatus and method for treating the skin |
CA2723215A1 (en) | 2008-05-01 | 2009-11-05 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
US8150525B2 (en) * | 2008-08-27 | 2012-04-03 | Johnson & Johnson Consumer Companies, Inc. | Treatment of hyperhydrosis |
RU2375955C1 (en) * | 2008-09-04 | 2009-12-20 | ООО "Исследовательско-технологический центр "Аусферр" | Device for determining acupuncture points parametres |
KR101523807B1 (en) | 2008-09-21 | 2015-05-28 | 시네론 메디컬 리미티드 | A method and apparatus for personal skin treatment |
MX349176B (en) | 2008-09-22 | 2017-07-14 | Biochemics Inc | Transdermal drug delivery using an osmolyte and vasoactive agent. |
US9675443B2 (en) | 2009-09-10 | 2017-06-13 | Johnson & Johnson Vision Care, Inc. | Energized ophthalmic lens including stacked integrated components |
US20110281834A1 (en) | 2008-11-10 | 2011-11-17 | Friden Phillip M | Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid |
US9278233B2 (en) * | 2008-12-04 | 2016-03-08 | Biochemics, Inc. | Methods and compositions for tattoo removal |
US8606366B2 (en) | 2009-02-18 | 2013-12-10 | Syneron Medical Ltd. | Skin treatment apparatus for personal use and method for using same |
WO2010098784A1 (en) * | 2009-02-25 | 2010-09-02 | Primaeva Medical , Inc | Devices and methods for percutaneous energy delivery |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
US20110066134A1 (en) * | 2009-04-07 | 2011-03-17 | Nitric Biotherapeutics, Inc. | Controlling Drug Transport and Current in Iontophoretic Onychomycosis Treatment |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
US20100286587A1 (en) * | 2009-05-07 | 2010-11-11 | Yossi Gross | Sublingual electrical drug delivery |
US8414559B2 (en) | 2009-05-07 | 2013-04-09 | Rainbow Medical Ltd. | Gastroretentive duodenal pill |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
WO2011002776A1 (en) * | 2009-06-29 | 2011-01-06 | Nitric Biotherapeutics, Inc. | Pharmaceutical formulations for iontophoretic delivery of an immunomodulator |
EP2451367B1 (en) | 2009-07-08 | 2020-01-22 | Edge Systems Corporation | Devices for treating the skin using time-release substances |
US9937343B2 (en) | 2009-08-28 | 2018-04-10 | Caci Microlift Limited | Electrostimulation skin massage devices |
US9415203B2 (en) * | 2009-08-28 | 2016-08-16 | Caci Microlift Limited | Electrostimulation devices |
US9017310B2 (en) * | 2009-10-08 | 2015-04-28 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including microneedles |
US9014799B2 (en) * | 2009-10-08 | 2015-04-21 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
US8882748B2 (en) | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
AU2010319733B2 (en) * | 2009-11-13 | 2014-08-07 | Johnson & Johnson Consumer Companies, Inc. | Galvanic skin treatment device |
JP5463136B2 (en) * | 2009-12-22 | 2014-04-09 | 帝國製薬株式会社 | Electrode device used for iontophoresis therapy |
US9492687B2 (en) | 2009-12-31 | 2016-11-15 | ZetrOZ Systems, LLC | Low-profile ultrasound transducer |
CA2792848C (en) * | 2010-03-17 | 2017-07-04 | Nanomed Devices, Inc. | A built-in non-verbal instructional device integratable to applicators |
CN101837163B (en) * | 2010-04-12 | 2013-04-10 | 上海现代药物制剂工程研究中心有限公司 | Heparin rectum iontophoretic drug delivery system |
US9237961B2 (en) * | 2010-04-23 | 2016-01-19 | Medtronic Vascular, Inc. | Stent delivery system for detecting wall apposition of the stent during deployment |
KR20130114581A (en) | 2010-05-07 | 2013-10-18 | 레발레시오 코퍼레이션 | Compositions and methods for enhancing physiological performance and recovery time |
EP2603202A4 (en) | 2010-08-12 | 2016-06-01 | Revalesio Corp | Compositions and methods for treatment of taupathy |
TWI394587B (en) * | 2011-01-07 | 2013-05-01 | Iner Aec Executive Yuan | A radiolabeled nucleoside analogue, a method for preparing the same and the use thereof |
AU2011200394B2 (en) * | 2011-01-31 | 2015-01-22 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including electrically-actuated permeation enhancement |
US8950862B2 (en) | 2011-02-28 | 2015-02-10 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus for an ophthalmic lens with functional insert layers |
US8970559B1 (en) * | 2011-03-08 | 2015-03-03 | Henry Lansing McVickar | Fingernail stylus |
US9698129B2 (en) | 2011-03-18 | 2017-07-04 | Johnson & Johnson Vision Care, Inc. | Stacked integrated component devices with energization |
US9110310B2 (en) | 2011-03-18 | 2015-08-18 | Johnson & Johnson Vision Care, Inc. | Multiple energization elements in stacked integrated component devices |
US10451897B2 (en) | 2011-03-18 | 2019-10-22 | Johnson & Johnson Vision Care, Inc. | Components with multiple energization elements for biomedical devices |
US9889615B2 (en) | 2011-03-18 | 2018-02-13 | Johnson & Johnson Vision Care, Inc. | Stacked integrated component media insert for an ophthalmic device |
US9804418B2 (en) * | 2011-03-21 | 2017-10-31 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus for functional insert with power layer |
EP2704759A4 (en) | 2011-05-05 | 2015-06-03 | Eksigent Technologies Llc | Gel coupling for electrokinetic delivery systems |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US10004526B2 (en) * | 2011-07-25 | 2018-06-26 | Covidien Lp | Ultrasonic dissection system |
CA2842852C (en) | 2011-07-27 | 2020-07-14 | Vision Quest Industries Incorporated Dba Vq Orthocare | Electrostimulation system |
WO2013033782A1 (en) * | 2011-09-09 | 2013-03-14 | International Scientific Pty Ltd | Method and device for transdermal delivery of substances |
US8857983B2 (en) | 2012-01-26 | 2014-10-14 | Johnson & Johnson Vision Care, Inc. | Ophthalmic lens assembly having an integrated antenna structure |
US9351827B2 (en) * | 2012-04-03 | 2016-05-31 | Johnson & Johnson Vision Care, Inc. | Lens driver for variable-optic electronic ophthalmic lens |
US9980810B2 (en) * | 2012-04-03 | 2018-05-29 | Johnson & Johnson Vision Care, Inc. | System controller for variable-optic electronic ophthalmic lens |
RU2495628C1 (en) * | 2012-04-18 | 2013-10-20 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Method of selecting tactics of treating actinic keratosis |
US9271783B2 (en) | 2012-07-17 | 2016-03-01 | Covidien Lp | End-effector assembly including a pressure-sensitive layer disposed on an electrode |
US20140088372A1 (en) * | 2012-09-25 | 2014-03-27 | Google Inc. | Information processing method |
US9005108B2 (en) | 2012-09-27 | 2015-04-14 | Palo Alto Research Center Incorporated | Multiple reservoir drug delivery device and methods |
US9999720B2 (en) | 2012-09-27 | 2018-06-19 | Palo Alto Research Center Incorporated | Drug reconstitution and delivery device and methods |
US9872812B2 (en) | 2012-09-28 | 2018-01-23 | Kpr U.S., Llc | Residual pressure control in a compression device |
US9744341B2 (en) | 2013-01-15 | 2017-08-29 | Palo Alto Research Center Incorporated | Devices and methods for intraluminal retention and drug delivery |
US9050053B2 (en) | 2013-02-15 | 2015-06-09 | Naimco, Inc. | Ultrasound device with cavity for conductive medium |
US20140257064A1 (en) * | 2013-03-11 | 2014-09-11 | Birchwood Laboratories, Inc. | Sweat analyte testing components and methods |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
EP2967633B1 (en) | 2013-03-15 | 2018-04-25 | Edge Systems LLC | Devices for treating the skin |
US10238812B2 (en) | 2013-03-15 | 2019-03-26 | Edge Systems Llc | Skin treatment systems and methods using needles |
EP2996756B1 (en) * | 2013-05-15 | 2020-12-16 | Solvamed GmbH | Skin applicator for applying highly volatile substances |
US9320645B2 (en) * | 2013-05-29 | 2016-04-26 | Terry Glasser | Approach to administering ocular medication |
JP2016523125A (en) * | 2013-05-30 | 2016-08-08 | グラハム エイチ. クリーシー | Local nervous stimulation |
US20150342661A1 (en) * | 2013-10-09 | 2015-12-03 | Venus Concept Ltd | Integrated Treatment System |
JP6538063B2 (en) * | 2013-11-05 | 2019-07-03 | シンアジャル コーポレイション | Device and method for continuous drug delivery through the mouth |
US9297083B2 (en) | 2013-12-16 | 2016-03-29 | Palo Alto Research Center Incorporated | Electrolytic gas generating devices, actuators, and methods |
US20150265825A1 (en) | 2014-03-21 | 2015-09-24 | L'oreal | Combined sonic and iontophoretic skin care device |
WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
JP6444069B2 (en) * | 2014-06-17 | 2018-12-26 | マクセルホールディングス株式会社 | Skin care equipment |
US9801660B2 (en) | 2014-07-31 | 2017-10-31 | Palo Alto Research Center Incorporated | Implantable fluid delivery devices, systems, and methods |
US10278675B2 (en) | 2014-07-31 | 2019-05-07 | Palo Alto Research Center Incorporated | Implantable estrus detection devices, systems, and methods |
US10381687B2 (en) | 2014-08-21 | 2019-08-13 | Johnson & Johnson Vision Care, Inc. | Methods of forming biocompatible rechargable energization elements for biomedical devices |
US9941547B2 (en) | 2014-08-21 | 2018-04-10 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes and cavity structures |
US10627651B2 (en) | 2014-08-21 | 2020-04-21 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers |
US10361404B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Anodes for use in biocompatible energization elements |
US10361405B2 (en) | 2014-08-21 | 2019-07-23 | Johnson & Johnson Vision Care, Inc. | Biomedical energization elements with polymer electrolytes |
US9793536B2 (en) | 2014-08-21 | 2017-10-17 | Johnson & Johnson Vision Care, Inc. | Pellet form cathode for use in a biocompatible battery |
US9383593B2 (en) | 2014-08-21 | 2016-07-05 | Johnson & Johnson Vision Care, Inc. | Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators |
US9715130B2 (en) | 2014-08-21 | 2017-07-25 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form separators for biocompatible energization elements for biomedical devices |
US9599842B2 (en) | 2014-08-21 | 2017-03-21 | Johnson & Johnson Vision Care, Inc. | Device and methods for sealing and encapsulation for biocompatible energization elements |
US10179229B2 (en) | 2014-12-23 | 2019-01-15 | Edge Systems Llc | Devices and methods for treating the skin using a porous member |
EP4324414A2 (en) | 2014-12-23 | 2024-02-21 | HydraFacial LLC | Devices and methods for treating the skin using a rollerball or a wicking member |
US9861818B2 (en) * | 2014-12-31 | 2018-01-09 | Ziip, Llc | Method and device for electrical current treatment |
CN107847722B (en) | 2015-05-06 | 2021-05-18 | 辛纳吉勒公司 | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of use thereof |
EP3319573A4 (en) | 2015-07-08 | 2019-01-23 | Edge Systems LLC | Devices, systems and methods for promoting hair growth |
US10130578B2 (en) * | 2015-07-23 | 2018-11-20 | Johnson & Johnson Consumer Inc. | Topical delivery of skin compositions having low pH |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
CN108348390B (en) * | 2015-11-13 | 2021-07-20 | 易希提卫生与保健公司 | Wearable absorbent hygiene article comprising an electronic unit |
US10512569B2 (en) * | 2015-11-13 | 2019-12-24 | Essity Hygiene And Health Aktiebolag | Wearable absorbent hygiene article comprising a magnetic switch |
US10345620B2 (en) | 2016-02-18 | 2019-07-09 | Johnson & Johnson Vision Care, Inc. | Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
WO2017184881A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
JP2018042886A (en) * | 2016-09-16 | 2018-03-22 | ロレアル | Portable iontophoresis device |
WO2018168925A1 (en) * | 2017-03-16 | 2018-09-20 | フクダ電子株式会社 | Bioelectrode sheet |
US10406358B1 (en) * | 2017-04-24 | 2019-09-10 | Todd M. Bertoch | Chronic pain treatment device |
US20200061357A1 (en) * | 2017-05-02 | 2020-02-27 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
CN107233084B (en) * | 2017-07-12 | 2024-03-12 | 上海坤浩信息科技有限公司 | Spring vibrator type pulse condition reproduction instrument |
DE102017123809A1 (en) | 2017-10-12 | 2019-04-18 | Swiss Spa System Ltd. | In one hand durable device for electrically assisted skin treatment, additional part for this device and blister for this additional part |
US11806163B2 (en) | 2018-10-09 | 2023-11-07 | Inter.mix, Inc. | Hydration testing article |
USD1016615S1 (en) | 2021-09-10 | 2024-03-05 | Hydrafacial Llc | Container for a skin treatment device |
CN116271113B (en) * | 2023-05-24 | 2023-08-08 | 四川大学华西医院 | Multifunctional photo-curing sound guide gel and preparation method and application thereof |
CN117462836A (en) * | 2023-12-26 | 2024-01-30 | 山东百多安医疗器械股份有限公司 | Functionalized ultrasonic controlled-release puncture dressing patch and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674546A (en) * | 1995-08-10 | 1997-10-07 | Nabisco Technology Company | Package for storing and cooking an omelet |
US5788666A (en) * | 1995-06-15 | 1998-08-04 | Empi, Inc. | Iontophoresis electrode |
US5846217A (en) * | 1997-07-29 | 1998-12-08 | Iomed, Inc. | Iontophoretic bioelectrode and method of using same |
US6148231A (en) * | 1998-09-15 | 2000-11-14 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes and method |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US600290A (en) | 1898-03-08 | Therapeutic electrode | ||
US279524A (en) | 1883-06-19 | Thimble | ||
US484522A (en) | 1892-10-18 | Edward h | ||
US206474A (en) | 1878-07-30 | Improvement in glove-electrodes | ||
DE603705C (en) | 1931-06-18 | 1934-10-08 | Desider Deutsch Dr | Electrode for introducing medicines into the body by means of iontophoresis |
US2126070A (en) | 1932-04-29 | 1938-08-09 | Wappler Frederick Charles | Electrotherapy |
US2047308A (en) | 1934-05-05 | 1936-07-14 | T M Chapman S Sons Co | Electrical therapeutic pad |
US2123980A (en) | 1934-07-21 | 1938-07-19 | G M Basford Company | Therapeutic treatment |
US2834344A (en) | 1954-07-22 | 1958-05-13 | Lion Brush K K | Device for penetrating teeth with fluoride |
US3107672A (en) | 1958-05-27 | 1963-10-22 | Ewald Rose | Electrical apparatus for cosmetic treatment of the skin |
US3019787A (en) | 1960-10-05 | 1962-02-06 | Joe J Simmons | Apparatus for electrolytic dental desensitization |
US3048170A (en) | 1960-11-08 | 1962-08-07 | Lemos Albano | Electrical devices for the application of fluid to the gums |
US3163166A (en) | 1961-04-28 | 1964-12-29 | Colgate Palmolive Co | Iontophoresis apparatus |
US3298368A (en) | 1964-04-24 | 1967-01-17 | Charos Peter | Heated cream applicator gloves |
FR1445703A (en) | 1965-06-03 | 1966-07-15 | Advanced ionization apparatus | |
US3520297A (en) | 1967-01-31 | 1970-07-14 | Chemway Corp | Iontophoretic toothbrush |
US3556105A (en) | 1968-05-24 | 1971-01-19 | Lillian B Shepard | Electrical stimulator and mitten |
US3645260A (en) | 1970-07-17 | 1972-02-29 | Health Systems Inc | Dental desensitizer |
US3716054A (en) | 1970-08-11 | 1973-02-13 | W Porter | Apparatus for applying medication to teeth and body tissue |
US3848600A (en) | 1972-02-03 | 1974-11-19 | Ndm Corp | Indifferent electrode in electrosurgical procedures and method of use |
US3831598A (en) | 1972-09-28 | 1974-08-27 | I Tice | Sterile anesthetic instruments |
US4116238A (en) | 1976-08-18 | 1978-09-26 | Midgard Electronics Company, Inc. | High voltage constant current source for iontophoresis |
US4211222A (en) | 1976-08-25 | 1980-07-08 | Robert Tapper | Iontophoretic burn-protection method |
SU654254A2 (en) | 1977-02-07 | 1979-03-30 | В. Н. Серов | Device for treating eyes |
US4325367A (en) | 1977-06-13 | 1982-04-20 | Robert Tapper | Iontophoretic treatment apparatus |
US4301794A (en) | 1978-10-18 | 1981-11-24 | Robert Tapper | Method for iontophoretic treatment |
US4838273A (en) | 1979-04-30 | 1989-06-13 | Baxter International Inc. | Medical electrode |
US4292968A (en) | 1979-11-26 | 1981-10-06 | Sybron Corporation | Electric supply for ion therapy |
SU931191A1 (en) | 1980-01-18 | 1982-05-30 | Предприятие П/Я А-3852 | Device for treating middle and internal ear |
SU1003853A1 (en) | 1980-03-17 | 1983-03-15 | Белорусский Научно-Исследовательский Институт Неврологии,Нейрохирургии И Физиотерапии | Device for electrophonoresis |
US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
US4416274A (en) | 1981-02-23 | 1983-11-22 | Motion Control, Inc. | Ion mobility limiting iontophoretic bioelectrode |
US4406658A (en) | 1981-03-06 | 1983-09-27 | Medtronic, Inc. | Iontophoretic device with reversible polarity |
US4820263A (en) | 1981-03-06 | 1989-04-11 | Medtronic, Inc. | Apparatus and method for iontophoretic drug delivery |
JPS5810066A (en) | 1981-07-10 | 1983-01-20 | 株式会社アドバンス | Plaster structure for ion tofuorese |
FR2513129A1 (en) | 1981-09-24 | 1983-03-25 | Moreau Lavaud Reine | Portable skin cosmetic treatment device - has current generator circuit breaker and holder for interchangeable electrodes incorporated into body |
US4393884A (en) | 1981-09-25 | 1983-07-19 | Jacobs Allen W | Demand inhaler for oral administration of tobacco, tobacco-like, or other substances |
US4429703A (en) | 1982-02-22 | 1984-02-07 | William Haber | Cigarette substitute |
US4510939A (en) | 1982-12-22 | 1985-04-16 | Biosonics, Inc. | Means for transferring electrical energy to and from living tissue |
US4639244A (en) | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4808152A (en) | 1983-08-18 | 1989-02-28 | Drug Delivery Systems Inc. | System and method for controlling rate of electrokinetic delivery of a drug |
US5865786A (en) | 1983-08-18 | 1999-02-02 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
US5135479A (en) | 1983-08-18 | 1992-08-04 | Drug Delivery Systems, Inc. | Programmable control and mounting system for transdermal drug applicator |
US4919648A (en) | 1983-08-18 | 1990-04-24 | Drug Delivery Systems Inc. | High tack drug patch |
US4708716A (en) | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
CA1262564A (en) | 1983-09-01 | 1989-10-31 | Minoru Sasaki | Iontophoresis device |
US4813437A (en) | 1984-01-09 | 1989-03-21 | Ray J Philip | Nicotine dispensing device and method for the manufacture thereof |
US4655229A (en) | 1984-01-30 | 1987-04-07 | R. J. Reynolds Tobacco Company | Flavor delivery system |
US4665921A (en) | 1984-05-28 | 1987-05-19 | Teranishi Electric Works, Ltd. | High potential generating toothbrush |
US4747819A (en) | 1984-10-29 | 1988-05-31 | Medtronic, Inc. | Iontophoretic drug delivery |
US5135477A (en) | 1984-10-29 | 1992-08-04 | Medtronic, Inc. | Iontophoretic drug delivery |
SE8405479D0 (en) | 1984-11-01 | 1984-11-01 | Nilsson Sven Erik | WANT TO ADMINISTER VOCABULARY, PHYSIOLOGY, ACTIVE SUBJECTS AND DEVICE FOR THIS |
US4702732A (en) | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
US4800903A (en) | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
JPS6222662A (en) | 1985-07-19 | 1987-01-30 | 林原 健 | Ion introducing electronic treatment device |
AT385664B (en) | 1985-07-31 | 1988-05-10 | Hepax Ltd | ELECTROMEDICAL THERAPY DEVICE |
US4756318A (en) | 1985-10-28 | 1988-07-12 | R. J. Reynolds Tobacco Company | Smoking article with tobacco jacket |
US4793366A (en) | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
US4763660A (en) | 1985-12-10 | 1988-08-16 | Cherne Industries, Inc. | Flexible and disposable electrode belt device |
JPS62139672A (en) | 1985-12-14 | 1987-06-23 | 林原 健 | Remedy device for positive and negative iontophoresis |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US5250022A (en) | 1990-09-25 | 1993-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose |
US5961482A (en) | 1986-07-25 | 1999-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US5042975A (en) | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US4735217A (en) | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
JPS63135179A (en) | 1986-11-26 | 1988-06-07 | 立花 俊郎 | Subcataneous drug administration set |
US4771796A (en) | 1987-01-07 | 1988-09-20 | Fritz Myer | Electrically operated simulated cigarette |
US4931046A (en) | 1987-05-15 | 1990-06-05 | Newman Martin H | Iontophoresis drug delivery system |
US4787888A (en) | 1987-06-01 | 1988-11-29 | University Of Connecticut | Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a) |
US4865582A (en) | 1987-06-05 | 1989-09-12 | Drug Delivery Systems Inc. | Disposable transdermal drug applicators |
FR2619308B1 (en) | 1987-08-12 | 1993-12-17 | Oreal | MASSAGE APPARATUS |
JPS6456060A (en) | 1987-08-27 | 1989-03-02 | Hayashibara Takeshi | Low frequency medical treatment device |
US4942883A (en) | 1987-09-29 | 1990-07-24 | Newman Martin H | Drug delivery device |
EP0398960B1 (en) | 1988-01-21 | 1995-12-06 | Massachusetts Institute Of Technology | Transport of molecules across tissue using electroporation |
US5362307A (en) | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
WO1989006989A1 (en) | 1988-01-29 | 1989-08-10 | The Regents Of The University Of California | Iontophoretic non-invasive sampling or delivery device |
US4957480A (en) | 1988-02-02 | 1990-09-18 | Universal Health Products, Inc. | Method of facial toning |
IL86076A (en) | 1988-04-14 | 1992-12-01 | Inventor S Funding Corp Ltd | Transdermal drug delivery device |
US4997418A (en) | 1988-04-21 | 1991-03-05 | C. P. Chambers | Epidermal iontophoresis device |
US5162042A (en) | 1988-07-05 | 1992-11-10 | Alza Corporation | Electrotransport transdermal system |
IL87004A (en) * | 1988-07-06 | 1992-08-18 | Technion Res & Dev Foundation | Method and apparatus for bioaffinity separation |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
CA2001444C (en) | 1988-10-28 | 2000-07-25 | Darrel F. Untereker | Iontophoresis electrode |
US5501705A (en) | 1988-10-31 | 1996-03-26 | Fakhri; Omar | Method for the treatment of psoriasis with electric current |
US5006108A (en) | 1988-11-16 | 1991-04-09 | Noven Pharmaceuticals, Inc. | Apparatus for iontophoretic drug delivery |
US4917119A (en) | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
US5135478A (en) | 1989-05-10 | 1992-08-04 | Drug Delivery Systems Inc. | Multi-signal electrical transdermal drug applicator |
US4979938A (en) | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
US5374241A (en) | 1989-07-21 | 1994-12-20 | Iomed, Inc. | Electrodes for iontophoresis |
US4950229A (en) | 1989-09-25 | 1990-08-21 | Becton, Dickinson And Company | Apparatus for an electrode used for iontophoresis |
US5060671A (en) | 1989-12-01 | 1991-10-29 | Philip Morris Incorporated | Flavor generating article |
US5047007A (en) | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
US5115805A (en) | 1990-02-23 | 1992-05-26 | Cygnus Therapeutic Systems | Ultrasound-enhanced delivery of materials into and through the skin |
JP2816886B2 (en) | 1990-03-05 | 1998-10-27 | 興和株式会社 | Bioelectric device |
JPH05506165A (en) | 1990-03-30 | 1993-09-16 | アルザ・コーポレーション | Delivery device for iontophoresis |
US6004309A (en) | 1990-03-30 | 1999-12-21 | Alza Corporation | Method and apparatus for controlled environment electrotransport |
US5133352A (en) | 1990-04-12 | 1992-07-28 | Kent, Lathrop And Johnston | Method for treating herpes simplex |
US5167242A (en) | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
US5147291A (en) | 1990-06-11 | 1992-09-15 | Cukier A David | Sound transmission apparatus for uniformly administering chemical composition through the skin |
US5037381A (en) | 1990-07-27 | 1991-08-06 | Bock C Randolph | Electrically assisted transdermal transport device and method for renewing the device |
US5160316A (en) | 1990-09-10 | 1992-11-03 | Henley Julian L | Iontophoretic drug delivery apparatus |
US5362308A (en) | 1990-09-25 | 1994-11-08 | Rutgers, The State University Of New Jersey | Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes |
DE4114677A1 (en) | 1990-10-10 | 1992-02-27 | Mario Bergner | APPLICATION ARRANGEMENT OF DIFFERENT ELECTRICALLY CONNECTED METALS ON THE HUMAN BODY TO A BIOELECTRIC SYSTEM IN THE MEANING OF THE ELECTROCHEMICAL VOLTAGE RANGE WITH VOLTAGE INCREASING WITH POSSIBLE USE OF COMMERCIAL ECG FLASHER ELEMENTS |
US6238381B1 (en) * | 1990-11-01 | 2001-05-29 | Robert Tapper | Iontophoretic treatment system |
US5254081A (en) | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
NL9100662A (en) | 1991-04-17 | 1992-11-16 | Optische Ind De Oude Delft Nv | DEVICE FOR PERFORMING AN ITHOPHORESIS TREATMENT ON A PATIENT. |
DE4120517A1 (en) | 1991-06-18 | 1992-12-24 | Kleditsch Bernhard Dr Med Dent | DC GENERATOR FOR THE TREATMENT OF THE INITIAL STAGE HERPES LABIALIS AND OTHER INITIAL INFLAMMATION OF THE HAUTAREAL |
GB2257632B (en) | 1991-07-17 | 1995-03-22 | Innovative Medical Devices | Skin treatment device |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
US5203768A (en) | 1991-07-24 | 1993-04-20 | Alza Corporation | Transdermal delivery device |
US5169384A (en) | 1991-08-16 | 1992-12-08 | Bosniak Stephen L | Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue |
US5171215A (en) | 1991-08-22 | 1992-12-15 | Flanagan Dennis F | Endermic method and apparatus |
ATE143279T1 (en) | 1991-12-03 | 1996-10-15 | Alza Corp | IONTOPHORETIC DISTRIBUTION DEVICE AND SUPPLY NETWORK THEREOF |
CA2087087C (en) | 1992-01-22 | 2000-07-18 | Burton H. Sage, Jr. | Molecules for iontophoretic delivery |
US5360440A (en) | 1992-03-09 | 1994-11-01 | Boston Scientific Corporation | In situ apparatus for generating an electrical current in a biological environment |
US5589563A (en) | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
US5310404A (en) | 1992-06-01 | 1994-05-10 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
US5312326A (en) | 1992-06-02 | 1994-05-17 | Alza Corporation | Iontophoretic drug delivery apparatus |
CA2183875C (en) | 1992-06-02 | 2003-10-14 | Robert M. Myers | Electrotransport drug delivery device |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5331979A (en) | 1992-07-27 | 1994-07-26 | Henley Julian L | Iontophoretic cigarette substitute |
US5688233A (en) | 1992-08-17 | 1997-11-18 | Genetronics, Inc. | Electronincorporation enhanced transdermal delivery of molecules |
US5421816A (en) | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
US5322520A (en) | 1992-11-12 | 1994-06-21 | Implemed, Inc. | Iontophoretic structure for medical devices |
US5298017A (en) | 1992-12-29 | 1994-03-29 | Alza Corporation | Layered electrotransport drug delivery system |
EP0676973B1 (en) | 1992-12-31 | 1998-01-28 | Alza Corporation | Electrotransport system having flexible means |
US5443441A (en) | 1993-03-05 | 1995-08-22 | De Claviere; Anne Marie | Apparatus and method for transdermal delivery of cosmetic compositions |
US6004547A (en) | 1997-09-29 | 1999-12-21 | Focal, Inc. | Apparatus and method for local application of polymeric material to tissue |
US5667487A (en) | 1993-04-07 | 1997-09-16 | Henley; Julian L. | Ionosonic drug delivery apparatus |
US5458569A (en) | 1993-06-08 | 1995-10-17 | Becton Dickinson And Company | Wearable iontophoresis system |
FR2709670B1 (en) | 1993-09-10 | 1995-10-20 | Asulab Sa | Device in three modules for transdermal administration of drugs by electrophoresis or iontophoresis. |
US5415629A (en) | 1993-09-15 | 1995-05-16 | Henley; Julian L. | Programmable apparatus for the transdermal delivery of drugs and method |
US5540669A (en) | 1993-09-30 | 1996-07-30 | Becton, Dickinson And Company | Iontophoretic drug delivery system and method for using same |
AU7923794A (en) | 1993-09-30 | 1995-04-18 | Becton Dickinson & Company | Iontophoretic drug delivery system and method |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5441936A (en) | 1993-12-07 | 1995-08-15 | Houghten Pharmaceuticals, Inc. | Antiviral peptides |
US5554361A (en) | 1994-01-21 | 1996-09-10 | Dixon; Gary W. | Processed product for skin and hair treatment |
JP3119486B2 (en) | 1994-06-17 | 2000-12-18 | 久光製薬株式会社 | Electrode for iontophoresis and device using the same |
US6048545A (en) | 1994-06-24 | 2000-04-11 | Biozone Laboratories, Inc. | Liposomal delivery by iontophoresis |
ES2153485T3 (en) | 1994-07-13 | 2001-03-01 | Alza Corp | COMPOSITION AND PROCEDURE THAT INCREASES THE PERCUTANEOUS DIFFUSION BY ELECTROTRANSPORT OF A SUBSTANCE. |
US5795321A (en) | 1994-09-30 | 1998-08-18 | Becton Dickinson And Company | Iontophoretic drug delivery system, including removable controller |
US5514167A (en) | 1994-10-24 | 1996-05-07 | Mgb Technologies Corporation | Hand holdable human skin treatment apparatus |
US5551953A (en) | 1994-10-31 | 1996-09-03 | Alza Corporation | Electrotransport system with remote telemetry link |
US5736580A (en) | 1994-11-14 | 1998-04-07 | Alza Croporation | Composition, device, and method for electrotransport agent delivery |
FR2726770B1 (en) | 1994-11-16 | 1997-01-31 | Lhd Lab Hygiene Dietetique | TRANSDERMAL DRUG DELIVERY DEVICE FOR THE TREATMENT OF MALE ERECTILE IMPOTENCE |
JP3170172B2 (en) | 1995-03-30 | 2001-05-28 | ティーディーケイ株式会社 | Chip component supply device and chip component supply case used for the device |
US5697896A (en) | 1994-12-08 | 1997-12-16 | Alza Corporation | Electrotransport delivery device |
US5562607A (en) | 1995-01-18 | 1996-10-08 | Alza Corporation | Electrotransport device having reusable controller power saver |
US5840057A (en) | 1995-01-27 | 1998-11-24 | Aloisi; Alessandro | Device for iontophoretic physiotherapy with frozen medicament crystals |
US6032073A (en) | 1995-04-07 | 2000-02-29 | Novartis Ag | Iontophoretic transdermal system for the administration of at least two substances |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
US5983130A (en) | 1995-06-07 | 1999-11-09 | Alza Corporation | Electrotransport agent delivery method and apparatus |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US6041253A (en) | 1995-12-18 | 2000-03-21 | Massachusetts Institute Of Technology | Effect of electric field and ultrasound for transdermal drug delivery |
CA2233068A1 (en) | 1995-09-28 | 1997-04-03 | Vyteris, Inc. | Iontophoretic drug delivery system, including disposable patch |
AU7286996A (en) | 1995-10-18 | 1997-05-07 | Ciba-Geigy Ag | Thermopile powered transdermal drug delivery device |
US5607461A (en) | 1995-10-20 | 1997-03-04 | Nexmed, Inc. | Apparatus and method for delivering electrical stimulus to tissue |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5755750A (en) | 1995-11-13 | 1998-05-26 | University Of Florida | Method and apparatus for selectively inhibiting activity in nerve fibers |
US5678273A (en) * | 1996-03-20 | 1997-10-21 | Porcelli; V. Lorenzo | Disposable oral hygiene applicator |
FR2747313B1 (en) | 1996-04-16 | 1998-06-05 | Lhd Lab Hygiene Dietetique | TRANSDERMAL MEDICINE DELIVERY DEVICE BY IONOPHORESIS |
US5676648A (en) | 1996-05-08 | 1997-10-14 | The Aps Organization, Llp | Iontophoretic drug delivery apparatus and method for use |
US5908401A (en) | 1996-05-08 | 1999-06-01 | The Aps Organization, Llp | Method for iontophoretic delivery of antiviral agents |
US6385487B1 (en) * | 1996-05-08 | 2002-05-07 | Biophoretic Therapeutic Systems, Llc | Methods for electrokinetic delivery of medicaments |
WO1997048444A1 (en) | 1996-06-19 | 1997-12-24 | Becton Dickinson And Company | Iontophoretic delivery of cell adhesion inhibitors |
US5713846A (en) | 1996-09-27 | 1998-02-03 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for activating same for attachment to patient |
US5797867A (en) | 1996-09-27 | 1998-08-25 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for activating same for attachment to patient |
EP0964722B1 (en) * | 1996-12-26 | 2004-09-01 | Elan International Services Limited | Electrode assembly for a device for the delivery of a substance to a subject |
US6018679A (en) | 1997-01-29 | 2000-01-25 | Novartis Finance Corp. | Iontophoretic transdermal delivery and control of adverse side-effects |
US5794774A (en) * | 1997-05-12 | 1998-08-18 | Porcelli; V. Lorenzo | Disposable oral hygiene applicator |
US5911319A (en) * | 1997-05-12 | 1999-06-15 | John J. Stoltzfus | Blister package for oral hygiene applicators |
US5904712A (en) | 1997-06-12 | 1999-05-18 | Axelgaard Manufacturing Co., Ltd. | Current-controlling electrode |
US5899876A (en) | 1997-08-27 | 1999-05-04 | Becton, Dickinson And Company | Multiple site drug delivery system |
TW368420B (en) | 1997-11-04 | 1999-09-01 | Genetronics Inc | Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum |
US5968005A (en) | 1998-01-07 | 1999-10-19 | Tu; Hosheng | Devices and means for treating canker sores |
IL122875A0 (en) * | 1998-01-08 | 1998-08-16 | S L P Ltd | An integrated sleep apnea screening system |
US6023639A (en) | 1998-05-01 | 2000-02-08 | Hakky; Said | Non-invasive bodily fluid withdrawal and monitoring system |
EP1121059A4 (en) * | 1998-09-15 | 2006-04-05 | Biophoretic Therapeutic System | Iontophoretic drug delivery electrodes |
US6101411A (en) | 1998-09-24 | 2000-08-08 | Newsome; David A. | Dilation enhancer |
US5931859A (en) | 1998-09-30 | 1999-08-03 | Burke; Robert E. | Facial toning system |
US6148232A (en) | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
US6553253B1 (en) * | 1999-03-12 | 2003-04-22 | Biophoretic Therapeutic Systems, Llc | Method and system for electrokinetic delivery of a substance |
-
2000
- 2000-05-31 US US09/584,138 patent/US6477410B1/en not_active Expired - Fee Related
-
2001
- 2001-05-21 CA CA002413806A patent/CA2413806C/en not_active Expired - Fee Related
- 2001-05-21 JP JP2001587863A patent/JP4199457B2/en not_active Expired - Lifetime
- 2001-05-21 CN CNB018103790A patent/CN1287877C/en not_active Expired - Fee Related
- 2001-05-21 RU RU2002135648/14A patent/RU2268075C2/en not_active IP Right Cessation
- 2001-05-21 AU AU7485101A patent/AU7485101A/en active Pending
- 2001-05-21 EP EP10012024A patent/EP2277584A1/en not_active Withdrawn
- 2001-05-21 BR BR0111288-0A patent/BR0111288A/en not_active Application Discontinuation
- 2001-05-21 AU AU2001274851A patent/AU2001274851B2/en not_active Ceased
- 2001-05-21 MX MXPA02011842A patent/MXPA02011842A/en active IP Right Grant
- 2001-05-21 EP EP01941502A patent/EP1294438A4/en not_active Withdrawn
- 2001-05-21 WO PCT/US2001/016069 patent/WO2001091853A1/en active IP Right Grant
-
2002
- 2002-09-18 US US10/245,337 patent/US6735470B2/en not_active Expired - Lifetime
-
2003
- 2003-09-16 HK HK03106645.3A patent/HK1054338A1/en unknown
-
2004
- 2004-03-24 US US10/807,295 patent/US7069073B2/en not_active Expired - Fee Related
-
2005
- 2005-04-13 US US11/104,568 patent/US20050182351A1/en not_active Abandoned
- 2005-10-24 AU AU2005225129A patent/AU2005225129B2/en not_active Ceased
- 2005-11-03 US US11/265,383 patent/US20060052739A1/en not_active Abandoned
-
2007
- 2007-10-24 AU AU2007231635A patent/AU2007231635A1/en not_active Abandoned
-
2010
- 2010-05-17 AU AU2010201975A patent/AU2010201975A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5788666A (en) * | 1995-06-15 | 1998-08-04 | Empi, Inc. | Iontophoresis electrode |
US5674546A (en) * | 1995-08-10 | 1997-10-07 | Nabisco Technology Company | Package for storing and cooking an omelet |
US5846217A (en) * | 1997-07-29 | 1998-12-08 | Iomed, Inc. | Iontophoretic bioelectrode and method of using same |
US6148231A (en) * | 1998-09-15 | 2000-11-14 | Biophoretic Therapeutic Systems, Llc | Iontophoretic drug delivery electrodes and method |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070066930A1 (en) * | 2005-06-20 | 2007-03-22 | Transcutaneous Technologies, Inc. | Iontophoresis device and method of producing the same |
US20090214625A1 (en) * | 2005-07-15 | 2009-08-27 | Mizuo Nakayama | Drug delivery patch |
US7793666B2 (en) | 2005-07-28 | 2010-09-14 | Innovation Biomedical Devices, Inc. | Apparatus and method for treatment of infected nail |
US20090216175A1 (en) * | 2005-08-05 | 2009-08-27 | Transcu Ltd. | Transdermal Administration Device and Method of Controlling the Same |
US20070060859A1 (en) * | 2005-08-08 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
US8386030B2 (en) | 2005-08-08 | 2013-02-26 | Tti Ellebeau, Inc. | Iontophoresis device |
US20070060860A1 (en) * | 2005-08-18 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20100016781A1 (en) * | 2005-08-29 | 2010-01-21 | Mizuo Nakayama | Iontophoresis device selecting drug to be administered on the basis of information form sensor |
US20100030128A1 (en) * | 2005-09-06 | 2010-02-04 | Kazuma Mitsuguchi | Iontophoresis device |
US7890164B2 (en) | 2005-09-15 | 2011-02-15 | Tti Ellebeau, Inc. | Iontophoresis device |
US20070066932A1 (en) * | 2005-09-15 | 2007-03-22 | Transcutaneous Technologies Inc. | Iontophoresis device |
US20090216177A1 (en) * | 2005-09-16 | 2009-08-27 | Tti Ellebeau,Inc | Catheter-type iontophoresis device |
US20090299265A1 (en) * | 2005-09-30 | 2009-12-03 | Tti Ellebeau, Inc. | Electrode Assembly for Iontophoresis Having Shape-Memory Separator and Iontophoresis Device Using the Same |
US20090187134A1 (en) * | 2005-09-30 | 2009-07-23 | Hidero Akiyama | Iontophoresis Device Controlling Amounts of a Sleep-Inducing Agent and a Stimulant to be Administered and Time at Which the Drugs are Administered |
US20070093787A1 (en) * | 2005-09-30 | 2007-04-26 | Transcutaneous Technologies Inc. | Iontophoresis device to deliver multiple active agents to biological interfaces |
US20070197955A1 (en) * | 2005-10-12 | 2007-08-23 | Transcutaneous Technologies Inc. | Mucous membrane adhesion-type iontophoresis device |
US20090005721A1 (en) * | 2005-12-09 | 2009-01-01 | Tti Ellebeau, Inc. | Packaged iontophoresis system |
US20080033338A1 (en) * | 2005-12-28 | 2008-02-07 | Smith Gregory A | Electroosmotic pump apparatus and method to deliver active agents to biological interfaces |
US20080033398A1 (en) * | 2005-12-29 | 2008-02-07 | Transcutaneous Technologies Inc. | Device and method for enhancing immune response by electrical stimulation |
US7848801B2 (en) | 2005-12-30 | 2010-12-07 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
US20080004564A1 (en) * | 2006-03-30 | 2008-01-03 | Transcutaneous Technologies Inc. | Controlled release membrane and methods of use |
US20080058701A1 (en) * | 2006-07-05 | 2008-03-06 | Transcutaneous Technologies Inc. | Delivery device having self-assembling dendritic polymers and method of use thereof |
US20080114282A1 (en) * | 2006-09-05 | 2008-05-15 | Transcu Ltd. | Transdermal drug delivery systems, devices, and methods using inductive power supplies |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
US8062783B2 (en) | 2006-12-01 | 2011-11-22 | Tti Ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
US20080175895A1 (en) * | 2007-01-16 | 2008-07-24 | Kentaro Kogure | System, devices, and methods for iontophoretic delivery of compositions including antioxidants encapsulated in liposomes |
US20080262581A1 (en) * | 2007-04-17 | 2008-10-23 | Transport Pharmaceuticals, Inc. | Current density detection and control system and method for an electrokinetic delivery of medicaments |
US20090022784A1 (en) * | 2007-06-12 | 2009-01-22 | Kentaro Kogure | Systems, devices, and methods for iontophoretic delivery of compositions including liposome-encapsulated insulin |
US20100021530A1 (en) * | 2008-07-25 | 2010-01-28 | Innovation Biomedical Devices, Inc. | Enhanced trans-keratin drug delivery |
US20100069877A1 (en) * | 2008-09-10 | 2010-03-18 | Smith Gregory A | Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process |
US20100312168A1 (en) * | 2009-06-09 | 2010-12-09 | Yoshimasa Yoshida | Long life high capacity electrode, device, and method of manufacture |
US10149970B2 (en) * | 2012-06-18 | 2018-12-11 | Michael Tavger | Method and system for delivering solution into the pores of recipient human skin |
US20140378889A1 (en) * | 2012-06-18 | 2014-12-25 | Michael Tavger | Method and system for delivering solution into the pores of recipient human skin |
US10152529B2 (en) | 2013-08-23 | 2018-12-11 | Elwha Llc | Systems and methods for generating a treatment map |
US10546651B2 (en) | 2013-08-23 | 2020-01-28 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9456777B2 (en) | 2013-08-23 | 2016-10-04 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9390312B2 (en) | 2013-08-23 | 2016-07-12 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US10448929B2 (en) | 2013-08-23 | 2019-10-22 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US10219789B2 (en) | 2013-08-23 | 2019-03-05 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
US9557331B2 (en) | 2013-08-23 | 2017-01-31 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
WO2015027055A1 (en) * | 2013-08-23 | 2015-02-26 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US10140424B2 (en) | 2013-08-23 | 2018-11-27 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9805171B2 (en) | 2013-08-23 | 2017-10-31 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US9811641B2 (en) | 2013-08-23 | 2017-11-07 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
US10010704B2 (en) | 2013-08-23 | 2018-07-03 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
US9526480B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US10575834B2 (en) | 2013-11-27 | 2020-03-03 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US9186278B2 (en) | 2013-11-27 | 2015-11-17 | Elwha Llc | Systems and devices for sampling and profiling microbiota of skin |
US9610037B2 (en) | 2013-11-27 | 2017-04-04 | Elwha Llc | Systems and devices for profiling microbiota of skin |
US9549703B2 (en) | 2013-11-27 | 2017-01-24 | Elwha Llc | Devices and methods for sampling and profiling microbiota of skin |
US9526450B2 (en) | 2013-11-27 | 2016-12-27 | Elwha Llc | Devices and methods for profiling microbiota of skin |
US10973874B2 (en) | 2014-10-21 | 2021-04-13 | Hexima Limited | Method of treatment |
US9713632B2 (en) | 2014-10-21 | 2017-07-25 | Hexima Limited | Method of treatment |
US10010576B2 (en) | 2014-10-21 | 2018-07-03 | Hexima Limited | Method of treatment |
US20210282831A1 (en) * | 2016-08-01 | 2021-09-16 | Drexel University | Devices and methods for treatment of skin conditions |
US11571249B2 (en) * | 2016-08-01 | 2023-02-07 | Drexel University | Devices and methods for treatment of skin conditions |
US20230371998A1 (en) * | 2016-08-01 | 2023-11-23 | Drexel University | Devices and Methods For Treatment Of Skin Conditions |
RU2709159C1 (en) * | 2018-10-26 | 2019-12-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Владимирский Государственный Университет имени Александра Григорьевича и Николая Григорьевича Столетовых" (ВлГУ) | Device for treating fungal infections of nails |
Also Published As
Publication number | Publication date |
---|---|
JP2003534108A (en) | 2003-11-18 |
CA2413806C (en) | 2006-09-19 |
CN1437493A (en) | 2003-08-20 |
EP1294438A4 (en) | 2005-12-07 |
AU7485101A (en) | 2001-12-11 |
EP2277584A1 (en) | 2011-01-26 |
CA2413806A1 (en) | 2001-12-06 |
JP4199457B2 (en) | 2008-12-17 |
RU2002135648A (en) | 2004-03-27 |
US6735470B2 (en) | 2004-05-11 |
AU2007231635A1 (en) | 2007-11-15 |
HK1054338A1 (en) | 2003-11-28 |
US7069073B2 (en) | 2006-06-27 |
AU2005225129A1 (en) | 2005-11-10 |
RU2268075C2 (en) | 2006-01-20 |
WO2001091853A1 (en) | 2001-12-06 |
BR0111288A (en) | 2003-09-30 |
US20050182351A1 (en) | 2005-08-18 |
MXPA02011842A (en) | 2004-03-02 |
US20040176737A1 (en) | 2004-09-09 |
CN1287877C (en) | 2006-12-06 |
AU2001274851B2 (en) | 2005-08-04 |
AU2010201975A1 (en) | 2010-06-03 |
EP1294438A1 (en) | 2003-03-26 |
US6477410B1 (en) | 2002-11-05 |
US20030018295A1 (en) | 2003-01-23 |
AU2005225129B2 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6477410B1 (en) | Electrokinetic delivery of medicaments | |
US8328788B2 (en) | Methods and systems for electrokinetic delivery of a substance | |
AU2001274851A2 (en) | Electrokinetic delivery device | |
AU2001274851A1 (en) | Electrokinetic delivery device | |
KR200403033Y1 (en) | Portable skin care device for beauty pack | |
US5158537A (en) | Iontophoretic delivery device and method of hydrating same | |
JP3821837B2 (en) | Electrically driven iontophoretic agent administration device | |
US5298017A (en) | Layered electrotransport drug delivery system | |
US5403275A (en) | Method for reducing sensation in iontophoretic drug delivery | |
US5385543A (en) | Iontophoretic delivery device and method of hydrating same | |
CA2038968C (en) | Iontophoretic delivery device | |
IE904437A1 (en) | Improved iontophoretic delivery method | |
IE83316B1 (en) | Device for reducing sensation during iontophoretic drug delivery | |
AU2002363106A1 (en) | Device and method for controlled delivery of active substance into the skin | |
WO2003035167A2 (en) | Device and method for controlled delivery of active substance into the skin | |
Parasrampuria et al. | Percutaneous delivery of proteins and peptides using iontophoretic techniques | |
US20080319371A1 (en) | Method and system for treating of onychomycosis with an applicator having a gel medicament layer | |
JP4297401B2 (en) | Drug delivery electrode by ion osmosis therapy | |
CA2042994C (en) | Iontophoretic delivery device | |
KR20230091270A (en) | A collagen-producing portable beauty device that maximizes the anti-aging effect that stimulates skin cells using microcurrents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, CONNECTICUT Free format text: SECURITY AGREEMENT;ASSIGNOR:TRANSPORT PHARMACEUTICALS, INC.;REEL/FRAME:022529/0922 Effective date: 20090410 |
|
AS | Assignment |
Owner name: TRANSPORT PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST RECORDED AT REEL 022529, FRAME 0922;ASSIGNOR:GENERAL ELECTRIC CAPITAL CORPORATION;REEL/FRAME:023456/0389 Effective date: 20091030 |